



(11) **EP 1 578 933 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 12, 19, 45, 58

(51) Int Cl.:
C12Q 1/68 ^(2006.01) **C07H 21/02** ^(2006.01)
C07H 21/04 ^(2006.01) **C12N 15/85** ^(2006.01)
C12N 15/86 ^(2006.01)

(48) Corrigendum issued on:
15.09.2010 Bulletin 2010/37

(86) International application number:
PCT/US2003/022444

(45) Date of publication and mention
of the grant of the patent:
10.03.2010 Bulletin 2010/10

(87) International publication number:
WO 2004/009769 (29.01.2004 Gazette 2004/05)

(21) Application number: **03765708.7**

(22) Date of filing: **18.07.2003**

(54) **COMPOSITIONS AND METHODS FOR SI-RNA INHIBITION OF ANGIOGENESIS**
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-INHIBITION DER ANGIOGENESE
COMPOSITIONS ET PROCEDE D'INHIBITION DE L'ANGIOGENESE PAR ARN-SI

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

(56) References cited:
WO-A-95/04142 WO-A-02/096927

(30) Priority: **24.07.2002 US 398417 P**
14.11.2002 US 294228

- **REICH S J ET AL: "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model" MOLECULAR VISION, SN, ATLANTA,, US, vol. 9, no. 31, 30 May 2003 (2003-05-30), pages 210-216, XP002343182 ISSN: 1090-0535**
- **SHU X ET AL: "Sphingosine kinase mediates vascular endothelial growth factor-induced activation of Ras and mitogen-activated protein kinases" MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 22, no. 22, November 2002 (2002-11), pages 7758-7768, XP002999707 ISSN: 0270-7306**
- **HOUCK ET AL: 'The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA' MOLECULAR ENDOCRINOLOGY vol. 12, 1991, pages 1806 - 1814, XP000613073**
- **ELBASHIR ET AL: 'RNA interference is mediated by 21- and 22-nucleotide RNAs' GENES AND DEVELOPMENT vol. 15, 2001, pages 188 - 200, XP002204651**

(43) Date of publication of application:
28.09.2005 Bulletin 2005/39

(60) Divisional application:
10151221.8 / 2 192 187

(73) Proprietor: **The Trustees of The University of Pennsylvania**
Philadelphia,
Pennsylvania 19104-6283 (US)

(72) Inventors:
• **TOLENTINO, Michael, J.,**
Celebration, Florida 34747 (US)
• **REICH, Samuel, Jotham**
Bala Cynwyd, PA 19004 (US)

(74) Representative: **Main, Malcolm Charles**
Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 578 933 B9

- **SHI ET AL:** 'Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor' **BRITISH JOURNAL OF CANCER** vol. 87, 2002, pages 119 - 126, XP002995137
- **BRANTL S.:** 'Antisense-RNA regulation and RNA interference' **BIOCHIMICA BIOPHYSICA ACTA** vol. 1575, 2002, pages 15 - 25, XP004356720

Description**Cross Reference to Related Application**

5 [0001] This application claims the benefit of U.S. provisional patent application serial no. 60/398,417, filed on July 24, 2002, and U.S. nonprovisional patent application serial no. 10/294,228, filed November 14, 2002.

Reference to Government Grant

10 [0002] The invention described herein was supported in part by NIH/NEI grant no. R01-EY10820, EY-13410 and EY12156. The U.S. government has certain rights in this invention.

Field of the Invention

15 [0003] This invention relates to the regulation of gene expression by small interfering RNA, in particular for treating diseases or conditions involving angiogenesis.

Background of the Invention

20 [0004] Angiogenesis, defined as the growth of new capillary blood vessels or "neovascularization," plays a fundamental role in growth and development. In mature humans, the ability to initiate angiogenesis is present in all tissues, but is held under strict control. A key regulator of angiogenesis is vascular endothelial growth factor ("VEGF"), also called vascular permeability factor ("VPF"). VEGF exists in at least four different alternative splice forms in humans VEGF₁₂₁, VEGF₁₆₅, VEGF₁₈₉ and VEGF₂₀₆, all of which exert similar biological activities.

25 [0005] Angiogenesis is initiated when secreted VEGF binds to the Flt-1 and Flk-1/KDR receptors (also called VEGF receptor 1 and VEGF receptor 2), which are expressed on the surface of endothelial cells. Flt-1 and Flk-1/KDR are transmembrane protein tyrosine kinases, and binding of VEGF initiates a cell signal cascade resulting in the ultimate neovascularization in the surrounding tissue.

30 [0006] Aberrant angiogenesis, or the pathogenic growth of new blood vessels, is implicated in a number of conditions. Among these conditions are diabetic retinopathy, psoriasis, exudative or "wet" age-related macular degeneration ("ARMD"), rheumatoid arthritis and other inflammatory diseases, and most cancers. The diseased tissues or tumors associated with these conditions express abnormally high levels of VEGF, and show a high degree of vascularization or vascular permeability.

35 [0007] ARMD in particular is a clinically important angiogenic disease. This condition is characterized by choroidal neovascularization in one or both eyes in aging individuals, and is the major cause of blindness in industrialized countries.

40 [0008] A number of therapeutic strategies exist for inhibiting aberrant angiogenesis, which attempt to reduce the production or effect of VEGF. For example, anti-VEGF or anti-VEGF receptor antibodies (Kim ES et al. (2002), PNAS USA 99: 11399-11404), and soluble VEGF "traps" which compete with endothelial cell receptors for VEGF binding (Holash J et al. (2002), PNAS USA 99: 11393-11398) have been developed. Classical VEGF "antisense" or aptamer therapies directed against VEGF gene expression have also been proposed (U.S. published application 2001/0021772 of Uhlmann et al.). However, the anti-angiogenic agents used in these therapies can produce only a stoichiometric reduction in VEGF or VEGF receptor, and the agents are typically overwhelmed by the abnormally high production of VEGF by the diseased tissue. The results achieved with available anti-angiogenic therapies have therefore been unsatisfactory.

45 [0009] RNA interference (hereinafter "RNAi") is a method of post-transcriptional gene regulation that is conserved throughout many eukaryotic organisms. RNAi is induced by short (*i.e.*, <30 nucleotide) double stranded RNA ("dsRNA") molecules which are present in the cell (Fire A et al. (1998), Nature 391: 806-811). These short dsRNA molecules, called "short interfering RNA" or "siRNA," cause the destruction of messenger RNAs ("mRNAs") which share sequence homology with the siRNA to within one nucleotide resolution (Elbashir SM et al. (2001), Genes Dev, 15: 188-200). It is believed that the siRNA and the targeted mRNA bind to an "RNA-induced silencing complex" or "RISC", which cleaves the targeted mRNA. The siRNA is apparently recycled much like a multiple-turnover enzyme, with 1 siRNA molecule capable of inducing cleavage of approximately 1000 mRNA molecules. siRNA-mediated RNAi degradation of an mRNA is therefore more effective than currently available technologies for inhibiting expression of a target gene.

50 [0010] Elbashir SM et al. (2001), *supra*, has shown that synthetic siRNA of 21 and 22 nucleotides in length, and which have short 3' overhangs, are able to induce RNAi of target mRNA in a Drosophila cell lysate. Cultured mammalian cells also exhibit RNAi degradation with synthetic siRNA (Elbashir SM et al. (2001) Nature, 411: 494-498), and RNAi degradation induced by synthetic siRNA has recently been shown in living mice (McCaffrey AP et al. (2002), Nature, 418: 38-39; Xia H et al. (2002), Nat. Biotech. 20: 1006-1010). The therapeutic potential of siRNA-induced RNAi degradation

has been demonstrated in several recent *in vitro* studies, including the siRNA-directed inhibition of HIV-1 infection (Novina CD et al. (2002), Nat. Med. 8: 681-686) and reduction of neurotoxic polyglutamine disease protein expression (Xia H et al. (2002), *supra*).

[0011] What is needed, therefore, are agents which selectively inhibit expression of VEGF or VEGF receptors in catalytic or sub-stoichiometric amounts.

Summary of the Invention

[0012] The present invention is directed to siRNAs having the sequence shown in SEQ ID NO 47, 48, 50, 51, 52, 56 which specifically target and cause RNAi-induced degradation of mRNA from VEGF, Flt-1 and Flk-1/KDR genes. The siRNA compounds and compositions of the invention are used to inhibit angiogenesis, in particular for the treatment of cancerous tumors, age-related macular degeneration, and other angiogenic diseases.

[0013] Thus, the invention provides an isolated siRNA which targets human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof. The siRNA comprises a sense RNA strand and an antisense RNA strand which form an RNA duplex. The sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in the target mRNA.

[0014] The invention also provides recombinant plasmids and viral vectors which express the siRNA of the invention, as well as pharmaceutical compositions comprising the siRNA of the invention and a pharmaceutically acceptable carrier.

[0015] The invention further provides a method of inhibiting expression of human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, comprising administering to a subject an effective amount of the siRNA of the invention such that the target mRNA is degraded.

[0016] The invention further provides a method of inhibiting angiogenesis in a subject, comprising administering to a subject an effective amount of an siRNA targeted to human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof.

[0017] The invention further provides a method of treating an angiogenic disease, comprising administering to a subject in need of such treatment an effective amount of an siRNA targeted to human VEGF mRNA, human Flt-1 mRNA, human Flk-1/KDR mRNA, or an alternative splice form, mutant or cognate thereof, such that angiogenesis associated with the angiogenic disease is inhibited.

Brief Description of the Drawings

[0018]

FIGS. 1A and 1B are histograms of VEGF concentration (in pg/ml) in hypoxic 293 and HeLa cells treated with no siRNA ("-"); nonspecific siRNA ("nonspecific"); or siRNA targeting human VEGF mRNA ("VEGF"). VEGF concentration (in pg/ml) in non-hypoxic 293 and HeLa cells is also shown. Each bar represents the average of four experiments, and the error is the standard deviation of the mean.

FIG. 2 is a histogram of murine VEGF concentration (in pg/ml) in hypoxic NIH 3T3 cells treated with no siRNA ("-"); nonspecific siRNA ("nonspecific"); or siRNA targeting human VEGF mRNA ("VEGF"). Each bar represents the average of six experiments and the error is the standard deviation of the mean.

FIG. 3 is a histogram of human VEGF concentration (pg/total protein) in retinas from mice injected with adenovirus expressing human VEGF ("AdVEGF") in the presence of either GFP siRNA (dark gray bar) or human VEGF siRNA (light grey bar). Each bar represent the average of 5 eyes and the error bars represent the standard error of the mean.

FIG. 4 is a histogram showing the mean area (in mm²) of laser-induced CNV in control eyes given subretinal injections of GFP siRNA (N=9; "GFP siRNA"), and in eyes given subretinal injections of mouse VEGF siRNA (N=7; "Mouse VEGF siRNA"). The error bars represent the standard error of the mean.

FIG. 5 is a schematic representation of pAAVsiRNA, a cis-acting plasmid used to generate a recombinant AAV viral vector of the invention. "ITR": AAV inverted terminal repeats; "U6": U6 RNA promoters; "Sense": siRNA sense coding sequence; "Anti": siRNA antisense coding sequence; "PolyT": polythymidine termination signals.

Fig. 6 shows histograms of the mean area (in mm²) of laser-induced CNV in treatment in mouse eyes injected (A) subretinally or (B) intravitreally with a mouse anti-VEGF siRNA ("mVEGF1.siRNA") or control siRNA ("GFP1.siRNA"). The error bars represent the standard error of the mean. **(C)** is a histogram of the mean area (in mm²) of laser-induced CNV in mouse eyes injected intravitreally with: phosphate-buffered saline with no siRNA at 1 day post-laser induction ("PBS"; CNV area measured at 14 days post-laser induction); control siRNA at 14 days post-laser induction ("GFP1.siRNA"; CNV area measured at 21 days post-laser induction); or a mouse anti-VEGF siRNA at 14 days post-laser induction ("mVEGF1.siRNA"; CNV area measured at 21 days post-laser induction). The error bars represent the standard error of the mean.

Fig. 7 is a graph of the percent of VEGF ("%VEGF") protein in mouse eyes injected sub-retinally with human anti-

VEGF siRNA ("Cand5") and control siRNA ("GFP1.siRNA") at 0 (n=2; pre-siRNA injection), 6 (n=3), 10 (n=3) and 14 (n=3) days post-injection. %VEGF = ([VEGF] in the Cand5 eye/[VEGF] in the GFP1.siRNA eye) *100.

Detailed Description of the Invention

5 [0019] Unless otherwise indicated, all nucleic acid sequences herein are given in the 5' to 3' direction. The invention specifically relates to SEQ ID NO. 47, 48, 50, 51, 52, 56. All references to other SEQ ID Nos are illustrative and do not define the invention. Also, all deoxyribonucleotides in a nucleic acid sequence are represented by capital letters (*e.g.*, deoxythymidine is "T"), and ribonucleotides in a nucleic acid sequence are represented by lower case letters (*e.g.*, uridine is "u").

10 [0020] Compositions and methods comprising siRNA targeted to VEGF, Flt-1 or Flk-1/KDR mRNA are advantageously used to inhibit angiogenesis, in particular for the treatment of angiogenic disease. The siRNA of the invention are believed to cause the RNAi-mediated degradation of these mRNAs, so that the protein product of the VEGF, Flt-1 or Flk-1/KDR genes is not produced or is produced in reduced amounts. Because VEGF binding to the Flt-1 or Flk-1/hDR receptors is required for initiating and maintaining angiogenesis, the siRNA-mediated degradation of VEGF, Flt-1 or Flk-1/KDR mRNA inhibits the angiogenic process.

15 [0021] The invention therefore provides isolated siRNA comprising short doublestranded RNA from about 17 nucleotides to about 29 nucleotides in length, preferably from about 19 to about 25 nucleotides in length, that are targeted to the target mRNA. The siRNA comprise a sense RNA strand and a complementary antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter "base-paired"). As is described in more detail below, the sense strand comprises a nucleic acid sequence which is identical to a target sequence contained within the target mRNA.

20 [0022] The sense and antisense strands of the present siRNA can comprise two complementary, single-stranded RNA molecules or can comprise a single molecule in which two complementary portions are base-paired and are covalently linked by a single-stranded "hairpin" area. Without wishing to be bound by any theory, it is believed that the hairpin area of the latter type of siRNA molecule is cleaved intracellularly by the "Dicer" protein (or its equivalent) to form an siRNA of two individual base-paired RNA molecules (see Tuschl, T. (2002), *supra*).

25 [0023] As used herein, "isolated" means altered or removed from the natural state through human intervention. For example, an siRNA naturally present in a living animal is not "isolated," but a synthetic siRNA, or an siRNA partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated siRNA can exist in substantially purified form, or can exist in a non-native environment such as, for example, a cell into which the siRNA has been delivered.

30 [0024] As used herein, "target mRNA" means human VEGF, Flt-1 or Flk-1/KDR mRNA, mutant or alternative splice forms of human VEGF, Flt-1 or Flk-1/KDR mRNA, or mRNA from cognate VEGF, Flt-1 or Flk-1/KDR genes.

35 [0025] As used herein, a gene or mRNA which is "cognate" to human VEGF, Flt-1 or Flk-1/KDR is a gene or mRNA from another mammalian species which is homologous to human VEGF, Flt-1 or Flk-1/KDR. For example, the cognate VEGF mRNA from the mouse is given in SEQ ID NO: 1.

40 [0026] Splice variants of human VEGF are known, including VEGF₁₂₁ (SEQ ID NO: 2), VEGF₁₆₅ (SEQ ID NO: 3), VEGF₁₈₉ (SEQ ID NO: 4) and VEGF₂₀₆ (SEQ ID NO: 5). The mRNA transcribed from the human VEGF, Flt-1 (SEQ ID NO: 6) or Flk-1/KDR (SEQ ID NO: 7) genes can be analyzed for further alternative splice forms using techniques well-known in the art. Such techniques include reverse transcription-polymerase chain reaction (RT-PCR), northern blotting and *in-situ* hybridization. Techniques for analyzing mRNA sequences are described, for example, in Busting SA (2000), *J. Mol. Endocrinol.* 25: 169-193, the entire disclosure of which is herein incorporated by reference. Representative techniques for identifying alternatively spliced mRNAs are also described below.

45 [0027] For example, databases that contain nucleotide sequences related to a given disease gene can be used to identify alternatively spliced mRNA. Such databases include GenBank, Embase, and the Cancer Genome Anatomy Project (CGAP) database. The CGAP database, for example, contains expressed sequence tags (ESTs) from various types of human cancers. An mRNA or gene sequence from the VEGF, Flt-1 or Flk-1/KDR genes can be used to query such a database to determine whether ESTs representing alternatively spliced mRNAs have been found for these genes.

50 [0028] A technique called "RNase protection" can also be used to identify alternatively spliced VEGF, Flt-1 or Flk-1/KDR mRNAs. RNase protection involves translation of a gene sequence into synthetic RNA, which is hybridized to RNA derived from other cells; for example, cells from tissue at or near the site of neovascularization. The hybridized RNA is then incubated with enzymes that recognize RNA:RNA hybrid mismatches. Smaller than expected fragments indicate the presence of alternatively spliced mRNAs. The putative alternatively spliced mRNAs can be cloned and sequenced by methods well known to those skilled in the art.

55 [0029] RT-PCR can also be used to identify alternatively spliced VEGF, Flt-1 or Flk-1/KDR mRNAs. In RT-PCR, mRNA from the diseased tissue is converted into cDNA by the enzyme reverse transcriptase, using methods well-known to those of ordinary skill in the art. The entire coding sequence of the cDNA is then amplified via PCR using a forward

primer located in the 3' untranslated region, and a reverse primer located in the 5' untranslated region. The amplified products can be analyzed for alternative splice forms, for example by comparing the size of the amplified products with the size of the expected product from normally spliced mRNA, *e.g.*, by agarose gel electrophoresis. Any change in the size of the amplified product can indicate alternative splicing.

5 **[0030]** mRNA produced from mutant VEGF, Flt-1 or Flk-1/KDR genes can also be readily identified through the techniques described above for identifying alternative splice forms. As used herein, "mutant" VEGF, Flt-1 or Flk-1/KDR genes or mRNA include human VEGF, Flt-1 or Flk-1/KDR genes or mRNA which differ in sequence from the VEGF, Flt-1 or Flk-1/KDR sequences set forth herein. Thus, allelic forms of these genes, and the mRNA produced from them, are considered "mutants" for purposes of this invention.

10 **[0031]** It is understood that human VEGF, Flt-1 or Flk-1/KDR mRNA may contain target sequences in common with their respective alternative splice forms, cognates or mutants. A single siRNA comprising such a common targeting sequence can therefore induce RNAi-mediated degradation of different RNA types which contain the common targeting sequence.

15 **[0032]** The siRNA of the invention can comprise partially purified RNA, substantially pure RNA, synthetic RNA, or recombinantly produced RNA, as well as altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or to one or more internal nucleotides of the siRNA, including modifications that make the siRNA resistant to nuclease digestion.

20 **[0033]** One or both strands of the siRNA of the invention can also comprise a 3' overhang. As used herein, a "3' overhang" refers to at least one unpaired nucleotide extending from the 3'-end of a duplexed RNA strand.

[0034] Thus in one embodiment, the siRNA of the invention comprises at least one 3' overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxynucleotides) in length, preferably from 1 to about 5 nucleotides in length, more preferably from 1 to about 4 nucleotides in length, and particularly preferably from about 2 to about 4 nucleotides in length.

25 **[0035]** In the embodiment in which both strands of the siRNA molecule comprise a 3' overhang, the length of the overhangs can be the same or different for each strand. In a most preferred embodiment, the 3' overhang is present on both strands of the siRNA, and is 2 nucleotides in length. For example, each strand of the siRNA of the invention can comprise 3' overhangs of dithymidylic acid ("TT") or diuridylic acid ("uu").

30 **[0036]** In order to enhance the stability of the present siRNA, the 3' overhangs can be also stabilized against degradation. In one embodiment, the overhangs are stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, *e.g.*, substitution of uridine nucleotides in the 3' overhangs with 2'-deoxythymidine, is tolerated and does not affect the efficiency of RNAi degradation. In particular, the absence of a 2' hydroxyl in the 2'-deoxythymidine significantly enhances the nuclease resistance of the 3' overhang in tissue culture medium.

35 **[0037]** In certain embodiments, the siRNA of the invention comprises the sequence AA(N19)TT or NA(N21), where N is any nucleotide. These siRNA comprise approximately 30-70% GC, and preferably comprise approximately 50% G/C. The sequence of the sense siRNA strand corresponds to (N19)TT or N21 (*i.e.*, positions 3 to 23), respectively. In the latter case, the 3' end of the sense siRNA is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense strand 3' overhangs. The antisense RNA strand is then synthesized as the complement to positions 1 to 21 of the sense strand.

40 **[0038]** Because position 1 of the 23-nt sense strand in these embodiments is not recognized in a sequence-specific manner by the antisense strand, the 3'-most nucleotide residue of the antisense strand can be chosen deliberately. However, the penultimate nucleotide of the antisense strand (complementary to position 2 of the 23-nt sense strand in either embodiment) is generally complementary to the targeted sequence.

45 **[0039]** In another embodiment, the siRNA of the invention comprises the sequence NAR(N17)YNN, where R is a purine (*e.g.*, A or G) and Y is a pyrimidine (*e.g.*, C or U/T). The respective 21-nt sense and antisense RNA strands of this embodiment therefore generally begin with a purine nucleotide. Such siRNA can be expressed from pol III expression vectors without a change in targeting site, as expression of RNAs from pol III promoters is only believed to be efficient when the first transcribed nucleotide is a purine.

50 **[0040]** The siRNA of the invention can be targeted to any stretch of approximately 19-25 contiguous nucleotides in any of the target mRNA sequences (the "target sequence"). Techniques for selecting target sequences for siRNA are given, for example, in Tuschl T et al., "The siRNA User Guide," revised Oct. 11, 2002, the entire disclosure of which is herein incorporated by reference. "The siRNA User Guide" is available on the world wide web at a website maintained by Dr. Thomas Tuschl, Department of Cellular Biochemistry, AG 105, Max-Planck-Institute for Biophysical Chemistry, 37077 Göttingen, Germany, and can be found by accessing the website of the Max Planck Institute and searching with the keyword "siRNA." Thus, the sense strand of the present siRNA comprises a nucleotide sequence identical to any contiguous stretch of about 19 to about 25 nucleotides in the target mRNA.

55 **[0041]** Generally, a target sequence on the target mRNA can be selected from a given cDNA sequence corresponding

EP 1 578 933 B9

to the target mRNA, preferably beginning 50 to 100 nt downstream (*i.e.*, in the 3' direction) from the start codon. The target sequence can, however, be located in the 5' or 3' untranslated regions, or in the region nearby the start codon (see, *e.g.*, the target sequences of SEQ ID NOS: 73 and 74 in Table 1 below, which are within 100 nt of the 5'-end of the VEGF₁₂₁ cDNA

5 **[0042]** For example, a suitable target sequence in the VEGF₁₂₁ cDNA sequence is:

TCATCACGAAGTGGTGAAG (SEQ ID NO: 8)

10 **[0043]** Thus, an siRNA of the invention targeting this sequence, and which has 3' uu overhangs on each strand (overhangs shown in bold), is:

5'-ucaucacgaaguggugaaguu-3' (SEQ ID NO: 9)

3'-uuaguagugcuucaccacuuc-5' (SEQ ID NO: 10)

15 **[0044]** An siRNA of the invention targeting this same sequence, but having 3' TT overhangs on each strand (overhangs shown in bold) is:

5'-ucaucacgaaguggugaagTT-3' (SEQ ID NO: 11)

3'-TTaguagugcuucaccacuuc-5' (SEQ ID NO: 12)

20 **[0045]** Other VEGF₁₂₁ target sequences from which siRNA of the invention can be derived are given in Table 1. It is understood that all VEGF₁₂₁ target sequences listed in Table 1 are within that portion of the VEGF₁₂₁ alternative splice form which is common to all human VEGF alternative splice forms. Thus, the VEGF₁₂₁ target sequences in Table 1 can also target VEGF₁₆₅, VEGF₁₈₉ and VEGF₂₀₆ mRNA. Target sequences which target a specific VEGF isoform can also be readily identified. For example, a target sequence which targets VEGF₁₆₅ mRNA but not VEGF₁₂₁ mRNA is AACG-TACTTGAGATGTGACA (SEQ ID NO: 13). Exemplary target sequences for human Flt-1 are given in SEQ ID NOS: 91 - 504, and exemplary target sequences for human Flk-1/KDR are given in SEQ ID NOS: 505 - 864.

Table 1 - VEGF Target Sequences

target sequence	SEQ ID NO:	target sequence	SEQ ID NO:
GTTTCATGGATGTCTATCAG	14	TCCCTGTGGCCTTGCTCA	30
TCGAGACCCCTGGTGGACAT	15	GCATTTGTTTGTACAAGAT	31
TGACGAGGGCCTGGAGTGT	16	GATCCGCAGACGTGTAAT	32
TGACGAGGGCCTGGAGTGT	17	ATGTTCTGCAAAAACACA	33
CATCACCATGCAGATTATG	18	TGTTCTGCAAAAACACAG	34
ACCTCACCAAGGCCAGCAC	19	AAACACAGACTCGCGTTGC	35
GGCCAGCATAGGAGAGA	20	AACACAGACTCGCGTTGCA	36
CAAATGTGAATGCAGACCA	21	ACACAGACTCGCGTTGCAA	37
ATGTGAATGCAGACCAAAG	22	CACAGACTCGCGTTGCAAG	38
TGCAGACCAAAGAAAGATA	23	GGCGAGGCAGCTTGAGTTA	39
AGAAAGATAGAGCAAGACA	24	ACGAACGTAAGTGCAGATG	40
GAAAGATAGAGCAAGACAA	25	CGAACGTAAGTGCAGATGT	41
GATAGAGCAAGACAAGAAA	26	CGTACTTGCAGATGTGACA	42
GACAAGAAAATCCCTGTGG	27	GTGGTCCCAGGCTGCACCC	43
GAAAATCCCTGTGGGCCTT	28	GGAGGAGGGCAGAATCATC	44
AATCCCTGTGGGCCTTGCT	29	GTGGTGAAGTTCATGGATG	45
AATCATCACGAAGTGGTGAAG	46	AAGCATTTGTTTGTACAAGATCC	62
AAGTTCATGGATGTCTATCAG	47	AAGATCCGCAGACGTGTAATGT	63

(continued)

	target sequence	SEQ ID NO:		target sequence	SEQ ID NO:
5	AATCGAGACCCTGGTGGACAT	48		AAATGTTCTGCAAAAACACAGA	64
	AATGACGAGGGCCTGGAGTGT	49		AATGTTCTGCAAAAACACAGAC	65
	AACATCACCATGCAGATTATG	50		AAAAACACAGACTCGCGTTGCAA	66
10	AAACCTCACCAAGGCCAGCAC	51		AAAACACAGACTCGCGTTGCAAG	67
	AAGGCCAGCACATAGGAGAGA	52		AAACACAGACTCGCGTTGCAAGG	68
	AACAAATGTGAATGCAGACCA	53		AACACAGACTCGCGTTGCAAGGC	69
	AAATGTGAATGCAGACCAAAG	54		AAGGCGAGGCAGCTTGAGTTAAA	70
15	AATGCAGACCAAAGAAAGATA	55		AAACGAACGTACTTGCAGATGTG	71
	AAAGAAAGATAGAGCAAGACA	56		AACGAACGTACTTGCAGATGTGA	72
	AAGAAAGATAGAGCAAGACAA	57		AAGTGGTCCCAGGCTGCACCCAT	73
20	AAGATAGAGCAAGACAAGAAAAT	58		AAGGAGGAGGGCAGAATCATCAC	74
	AAGACAAGAAAATCCCTGTGGGC	59		AAGTGGTGAAGTTCATGGATGTC	75
	AAGAAAATCCCTGTGGGCCTTGC	60		AAAATCCCTGTGGGCCTTGCTCA	76
	AATCCCTGTGGGCCTTGCTCAGA	61		GGCAGAATCATCACGAAGTGG	81
25	CCTGGTGGACATCTTCCAGGA	82		CACACACTCGCGTTGCAAGGC	87
	GAGATCGAGTACATCTTCAAG	83		TCACCATGCAGATTATGCGGA	88
	TGGAGTGTGTGCCACTGAGG	84		TAGAGCAAGACAAGAAAATCC	89
30	GAGCTTCTACAGCACAACAA	85		CCGCAGACGTGTAATGTTCC	90
	TTGCTCAGAGCGGAGAAAGCA	86			

[0046] The siRNA of the invention can be obtained using a number of techniques known to those of skill in the art. For example, the siRNA can be chemically synthesized or recombinantly produced using methods known in the art, such as the *Drosophila in vitro* system described in U.S. published application 2002/0086356 of Tuschl et al., the entire disclosure of which is herein incorporated by reference.

[0047] Preferably, the siRNA of the invention are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. The siRNA can be synthesized as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions. Commercial suppliers of synthetic RNA molecules or synthesis reagents include Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, CO, USA), Pierce Chemical (part of Perbio Science, Rockford, IL, USA), Glen Research (Sterling, VA, USA), ChemGenes (Ashland, MA, USA) and Cruachem (Glasgow, UK).

[0048] Alternatively, siRNA can also be expressed from recombinant circular or linear DNA plasmids using any suitable promoter. Suitable promoters for expressing siRNA of the invention from a plasmid include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant plasmids of the invention can also comprise inducible or regulatable promoters for expression of the siRNA in a particular tissue or in a particular intracellular environment.

[0049] The siRNA expressed from recombinant plasmids can either be isolated from cultured cell expression systems by standard techniques, or can be expressed intracellularly at or near the area of neovascularization *in vivo*. The use of recombinant plasmids to deliver siRNA of the invention to cells *in vivo* is discussed in more detail below.

[0050] siRNA of the invention can be expressed from a recombinant plasmid either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.

[0051] Selection of plasmids suitable for expressing siRNA of the invention, methods for inserting nucleic acid sequences for expressing the siRNA into the plasmid, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art. See, for example Tuschl, T. (2002), Nat. Biotechnol. 20: 446-448; Brummelkamp TR et al. (2002), Science 296: 550-553; Miyagishi M et al. (2002), Nat. Biotechnol. 20: 497-500; Paddison PJ et al. (2002), Genes Dev. 16: 948-958; Lee NS et al. (2002), Nat. Biotechnol. 20: 500-505; and Paul CP et al. (2002), Nat.

Biotechnol. 20: 505-508, the entire disclosures of which are herein incorporated by reference.

5 [0052] A plasmid comprising nucleic acid sequences for expressing an siRNA of the invention is described in Example 7 below. That plasmid, called pAAVsiRNA, comprises a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter. The plasmid pAAVsiRNA is ultimately intended for use in producing a recombinant adeno-associated viral vector comprising the same nucleic acid sequences for expressing an siRNA of the invention.

10 [0053] As used herein, "in operable connection with a polyT termination sequence" means that the nucleic acid sequences encoding the sense or antisense strands are immediately adjacent to the polyT termination signal in the 5' direction. During transcription of the sense or antisense sequences from the plasmid, the polyT termination signals act to terminate transcription.

[0054] As used herein, "under the control" of a promoter means that the nucleic acid sequences encoding the sense or antisense strands are located 3' of the promoter, so that the promoter can initiate transcription of the sense or antisense coding sequences.

15 [0055] The siRNA of the invention can also be expressed from recombinant viral vectors intracellularly at or near the area of neovascularization *in vivo*. The recombinant viral vectors of the invention comprise sequences encoding the siRNA of the invention and any suitable promoter for expressing the siRNA sequences. Suitable promoters include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the siRNA in a particular tissue or in a particular intracellular environment. The use of recombinant viral vectors to deliver siRNA of the invention to cells *in vivo* is discussed in more detail below.

20 [0056] siRNA of the invention can be expressed from a recombinant viral vector either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.

25 [0057] Any viral vector capable of accepting the coding sequences for the siRNA molecule(s) to be expressed can be used, for example vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (*e.g.*, lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of the viral vectors can also be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses. For example, an AAV vector of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like.

30 [0058] Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing the siRNA into the vector, and methods of delivering the viral vector to the cells of interest are within the skill in the art. See, for example, Dornburg R (1995), *Gene Therap.* 2: 301-310; Eglitis MA (1988), *Bio-techniques* 6: 608-614; Miller AD (1990), *Hum Gene Therap.* 1: 5-14; and Anderson WF (1998), *Nature* 392: 25-30, the entire disclosures of which are herein incorporated by reference.

35 [0059] Preferred viral vectors are those derived from AV and AAV. In a particularly preferred embodiment, the siRNA of the invention is expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector comprising, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter.

40 [0060] A suitable AV vector for expressing the siRNA of the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), *Nat. Biotech.* 20: 1006-1010.

45 [0061] Suitable AAV vectors for expressing the siRNA of the invention, methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), *J. Virol.* 61: 3096-3101; Fisher KJ et al. (1996), *J. Virol.*, 70: 520-532; Samulski R et al. (1989), *J. Virol.* 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference. An exemplary method for generating a recombinant AAV vector of the invention is described in Example 7 below.

50 [0062] The ability of an siRNA containing a given target sequence to cause RNAi-mediated degradation of the target mRNA can be evaluated using standard techniques for measuring the levels of RNA or protein in cells. For example, siRNA of the invention can be delivered to cultured cells, and the levels of target mRNA can be measured by Northern blot or dot blotting techniques, or by quantitative RT-PCR. Alternatively, the levels of VEGF, Flt-1 or Flk-1/KDR receptor protein in the cultured cells can be measured by ELISA or Western blot. A suitable cell culture system for measuring the effect of the present siRNA on target mRNA or protein levels is described in Example 1 below.

55 [0063] RNAi-mediated degradation of target mRNA by an siRNA containing a given target sequence can also be evaluated with animal models of neovascularization, such as the ROP or CNV mouse models. For example, areas of neovascularization in an ROP or CNV mouse can be measured before and after administration of an siRNA. A reduction in the areas of neovascularization in these models upon administration of the siRNA indicates the down-regulation of the target mRNA (see Example 6 below).

[0064] As discussed above, the siRNA of the invention target and cause the RNAi-mediated degradation of VEGF,

Flt-1 or Flk-1/KDR mRNA, or alternative splice forms, mutants or cognates thereof. Degradation of the target mRNA by the present siRNA reduces the production of a functional gene product from the VEGF, Flt-1 or Flk-1/KDR genes. Thus, the invention provides a method of inhibiting expression of VEGF, Flt-1 or Flk-1/KDR in a subject, comprising administering an effective amount of an siRNA of the invention to the subject, such that the target mRNA is degraded. As the products of the VEGF, Flt-1 and Flk-1/KDR genes are required for initiating and maintaining angiogenesis, the invention also provides a method of inhibiting angiogenesis in a subject by the RNAi-mediated degradation of the target mRNA by the present siRNA.

[0065] As used herein, a "subject" includes a human being or non-human animal. Preferably, the subject is a human being.

[0066] As used herein, an "effective amount" of the siRNA is an amount sufficient to cause RNAi-mediated degradation of the target mRNA, or an amount sufficient to inhibit the progression of angiogenesis in a subject.

[0067] RNAi-mediated degradation of the target mRNA can be detected by measuring levels of the target mRNA or protein in the cells of a subject, using standard techniques for isolating and quantifying mRNA or protein as described above.

[0068] Inhibition of angiogenesis can be evaluated by directly measuring the progress of pathogenic or nonpathogenic angiogenesis in a subject; for example, by observing the size of a neovascularized area before and after treatment with the siRNA of the invention. An inhibition of angiogenesis is indicated if the size of the neovascularized area stays the same or is reduced. Techniques for observing and measuring the size of neovascularized areas in a subject are within the skill in the art; for example, areas of choroid neovascularization can be observed by ophthalmoscopy.

[0069] Inhibition of angiogenesis can also be inferred through observing a change or reversal in a pathogenic condition associated with the angiogenesis. For example, in ARMD, a slowing, halting or reversal of vision loss indicates an inhibition of angiogenesis in the choroid. For tumors, a slowing, halting or reversal of tumor growth, or a slowing or halting of tumor metastasis, indicates an inhibition of angiogenesis at or near the tumor site. Inhibition of non-pathogenic angiogenesis can also be inferred from, for example, fat loss or a reduction in cholesterol levels upon administration of the siRNA of the invention.

[0070] It is understood that the siRNA of the invention can degrade the target mRNA (and thus inhibit angiogenesis) in substoichiometric amounts. Without wishing to be bound by any theory, it is believed that the siRNA of the invention causes degradation of the target mRNA in a catalytic manner. Thus, compared to standard anti-angiogenic therapies, significantly less siRNA needs to be delivered at or near the site of neovascularization to have a therapeutic effect.

[0071] One skilled in the art can readily determine an effective amount of the siRNA of the invention to be administered to a given subject, by taking into account factors such as the size and weight of the subject; the extent of the neovascularization or disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic. Generally, an effective amount of the siRNA of the invention comprises an inter-cellular concentration at or near the neovascularization site of from about 1 nanomolar (nM) to about 100 nM, preferably from about 2 nM to about 50 nM, more preferably from about 2.5 nM to about 10 nM. It is contemplated that greater or lesser amounts of siRNA can be administered.

[0072] The present methods can be used to inhibit angiogenesis which is non-pathogenic; *i.e.*, angiogenesis which results from normal processes in the subject. Examples of non-pathogenic angiogenesis include endometrial neovascularization, and processes involved in the production of fatty tissues or cholesterol. Thus, the invention provides a method for inhibiting non-pathogenic angiogenesis, *e.g.*, for controlling weight or promoting fat loss, for reducing cholesterol levels, or as an abortifacient.

[0073] The present methods can also inhibit angiogenesis which is associated with an angiogenic disease; *i.e.*, a disease in which pathogenicity is associated with inappropriate or uncontrolled angiogenesis. For example, most cancerous solid tumors generate an adequate blood supply for themselves by inducing angiogenesis in and around the tumor site. This tumor-induced angiogenesis is often required for tumor growth, and also allows metastatic cells to enter the bloodstream.

[0074] Other angiogenic diseases include diabetic retinopathy, age-related macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases. These diseases are characterized by the destruction of normal tissue by newly formed blood vessels in the area of neovascularization. For example, in ARMD, the choroid is invaded and destroyed by capillaries. The angiogenesis-driven destruction of the choroid in ARMD eventually leads to partial or full blindness.

[0075] Preferably, an siRNA of the invention is used to inhibit the growth or metastasis of solid tumors associated with cancers; for example breast cancer, lung cancer, head and neck cancer, brain cancer, abdominal cancer, colon cancer, colorectal cancer, esophagus cancer, gastrointestinal cancer, glioma, liver cancer, tongue cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, Wilm's tumor, multiple myeloma; skin cancer (*e.g.*, melanoma), lymphomas and blood cancer.

[0076] More preferably, an siRNA of the invention is used to inhibit choroidal neovascularization in age-related macular degeneration.

[0077] For treating angiogenic diseases, the siRNA of the invention can administered to a subject in combination with a pharmaceutical agent which is different from the present siRNA. Alternatively, the siRNA of the invention can be administered to a subject in combination with another therapeutic method designed to treat the angiogenic disease. For example, the siRNA of the invention can be administered in combination with therapeutic methods currently employed for treating cancer or preventing tumor metastasis (*e.g.*, radiation therapy, chemotherapy, and surgery). For treating tumors, the siRNA of the invention is preferably administered to a subject in combination with radiation therapy, or in combination with chemotherapeutic agents such as cisplatin, carboplatin, cyclophosphamide, 5-fluorouracil, adriamycin, daunorubicin or tamoxifen.

[0078] In the present methods, the present siRNA can be administered to the subject either as naked siRNA, in conjunction with a delivery reagent, or as a recombinant plasmid or viral vector which expresses the siRNA.

[0079] Suitable delivery reagents for administration in conjunction with the present siRNA include the Mirus Transit TKO lipophilic reagent; lipofectin; lipofectamine; cellfectin; or polycations (*e.g.*, polylysine), or liposomes. A preferred delivery reagent is a liposome.

[0080] Liposomes can aid in the delivery of the siRNA to a particular tissue, such as retinal or tumor tissue, and can also increase the blood half-life of the siRNA. Liposomes suitable for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of factors such as the desired liposome size and half-life of the liposomes in the blood stream. A variety of methods are known for preparing liposomes, for example as described in Szoka et al. (1980), *Ann. Rev. Biophys. Bioeng.* 9: 467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are herein incorporated by reference.

[0081] Preferably, the liposomes encapsulating the present siRNA comprises a ligand molecule that can target the liposome to a particular cell or tissue at or near the site of angiogenesis. Ligands which bind to receptors prevalent in tumor or vascular endothelial cells, such as monoclonal antibodies that bind to tumor antigens or endothelial cell surface antigens, are preferred.

[0082] Particularly preferably, the liposomes encapsulating the present siRNA are modified so as to avoid clearance by the mononuclear macrophage and reticuloendothelial systems, for example by having opsonization-inhibition moieties bound to the surface of the structure. In one embodiment, a liposome of the invention can comprise both opsonization-inhibition moieties and a ligand.

[0083] Opsonization-inhibiting moieties for use in preparing the liposomes of the invention are typically large hydrophilic polymers that are bound to the liposome membrane. As used herein, an opsonization inhibiting moiety is "bound" to a liposome membrane when it is chemically or physically attached to the membrane, *e.g.*, by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of membrane lipids. These opsonization-inhibiting hydrophilic polymers form a protective surface layer which significantly decreases the uptake of the liposomes by the macrophage-monocyte system ("MMS") and reticuloendothelial system ("RES"); *e.g.*, as described in U.S. Pat. No. 4,920,016, the entire disclosure of which is herein incorporated by reference. Liposomes modified with opsonization-inhibition moieties thus remain in the circulation much longer than unmodified liposomes. For this reason, such liposomes are sometimes called "stealth" liposomes.

[0084] Stealth liposomes are known to accumulate in tissues fed by porous or "leaky" microvasculature. Thus, target tissue characterized by such microvasculature defects, for example solid tumors, will efficiently accumulate these liposomes; see Gabizon, et al. (1988), *P.N.A.S., USA*, 18: 6949-53. In addition, the reduced uptake by the RES lowers the toxicity of stealth liposomes by preventing significant accumulation in the liver and spleen. Thus, liposomes of the invention that are modified with opsonization-inhibition moieties can deliver the present siRNA to tumor cells.

[0085] Opsonization inhibiting moieties suitable for modifying liposomes are preferably water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, and more preferably from about 2,000 to about 20,000 daltons. Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) derivatives; *e.g.*, methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers such as polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, *e.g.*, polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GM₁. Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable. In addition, the opsonization inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyle-
neamine, or polynucleotide. The opsonization inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, *e.g.*, galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; aminated polysaccharides or oligosaccharides (linear or branched); or carboxylated polysaccharides or oligosaccharides, *e.g.*, reacted with derivatives of carbonic acids with resultant linking of carboxylic groups.

[0086] Preferably, the opsonization-inhibiting moiety is a PEG, PPG, or derivatives thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called "PEGylated liposomes."

[0087] The opsonization inhibiting moiety can be bound to the liposome membrane by any one of numerous well-

known techniques. For example, an N-hydroxysuccinimide ester of PEG can be bound to a phosphatidyl-ethanolamine lipid-soluble anchor, and then bound to a membrane. Similarly, a dextran polymer can be derivatized with a stearylamine lipid-soluble anchor via reductive amination using $\text{Na}(\text{CN})\text{BH}_3$ and a solvent mixture such as tetrahydrofuran and water in a 30:12 ratio at 60 °C.

5 **[0088]** Recombinant plasmids which express siRNA of the invention are discussed above. Such recombinant plasmids can also be administered directly or in conjunction with a suitable delivery reagent, including the Mirus Transit LT1 lipophilic reagent; lipofectin; lipofectamine; cellfectin; polycations (*e.g.*, polylysine) or liposomes. Recombinant viral vectors which express siRNA of the invention are also discussed above, and methods for delivering such vectors to an area of neovascularization in a patient are within the skill in the art.

10 **[0089]** The siRNA of the invention can be administered to the subject by any means suitable for delivering the siRNA to the cells of the tissue at or near the area of neovascularization. For example, the siRNA can be administered by gene gun, electroporation, or by other suitable parenteral or enteral administration routes.

[0090] Suitable enteral administration routes include oral, rectal, or intranasal delivery.

15 **[0091]** Suitable parenteral administration routes include intravascular administration (*e.g.* intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue administration (*e.g.*, peri-tumoral and intra-tumoral injection, intra-retinal injection or subretinal injection); subcutaneous injection or deposition including subcutaneous infusion (such as by osmotic pumps); direct (*e.g.*, topical) application to the area at or near the site of neovascularization, for example by a catheter or other placement device (*e.g.*, a corneal pellet or a suppository, eye-dropper, or an implant comprising a porous, non-porous, or gelatinous material); and inhalation. Suitable placement devices include the ocular implants described in U.S. Pat. Nos. 5,902,598 and 6,375,972, and the biodegradable ocular implants described in U.S. Pat. No 6,331,313, the entire disclosures of which are herein incorporated by reference. Such ocular implants are available from Control Delivery Systems, Inc. (Watertown, MA) and Oculex Pharmaceuticals, Inc. (Sunnyvale, CA).

25 **[0092]** In a preferred embodiment, injections or infusions of the siRNA are given at or near the site of neovascularization. More preferably, the siRNA is administered topically to the eye, *e.g.* in liquid or gel form to the lower eye lid or conjunctival cul-de-sac, as is within the skill in the art (see, *e.g.*, Acheampong AA et al, 2002, Drug Metabol. and Disposition 30: 421-429, the entire disclosure of which is herein incorporated by reference).

30 **[0093]** Typically, the siRNA of the invention is administered topically to the eye in amounts of from about 5 microliters to about 75 microliters, for example from about 7 microliters to about 50 microliters, preferably from about 10 microliters to about 30 microliters. It is understood that topical instillation in the eye of siRNA in volumes greater than 75 microliters can result in loss of siRNA from the eye through spillage and drainage. Thus, it is preferable to administer a high concentration of siRNA (*e.g.*, 100-1000 nM) in as small a volume as possible.

35 **[0094]** A particularly preferred parenteral administration route is intraocular administration. It is understood that intraocular administration of the present siRNA can be accomplished by injection or direct (*e.g.*, topical) administration to the eye, as long as the administration route allows the siRNA to enter the eye. In addition to the topical routes of administration to the eye described above, suitable intraocular routes of administration include intravitreal, intraretinal, subretinal, subtenon, peri- and retro-orbital, trans-corneal and trans-scleral administration. Such intraocular administration routes are within the skill in the art; see, *e.g.*, and Acheampong AA et al, 2002, *supra*; and Bennett et al. (1996), Hum. Gene Ther. 7: 1763-1769 and Ambati J et al., 2002, Progress in Retinal and Eye Res. 21: 145-151, the entire disclosures of which are herein incorporated by reference.

40 **[0095]** The siRNA of the invention can be administered in a single dose or in multiple doses. Where the administration of the siRNA of the invention is by infusion, the infusion can be a single sustained dose or can be delivered by multiple infusions. Injection of the agent directly into the tissue is at or near the site of neovascularization preferred. Multiple injections of the agent into the tissue at or near the site of neovascularization are particularly preferred.

45 **[0096]** One skilled in the art can also readily determine an appropriate dosage regimen for administering the siRNA of the invention to a given subject. For example, the siRNA can be administered to the subject once, such as by a single injection or deposition at or near the neovascularization site. Alternatively, the siRNA can be administered to a subject multiple times daily or weekly. For example, the siRNA can be administered to a subject once weekly for a period of from about three to about twenty-eight weeks, more preferably from about seven to about ten weeks. In a preferred dosage regimen, the siRNA is injected at or near the site of neovascularization (*e.g.*, intravitreally) once a week for seven weeks. It is understood that periodic administrations of the siRNA of the invention for an indefinite length of time may be necessary for subjects suffering from a chronic neovascularization disease, such as wet ARMD or diabetic retinopathy.

[0097] Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of siRNA administered to the subject can comprise the total amount of siRNA administered over the entire dosage regimen.

55 **[0098]** The siRNA of the invention are preferably formulated as pharmaceutical compositions prior to administering to a subject, according to techniques known in the art. Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. As used herein, "pharmaceutical formulations" include formulations for human and veterinary use. Methods for preparing pharmaceutical compositions of the invention are within the skill

in the art, for example as described in Remington's Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, Pa. (1985), the entire disclosure of which is herein incorporated by reference.

[0099] The present pharmaceutical formulations comprise an siRNA of the invention (e.g., 0.1 to 90% by weight), or a physiologically acceptable salt thereof, mixed with a physiologically acceptable carrier medium. Preferred physiologically acceptable carrier media are water, buffered water, saline solutions (e.g., normal saline or balanced saline solutions such as Hank's or Earle's balanced salt solutions), 0.4% saline, 0.3% glycine, hyaluronic acid and the like.

[0100] Pharmaceutical compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives. Suitable pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH adjusting agents. Suitable additives include physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA or DTPA-bisamide) or calcium chelate complexes (as for example calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate). Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.

[0101] For topical administration to the eye, conventional intraocular delivery reagents can be used. For example, pharmaceutical compositions of the invention for topical intraocular delivery can comprise saline solutions as described above, corneal penetration enhancers, insoluble particles, petrolatum or other gel-based ointments, polymers which undergo a viscosity increase upon instillation in the eye, or mucoadhesive polymers. Preferably, the intraocular delivery reagent increases corneal penetration, or prolongs precorneal retention of the siRNA through viscosity effects or by establishing physicochemical interactions with the mucin layer covering the corneal epithelium.

[0102] Suitable insoluble particles for topical intraocular delivery include the calcium phosphate particles described in U.S. Pat. No. 6,355,271 of Bell et al., the entire disclosure of which is herein incorporated by reference. Suitable polymers which undergo a viscosity increase upon instillation in the eye include polyethylenepolyoxypropylene block copolymers such as poloxamer 407 (e.g., at a concentration of 25%), cellulose acetophthalate (e.g., at a concentration of 30%), or a low-acetyl gellan gum such as Gelrite® (available from CP Kelco, Wilmington, DE). Suitable mucoadhesive polymers include hydrocolloids with multiple hydrophilic functional groups such as carboxyl, hydroxyl, amide and/or sulfate groups; for example, hydroxypropylcellulose, polyacrylic acid, high-molecular weight polyethylene glycols (e.g., >200,000 number average molecular weight), dextrans, hyaluronic acid, polygalacturonic acid, and xylocan. Suitable corneal penetration enhancers include cyclodextrins, benzalkonium chloride, polyoxyethylene glycol lauryl ether (e.g., Brij® 35), polyoxyethylene glycol stearyl ether (e.g., Brij® 78), polyoxyethylene glycol oleyl ether (e.g., Brij® 98), ethylene diamine tetraacetic acid (EDTA), digitonin, sodium taurocholate, saponins and polyoxyethylated castor oil such as Cremaphor EL.

[0103] For solid compositions, conventional nontoxic solid carriers can be used; for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

[0104] For example, a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%, preferably 25%-75%, of one or more siRNA of the invention. A pharmaceutical composition for aerosol (inhalational) administration can comprise 0.01-20% by weight, preferably 1%-10% by weight, of one or more siRNA of the invention encapsulated in a liposome as described above, and propellant. A carrier can also be included as desired; e.g., lecithin for intranasal delivery.

[0105] The invention will now be illustrated with the following non-limiting examples. The animal experiments described in Examples 4-6 and 8-9 were performed using the University of Pennsylvania institutional guidelines for the care and use of animals in research. The animal experiment described in Example 10 will be performed in accordance with the Standard Operating Procedures of Sierra Biomedical, 587 Dunn Circle, Sparks, NV, 89431.

Example 1 - siRNA Transfection and Hypoxia Induction *In Vitro*

[0106] *siRNA Design* - A 19 nt sequence located 329 nt from the 5' end of human VEGF mRNA was chosen as a target sequence: AACCTCACCAAGGCCAGCAC (SEQ ID NO: 51). To ensure that it was not contained in the mRNA from any other genes, this target sequence was entered into the BLAST search engine provided by NCBI. The use of the BLAST algorithm is described in Altschul et al. (1990), J. Mol. Biol. 215: 403-410 and Altschul et al. (1997), Nucleic Acids Res. 25: 3389-3402, the disclosures of which are herein incorporated by reference in their entirety. As no other mRNA was found which contained the target sequence, an siRNA duplex was synthesized to target this sequence (Dharmacon Research, Inc., Lafayette, CO).

[0107] The siRNA duplex had the following sense and antisense strands.

sense:

5'-accucaccaaggccagcacTT-3' (SEQ ID NO: 77).

antisense:

5'-gugcuggccuuggugagguTT-3' (SEQ ID NO: 78).

[0108] Together, the siRNA sense and antisense strands formed a 19 nt doublestranded siRNA with TT 3' overhangs (shown in bold) on each strand. This siRNA was termed "Candidate 5" or "Cand5." Other siRNA which target human VEGF mRNA were designed and tested as described for Cand5.

[0109] An siRNA targeting the following sequence in green fluorescent protein (GFP) mRNA was used as a nonspecific control: GGCTACGTCCAGCGCACC (SEQ ID NO: 79). The siRNA was purchased from Dharmacon (Lafayette, CO).

[0110] *siRNA Transfection and Hypoxia Induction In Vitro* - Human cell lines (293; HeLa and ARPE19) were separately seeded into 24-well plates in 250 microliters of complete DMEM medium one day prior to transfection, so that the cells were ~50% confluent at the time of transfection. Cells were transfected with 2.5 nM Cand5 siRNA, and with either no siRNA or 2.5 nM non-specific siRNA (targeting GFP) as controls. Transfections were performed in all cell lines with the "Transit TKO Transfection" reagent, as recommended by the manufacturer (Mirus).

[0111] Twenty four hours after transfection, hypoxia was induced in the cells by the addition of desferoxamide mesylate to a final concentration of 130 micromolar in each well. Twenty four hours post-transfection, the cell culture medium was removed from all wells, and a human VEGF ELISA (R&D systems, Minneapolis, MN) was performed on the culture medium as described in the Quantikine human VEGF ELISA protocol available from the manufacturer, the entire disclosure of which is herein incorporated by reference.

[0112] As can be seen in Fig. 1, RNAi degradation induced by Cand5 siRNA significantly reduces the concentration of VEGF produced by the hypoxic 293 and HeLa cells. There was essentially no difference in the amount of VEGF produced by hypoxic cells treated with either no siRNA or the non-specific siRNA control. Similar results were also seen with human ARPE19 cells treated under the same conditions. Thus, RNA interference with VEGF-targeted siRNA disrupts the pathogenic up-regulation of VEGF in human cultured cells *in vitro*.

[0113] The experiment outlined above was repeated on mouse NIH 3T3 cells using a mouse-specific VEGF siRNA (see Example 6 below), and VEGF production was quantified with a mouse VEGF ELISA (R&D systems, Minneapolis, MN) as described in the Quantikine mouse VEGF ELISA protocol available from the manufacturer, the entire disclosure of which is herein incorporated by reference. Results similar to those reported in Fig. 1 for the human cell lines were obtained.

Example 2 - Effect of Increasing siRNA Concentration on VEGF Production in Human Cultured Cells

[0114] The experiment outlined in Example 1 was repeated with human 293, HeLa and ARPE19 cells using a range of siRNA concentrations from 10 nM to 50 nM. The ability of the Cand5 siRNA to down-regulate VEGF production increased moderately up to approximately 13 nM siRNA, but a plateau effect was seen above this concentration. These results highlight the catalytic nature of siRNA-mediated RNAi degradation of mRNA, as the plateau effect appears to reflect VEGF production from the few cells not transfected with the siRNA. For the majority of cells which had been transfected with the siRNA, the increased VEGF mRNA production induced by the hypoxia is outstripped by the siRNA-induced degradation of the target mRNA at siRNA concentrations greater than about 13 nM.

Example 3 - Specificity of siRNA Targeting

[0115] NIH 3T3 mouse fibroblasts were grown in 24-well plates under standard conditions, so that the cells were ~50% confluent one day prior to transfection. The human VEGF siRNA Cand5 was transfected into a NIH 3T3 mouse fibroblasts as in Example 1. Hypoxia was then induced in the transfected cells, and murine VEGF concentrations were measured by ELISA as in Example 1.

[0116] The sequence targeted by the human VEGF siRNA Cand5 differs from the murine VEGF mRNA by one nucleotide. As can be seen in Fig. 2, the human VEGF siRNA has no affect on the ability of the mouse cells to up-regulate mouse VEGF after hypoxia. These results show that siRNA induced RNAi degradation is sequence-specific to within a one nucleotide resolution.

Example 4 - *In Vivo* delivery of siRNA to Murine Retinal Pigment Epithelial Cells

[0117] VEGF is upregulated in the retinal pigment epithelial (RPE) cells of human patients with age-related macular degeneration (ARMD). To show that functional siRNA can be delivered to RPE cells *in vivo*, GFP was expressed in mouse retinas with a recombinant adenovirus, and GFP expression was silenced with siRNA. The experiment was conducted as follows.

[0118] One eye from each of five adult C57/Black6 mice (Jackson Labs, Bar Harbor, ME) was injected subretinally as described in Bennett et al. (1996), *supra.*, with a mixture containing ~1x10⁸ particles of adenovirus containing eGFP driven by the CMV promoter and 20 picomoles of siRNA targeting eGFP conjugated with transit TKO reagent (Mirus).

[0119] As positive control, the contralateral eyes were injected with a mixture containing ~1x10⁸ particles of adenovirus containing eGFP driven by the CMV promoter and 20 picomoles of siRNA targeting human VEGF conjugated with transit

TKO reagent (Mirus). Expression of GFP was detected by fundus ophthalmoscopy 48 hours and 60 hours after injection. Animals were sacrificed at either 48 hours or 60 hours post-injection. The eyes were enucleated and fixed in 4% paraformaldehyde, and were prepared either as flat mounts or were processed into 10 micron cryosections for fluorescent microscopy.

5 [0120] No GFP fluorescence was detectable by ophthalmoscopy in the eyes which received the siRNA targeted to GFP mRNA in 4 out of 5 mice, whereas GFP fluorescence was detectable in the contralateral eye which received the non-specific control siRNA. A representative flat mount analyzed by fluorescence microscopy showed a lack of GFP fluorescence in the eye which received GFP siRNA, as compared to an eye that received the non-specific control siRNA. Cryosections of another retina showed that the recombinant adenovirus efficiently targets the RPE cells, and when the

10 [0121] While there is some GFP fluorescence detectable by fluorescence microscopy in eyes that received siRNA targeted to GFP mRNA, the fluorescence is greatly suppressed as compared to controls that received non-specific siRNA. These data demonstrate that functional siRNA can be delivered *in vivo* to RPE cells.

15 **Example 5 *In Vivo* Expression and siRNA-Induced RNAi Degradation of Human VEGF in Murine Retinas**

[0122] In order to demonstrate that siRNA targeted to VEGF functioned *in vivo*, an exogenous human VEGF expression cassette was delivered to mouse RPE cells via an adenovirus by subretinal injection, as in Example 4. One eye received Cand5 siRNA, and the contralateral eye received siRNA targeted to GFP mRNA. The animals were sacrificed 60 hours

20 post-injection, and the injected eyes were removed and snap frozen in liquid N₂ following enucleation. The eyes were then homogenized in lysis buffer, and total protein was measured using a standard Bradford protein assay (Roche, Germany). The samples were normalized for total protein prior to assaying for human VEGF by ELISA as described in Example 1.

25 [0123] The expression of VEGF was somewhat variable from animal to animal. The variability of VEGF levels correlated well to those observed in the GFP experiments of Example 4, and can be attributed to some error from injection to injection, and the differential ability of adenovirus to delivery the target gene in each animal. However, there was a significant attenuation of VEGF expression in each eye that received VEGF siRNA, as compared to the eyes receiving the non-specific control siRNA (Figure 4). These data indicate that the Cand5 siRNA was potent and effective in silencing human VEGF expression in murine RPE cells *in vivo*.

30 **Example 6 - Inhibition of Choroidal Neovascularization in the Mouse CNV Model**

[0124] There is evidence that choroidal neovascularization in ARMD is due to the upregulation of VEGF in the RPE cells. This human pathologic condition can be modeled in the mouse by using a laser to burn a spot on the retina ("laser photo-coagulation" or "laser induction"). During the healing process, VEGF is believed to be up-regulated in the RPE cells of the burned region, leading to re-vascularization of the choroid. This model is called the mouse choroidal neovascularization ("CNV") model.

35 [0125] For rescue of the mouse CNV model, a mouse siRNA was designed that incorporated a one nucleotide change from the human "Cand5" siRNA from Example 1. The mouse siRNA specifically targeted mouse VEGF mRNA at the sequence AAACCUCACCAAAGCCAGCAC (SEQ ID NO: 80). Other siRNA that target mouse VEGF were also designed and tested. The GFP siRNA used as a nonspecific control in Example 1 was also used as a non-specific control here.

40 [0126] Twenty four hours after laser induction, one eye from each of eleven adult C57/Black6 mice (Jackson Labs, Bar Harbor, ME) was injected subretinally with a mixture containing ~1x10⁸ particles of adenovirus containing LacZ driven by the CMV promoter and 20 picomoles of siRNA targeting mouse VEGF conjugated with transit TKO reagent (Mirus), as in Example 4. As a control, contralateral eyes received a mixture containing ~1x10⁸ particles of adenovirus containing LacZ driven by the CMV promoter and 20 picomoles of siRNA targeting GFP conjugated with transit TKO reagent (Mirus).

45 [0127] Fourteen days after the laser treatment, the mice were perfused with fluorescein and the area of neovascularization was measured around the burn spots. Areas of the burn spots in the contra-lateral eye were used as a control. The site of neovascularization around the burn spots in animals that received siRNA targeting mouse VEGF was, on average, 1/4 the area of the control areas. These data support the use of VEGF-directed siRNA (also called "anti-VEGF siRNA") for therapy of ARMD.

50 **Example 7 - Generation of an Adeno-Associated Viral Vector for Expression of siRNA**

55 [0128] A "cis-acting" plasmid for generating a recombinant AAV vector for delivering an siRNA of the invention was generated by PCR based subcloning, essentially as described in Samulski R et al. (1987), *supra*. The cis-acting plasmid was called "pAAVsiRNA."

[0129] The *rep* and *cap* genes of psub201 were replaced with the following sequences in this order: a 19 nt sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and a 19 nt antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter. A schematic representation of pAAVsiRNA is given in Fig. 5.

[0130] A recombinant AAV siRNA vector was obtained by transfecting pAAVsiRNA into human 293 cells previously infected with EI-deleted adenovirus, as described in Fisher KJ et al. (1996), *supra*. The AAV *rep* and *cap* functions were provided by a trans-acting plasmid pAAV/Ad as described in Samulski R et al. (1989), *supra*. Production lots of the recombinant AAV siRNA vector were titered according to the number of genome copies/ml, as described in Fisher KJ et al. (1996), *supra*.

Example 8 - VEGF-Directed siRNA Inhibits Experimental Choroidal Neovascularization

[0131] The ability of murine VEGF-directed siRNA to inhibit experimental laser-induced choroidal neovascularization (CNV) in mice was tested as follows.

[0132] The retinas of adult female C57BL/6 mice were laser photocoagulated using an 810 nm diode laser (75 μ m, 140 mw, 0.10 seconds) (OcuLight Six; IRIS Medical, Mountain View, CA). Three laser spots were applied to both eyes of each mouse. Thirty-six hours following laser photocoagulation, an siRNA targeted to mouse VEGF ("mVEGF1.siRNA") was delivered subretinally or intravitreally to one eye of each mouse. For subretinal injection, the siRNA was conjugated with Transit TKO transfection reagent (Mirus) and mixed with recombinant adenovirus (rAdenovirus). For intravitreal injection, the siRNA was delivered in the absence of transfection reagent and rAdenovirus. As a control, the contralateral eyes of each mouse received subretinal or intravitreal injections of identical formulations with an siRNA targeted to GFP ("GFP1.siRNA"), which has no homology to mouse VEGF.

[0133] Fourteen days following laser treatment, all animals were perfused with high molecular weight FITC-dextran, choroidal flat mounts were prepared as described above, and the flat mounts were photographed and analyzed microscopically in a masked fashion. The area of CNV in each flat mount was measured with Openlab software (Improvision, Boston, MA). The mean areas of CNV in eyes treated with mVEGF1.siRNA were significantly smaller than those areas from GFP1.siRNA-treated eyes for both subretinal (Fig. 6A; $P < 0.003$) and intravitreal (Fig. 6B; $P < 0.04$) delivery.

[0134] In a second experiment, the retinas of adult female C57BL/6 mice were laser photocoagulated as described above, and the animals were divided into control and test groups. One day following laser photocoagulation, phosphate buffered saline was delivered intravitreally to the animals of the control group, which were perfused with dextran-fluorescein 14 days after laser treatment. Choroidal flat mounts were then prepared and the areas of CNV in each flat mount were measured as above.

[0135] Fourteen days following laser photocoagulation, mVEGF1.siRNA was delivered by intravitreal injection into one eye of each mouse in the test group. Contralateral eyes were injected with GFP1.siRNA as a control. The test group animals were perfused with high molecular weight dextran-fluorescein 21 days after laser treatment. Choroidal flat mounts were then prepared and the areas of CNV in each flat mount were measured, as above.

[0136] In this latter experiment, the anti-VEGF siRNA was administered during CNV growth, as opposed to before CNV growth, and thus is more representative of the condition of human patients presenting with wet AMD. As can be seen from Fig. 6, the mean areas of CNV in mVEGF1.siRNA-treated eyes were significantly smaller than those areas measured in GFP1.siRNA-treated eyes (Fig. 6C; $P < 0.05$). The mean areas of CNV in mVEGF1.siRNA-treated eyes at day 21 and control ("PBS") eyes at day 14 were not significantly different (Fig. 6C; $P = 0.469$).

[0137] The results of these experiments indicate that age-related macular degeneration can be treated with anti-VEGF siRNA.

Example 9 - In Vivo RNA Interference of Human VEGF Induced by anti-VEGF siRNA in Murine RPE Cells

[0138] The ability of Cand5 siRNA to induce RNAi of VEGF *in vivo* over time was evaluated as follows.

[0139] AAV.CMV.VEGF, which expresses human VEGF from an adeno-associated viral vector, was generously provided by Dr. A. Auricchio. AAV.CMV.VEGF was injected subretinally and bilaterally in eyes of five C57BL/6 mice. Twenty-eight days after injection of AAV.CMV.VEGF, Cand5 siRNA was delivered by intravitreal injection into one eye and control GFP1.siRNA was delivered by intravitreal injection in the contralateral eye of each animal.

[0140] At day 0 (pre-siRNA injection), and at 6, 10 and 14 days after siRNA injection, the mice were sacrificed and the eyes were snap frozen in liquid nitrogen following enucleation. The eyes were then homogenized in lysis buffer (Roche, Basel, Switzerland), and total protein was measured using a Bradford assay, as in Example 5 above. Two mice were used for the 0 day time point ($n=2$), and three mice each were used for the 6, 10 and 14 day time points ($n=3$). The samples were normalized for total protein prior to assaying for human VEGF by ELISA, according to the manufacturer's recommendations (R&D systems, Minneapolis, Minnesota). Percent of VEGF (%VEGF) for each mouse was calculated as the concentration of VEGF ("[VEGF]") in the eye injected with Cand5 divided by the [VEGF] in the eye

injected with GFP1.siRNA, multiplied by 100.

[0141] As can be seen from Figure 7, a single injection of Cand5 induced an RNAi-mediated decrease in VEGF levels of approximately 70% by day 6 post-siRNA injection, with a reduction in VEGF production of approximately 35% continuing through at least day 14 post-siRNA injection. These results indicate that siRNA directed against human VEGF is capable of inducing RNAi of human VEGF *in vivo* for a sustained period of time.

Example 10 - In Vivo RNA Interference of VEGF in Monkeys with Anti-VEGF siRNA

[0142] It is expected that 10 naïve cynomolgus monkeys (*Macaca fascicularis*) will be subjected to laser photocoagulation of the retina in both eyes to induce choroidal neovascularization ("CNV"). The following represents the intended experimental plan to evaluate the ability of Cand5 siRNA to reduce the area of CNV in the monkeys. As the VEGF RNA sequence targeted by Cand5 is identical in both *Homo sapiens* and *M. fascicularis*, Cand5 is expected to induce RNAi of *M. fascicularis* VEGF RNA.

[0143] The experiment will be carried out by Sierra Biomedical ("SBI"), 587 Dunn Circle, Sparks, NV, 89431, in accordance with SBI's Standard Operating Procedures. All monkeys will undergo a full pre-study health screen consisting of a physical examination, hematologic and ophthalmologic evaluations, serum chemistry, and electroretinography ("ERG"). A pre-study fluorescein angiography of the monkeys' eyes will also be performed, and intraocular pressure will be measured pre-study and at two additional time points during the study period.

[0144] On day zero, both eyes of all 10 monkeys will be laser photocoagulated to induce choroidal neovascularization. The animals will receive twice-daily cageside observations and a once-daily qualitative assessment of food consumption throughout the experiment. At 14 days post laser induction, the monkeys will receive intravitreally one 50 microliter dose of a Treatment or Control formulation (see below) in each eye, in a randomized, double-blind fashion. For example, a given animal could receive a Treatment 1 dose in the right eye, and a Control dose in the left eye. Another animal could receive a Treatment 1 dose in the right eye, and a Treatment 3 dose in the left eye. It is expected that four eyes will receive each formulation, for a total of 1 control and four treatment groups of four eyes each.

[0145] The formulations will be: Control - balanced saline solution ("BSS") alone; Treatment 1 - 1 mg/ml Cand5 in BSS; Treatment 2 - 2.5 mg/ml Cand5 in BSS; Treatment 3 - 5 mg/ml Cand5 in BSS; and Treatment 4 - 10 mg/ml Cand5 in BSS. Prior to injection, it is expected that the pH, osmolarity, and the absorbance at 260 nm of each formulation will be measured.

[0146] After laser induction, a fluorescein angiography will be performed on both eyes of each monkey weekly up through the seventh week after laser induction. The monkeys will then be sacrificed, and a complete necropsy will be performed with a full tissue collection (~45 tissues including a vitreous sample) and histopathologic evaluation of the collected tissues. An ERG will be taken pre-necropsy.

[0147] It is expected that the laser-induced areas of CNV will be reduced upon administration of the Cand5 siRNA, with the CNV area decreasing with increasing dose of Can5. However, a plateau effect such as is described above in Example 2 may be observed. The Cand5 siRNA is not expected to effect any other organ or tissue except the choroid in the eye.

SEQUENCE LISTING

[0148]

<110> The Trustees of the University of Pennsylvania
Tolentino, Michael J.
Reich, Samuel Jotham

<120> Compositions and Methods for siRNA
Inhibition of Angiogenesis

<130> 43826-1 PC

<150> US 60/398,417

<151> 2002-07-24

<150> US 10/294,228

<151> 2002-11-14

<160> 864

EP 1 578 933 B9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2250

5

<212> DNA

<213> Mus musculus

<400> 1

10

```

tgagccaggc tggcaggaag gagcctccct cagggtttcg ggaaccagac ctctcaccgg 60
aaagaccgat taaccatgtc accaccacgc catcatcgtc accgttgaca gaacagtcct 120
taatccagaa agcctgacat gaaggaagag gagactcttc gaggagcact ttgggtccgg 180
agggcgagac tccggcagac gcattcccgg gcaggtgacc aagcacggtc cctcgtggga 240
ctggattcgc cattttctta tatctgctgc taaatcgcca agcccggaag attagggttg 300
15 tttctgggat tcctgtagac acaccaccc acatacacac atatatatat attatatata 360
taaataaata tatatgtttt atataataaa tatatatata ttcttttttt taaattaact 420
ctgctaattg tattgggtgc ttcactggat atgtttgact gctgtggact tgtgttggga 480
ggaggatgtc ctcaactcga tgccgacatg ggagacaatg ggatgaaagg cttcagtggtg 540
gtctgagaga ggccgaagtc cttttgcctg ccggggagca agcaaggcca gggcacgggg 600
20 gcacattggc tcacttccag aaacacgaca aaccattcc tggccctgag tcaagaggac 660
agagagacag atgatgacac agaaagagat aaagatgccg gttccaacca gaagtttggg 720
gagcctcagg acatggcatg ctttgtggat ccccatgata gtctacaaaa gcaccccgcc 780
cctctgggca ctgcctggaa gaatcgggag cctggccagc cttcagctcg ctctccact 840
tctgaggggc ctaggaggcc tcccacaggt gtcccggcaa gagaagacac ggtggtggaa 900
25 gaagaggcct ggtaatggcc cctcctcctg ggacccttc gtctctctct taccocact 960
cctgggtaca gccacggagg accttgtgtg atcagaccat tgaaaccact aattctgtcc 1020
ccaggagact tggctctgtg tgtgagtggc ttacccttcc tcatcttccc ttccaaggc 1080
acagagcaat ggggcaggac ccgcaagccc ctcacggagg cagagaaaag agaaagtgtt 1140
ttatatacgg tacttattta atagcccttt ttaattagaa ataaaacag ttaatttaat 1200
30 taaagagtag ggtttttttc agtattcttg gttaatatit aatttcaact atttatgaga 1260
tgtatctctc gctctctctt atttgtactt atgtgtgtgt gtgtgtgtgt gtgtgtgtgt 1320
gtgtgtgtgt gtatgaaatc tgtgtttcca atctctctct cccagatcgg tgacagtcac 1380
tagcttgtcc tgagaagata ttttaattttg ctaacactca gctctgccct cccttgtccc 1440
caccacacat tcctttgaaa taaggtttca atatacattt acatactata tatatatttg 1500
35 gcaacttgtg tttgtatata aatataatata tatatatatg tttatgtata tatgtgattc 1560
tgataaaaata gacattgcta ttctgttttt tatatgtaaa aacaaaacaa gaaaaataga 1620
gaattctaca tactaaatct ctctcctttt ttaattttaa tttttgttat cattatttta 1680
ttggtgctac tgtttatccg taataattgt gggggaaaaa gatattaaca tcacgtcttt 1740
gtctctagag cagttttccg agatattccg tagtacatat ttatttttaa acagcaacaa 1800
40 agaaatacag atatatctta aaaaaaaagc attttgtatt aaagaattga attctgatct 1860

```

45

```

caaagctctc cctggctctc cttctctctc tgggccctcc tgtctcgctt tccctcctcc 1920
tttggggtac atagtttttg tcttaggttt gagaagcagt ccctggagta gaatatgggg 1980
tgacccatcc attcctgggc ggaggggaga tggtccttt gccagggtc ctcacactac 2040
gtggtactct gttccttgtc agacaaggat gggggcatgt ctccagggtc taactggaga 2100
tcggagagag ctggttgctg cagctggcca ggatttgggc atgccgggga catgggaggc 2160
tgtgagccca gcatgcagtt tacttctggg tgctaaatgg aagagtccag taaaaagagt 2220
50 cttgcccatg ggattccatt ccgctttgtg

```

<210> 2

<211> 444

55

<212> DNA

<213> Homo sapiens

<400> 2

EP 1 578 933 B9

5
atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta cctccacat 60
gccaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
aatgtgaca agccgaggcg gtga 444

10
<210> 3
<211> 576
<212> DNA
<213> Homo sapiens

15
<400> 3

20
atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta cctccacat 60
gccaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
25
aatccctgtg ggcttctgctc agagcggaga aagcatttgt ttgtacaaga tccgagacg 480
tgtaaatgtt cctgcaaaaa cacagactcg cgttgaagg cgaggcagct tgagttaaac 540
gaacgtactt gcagatgtga caagccgagg cggatga 576

30
<210> 4
<211> 648
<212> DNA
<213> Homo sapiens

35
<400> 4

40
atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta cctccacat 60
gccaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240
atgcatgacg ggggctgctg caatgacgag ggctggagt gtgtgcccac tgaggagtcc 300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420
45
aaaaaatcag ttcgaggaaa gggaaagggg caaaaacgaa agcgcaagaa atcccggat 480
aagtccctga gcgttccctg tggccttgc tcagagcggg gaaagcattt gtttgtacaa 540
gatccgcaga cgtgtaaatg ttcttgcaaa aacacagact cgcgttgcaa ggcgaggcag 600
cttgagttaa acgaacgtac ttgcagatgt gacaagccga ggcggtga 648

50
<210> 5
<211> 670
<212> DNA
<213> Homo sapiens

55
<400> 5

EP 1 578 933 B9

gccttgctgc tctacctcca ccatgccaaag tgggtcccagg ctgcacccat ggcagaagga 60
 ggagggcaga atcatcacga agtgggtgaag ttcattgatg tctatcagcg cagctactgc 120
 catccaatcg agaccctggg ggacatcttc caggagtacc ctgatgagat cgagtacatc 180
 5 ttcaagccat cctgtgtgcc cctgatgcga tgcgggggct gctgcaatga cgagggcctg 240
 gagtgtgtgc ccaactgagga gtccaacatc accatgcaga ttatgcggat caaacctcac 300
 caaggccagc acataggaga gatgagcttc ctacagcaca acaaatgtga atgcagacca 360
 aagaaggata gagcaagaca agaaaaaaaaa tcagttcgag gaaagggaaa ggggcaaaaa 420
 cgaaagcgca agaaatcccg gtataagtcc tggagcgttt acgttgggtgc ccgctgctgt 480
 10 ctaatgccct ggagcctccc tggcccccat ccctgtgggc cttgctcaga gcggagaaaag 540
 catttgtttg tacaagatcc gcagacgtgt aaatgttcct gcaaaaacac agactcgcgt 600
 tgcaaggcga ggcagcttga gttaaacgaa cgtacttgca gatgtgacaa gccgagggcg 660
 tgatgaatga 670

15 <210> 6
 <211> 1137
 <212> DNA
 <213> Homo sapiens

20 <400> 6

atgctcattg tccagactgg ggtcagatca gcaaacaag ggcctctgat ggtgattggt 60
 gaatattgca aatatggaaa tctatccaac tacctcaaga gcaaatatga cttatTTTTT 120
 25 ctcgacaagg atgtggcatc acacatggag cgtaagaaaag aaaaaatgga gccaggcctg 180
 gaacaaggca agaaaccaa actagatagc atcaccagca gcgagagctt tgggagctcc 240
 aagtttcagg aagataaaaa tctgagtgat gttgaggaag aggaggattc tgatggtttc 300
 taccaggagc ccatcactat ggaagatctg atttcttaca gttttcaagt ggccagaggc 360
 atgaagtctc tgtcttccag aaagtgcatt cattgggacc tggcagcaag aaacattctt 420
 30 ttatctgaga acaatgtggt gaagatttgt gatTTTggcc ttgcccagga tatttacaag 480
 aacgccgatt atgtgagaaa aggaggtggg tctccatacc caggagtgca aatggatgag 540
 cacttctgca gttgcctgag ggaagccatg aggatgagag ctgctgagta ctccactcct 600
 gaaatctatc agatcatgct ggactgcagg cacaaagacc caaaagaaag gccaaagatt 660
 gcagaacttg tggaaaaact agaaaatagt gggtttacat actcaactcc tgccttctct 720
 gaggacttct tcaaggaagg tatttcagct cccaagttta gttcaggaag ctctgatgat 780
 35 gtcagatacg taaatgcttt caagttcatg agcctggaaa gaatcaaac ctttgaagaa 840
 cttttgcaa atgccacctc catgtttgat gactaccagg gggacagcag cgctctgctg 900
 gcctctccca tgctgaagcg cttcaccagg actgacagca aaccaaggc ctcgctcaag 960
 attgacttga gactaactag caaaagtaag aagtcggggc tttctgatgt cagcaggccc 1020
 agtttctgcc attccaacag tgggcacatc agcaaaggca agggcagggt cacctacgac 1080
 40 aacgccgagc tggaaaggaa gacggcgtgc tgetccccgc ccctctggga gttgtag 1137

45 <210> 7
 <211> 5830
 <212> DNA
 <213> Homo sapiens

50 <400> 7

55

EP 1 578 933 B9

actgagtccc gggacccccg gagagcggtc agtgtgtggt cgctgcgttt cctctgcctg 60
cgccgggcat cacttgcgcg ccgcagaaag tccgtctggc agcctggata tcctctccta 120
ccggcaccocg cagacgcccc tgcagccgcc ggtcggcgcc cgggctccct agccctgtgc 180
5 gctcaactgt cctgcgctgc ggggtgccgc gagttccacc tccgcgcctc cttctctaga 240
caggcgctgg gagaaagaac cggctcccga gttctgggca tttcgcccg gctcgaggtgc 300
aggatgcaga gcaagggtgct gctggccgtc gccctgtggc tctgcgtgga gacccgggccc 360
gcctctgtgg gtttgccctag tgtttctctt gatctgceca ggctcagcat acaaaaagac 420
atacttacia ttaaggctaa tacaactctt caaattactt gcaggggaca gagggacttg 480
10 gactggcttt ggccaataa tcagagtggc agtgagcaaa ggggtggagg gactgagtgc 540
agcgatggcc tcttctgtaa gacactcaca attccaaaag tgatcggaaa tgacactgga 600
gcctacaagt gcttctaccg ggaaactgac ttggcctcgg tcatttatgt ctatgttcaa 660
gattacagat ctccatttat tgcttctgtt agtgaccaac atggagtcgt gtacattact 720
gagaacaaaa acaaaaactgt ggtgattcca tgtctcgggt ccatttcaa tctcaacgtg 780

15

20

25

30

35

40

45

50

55

EP 1 578 933 B9

	tcactttgtg	caagataccc	agaaaagaga	tttgttctcg	atggtaacag	aatttcctgg	840
	gacagcaaga	agggctttac	tattcccagc	tacatgatca	gctatgctgg	catggtcttc	900
	tgtgaagcaa	aaattaatga	tgaaagtac	cagtctatta	tgtacatagt	tgtcgttgta	960
	gggtatagga	tttatgatgt	ggttctgagt	ccgtctcatg	gaattgaact	atctgttgga	1020
5	gaaaagcttg	tcttaaattg	tacagcaaga	actgaactaa	atgtggggat	tgacttcaac	1080
	tggaataacc	cttcttcgaa	gcatcagcat	aagaaacttg	taaaccgaga	cctaaaaacc	1140
	cagtctggga	gtgagatgaa	gaaatttttg	agcaccttaa	ctatagatgg	tgtaaccggg	1200
	agtgaccaag	gattgtacac	ctgtgcagca	tccagtgggc	tgatgaccaa	gaagaacagc	1260
	acatttgtca	gggtccatga	aaaacctttt	gttgcttttg	gaagtggcat	ggaatctctg	1320
10	gtggaagcca	cgggtggggga	gcgtgtcaga	atccctgcga	agtaccttgg	ttaccaccac	1380
	ccagaaataa	aatggtataa	aaatggaata	ccccttgagt	ccaatcacac	aattaaagcg	1440
	gggcatgtac	tgacgattat	ggaagtgagt	gaaagagaca	caggaaatta	cactgtcatc	1500
	cttaccaatc	ccatttcaaa	ggagaagcag	agccatgtgg	tctctctggt	tgtgtatgtc	1560
	ccaccccaga	ttggtgagaa	atctctaate	tctctgtggg	attcctacca	gtacggcacc	1620
	actcaaacgc	tgacatgtac	ggtctatgcc	attcctcccc	cgcacacat	ccactggtat	1680
15	tggcaatggg	aggaagagtg	cggcaacgag	cccagccaag	ctgtctcagt	gacaaacca	1740
	tacccttgtg	aagaatggag	aagtgtggag	gacttccagg	gaggaaataa	aattgaagtt	1800
	aataaaaaatc	aatttgcctc	aattgaagga	aaaaacaaaa	ctgtaagtac	ccttgtttatc	1860
	caagcggcaa	atgtgtcagc	tttgtacaaa	tgtgaagcgg	tcaacaaagt	cgggagagga	1920
	gagaggggta	tctccttcca	cgtgaccagg	ggtcctgaaa	ttactttgca	acctgacatg	1980
20	cagcccactg	agcaggagag	cgtgtctttg	tggtgcaactg	cagacagatc	tacgtttgag	2040
	aacctcacat	ggtacaagct	tgccccacag	cctctgccaa	tccatgtggg	agagttgccc	2100
	acacctgttt	gcaagaactt	ggatactctt	tggaaattga	atgccaccat	gttctctaat	2160
	agcacaatg	acattttgat	catggagctt	aagaatgcat	ccttgccagg	ccaaggagac	2220
	tatgtctgcc	ttgctcaaga	caggaagacc	aagaaaagac	attgctgtgt	caggcagctc	2280
	acagtcctag	agcgtgtggc	acccacgac	acaggaaacc	tggagaatca	gacgacaagt	2340
25	attggggaaa	gcatcgaagt	ctcatgcacg	gcatctggga	atccccctcc	acagatcatg	2400
	tggttttaaag	ataatgagac	ccttgttagaa	gactcaggca	ttgtattgaa	ggatgggaa	2460
	cggaaacctca	ctatccgcag	agtgaggaag	gaggacgaag	gcctctacac	ctgccaggga	2520
	tgcagtgctc	ttggctgtgc	aaaagtggag	gcatttttca	taatagaagg	tgcccaggaa	2580
	aagacgaact	tggaaatcat	tattctagta	ggcaccggcg	tgattgccat	gttctctgg	2640
30	ctacttcttg	tcacatcctc	acggaccggt	aagcgggcca	atggagggga	actgaagaca	2700
	tgctacttgt	ccatcgtcat	ggatccagat	gaactcccat	tggatgaaca	ttgtgaacga	2760
	ctgccttatg	atgccagcaa	atgggaattc	cccagagacc	ggctgaagct	aggtaagcct	2820
	cttggccgtg	gtgcctttgg	ccaagtgatt	gaagcagatg	cctttggaat	tgacaagaca	2880
	gcaacttgca	ggacagtagc	agtcaaaatg	ttgaaagaag	gagcaacaca	cagtgagcat	2940
	cgagctctca	tgtctgaact	caagatcctc	attcatattg	gtcaccatct	caatgtggtc	3000
35	aaccttctag	gtgcctgtac	caagccagga	gggcccactca	tgggtattgt	ggaattctgc	3060
	aaatttggaa	acctgtccac	ttacctgagg	agcaagagaa	atgaatttgt	cccctacaag	3120
	accaaagggg	cagcattccg	tcaagggaaa	gactacgttg	gagcaatccc	tgtggatctg	3180
	aaacggcgct	tggacagcat	caccagtagc	cagagctcag	ccagctctgg	atltgtggag	3240
	gagaagtccc	tcagtgatgt	agaagaagag	gaagctcctg	aagatctgta	taaggacttc	3300
	ctgaccttgg	agcatctcat	ctgttacagc	ttccaagtgg	ctaagggcat	ggagttcttg	3360
40	gcatcgcgaa	agtgtatcca	cagggacctg	gcggcacgaa	atatectctt	atcggagaag	3420
	aacgtgggta	aaatctgtga	ctttggcttg	gcccgggata	tttataaaga	tccagattat	3480
	gtcagaaaag	gagatgctcg	cctccctttg	aaatggatgg	cccagaaac	aatttttgac	3540
	agagtgtaca	caatccagag	tgacgtctgg	tcttttgggtg	ttttgctgtg	ggaaatattt	3600
	tocttaggtg	cttctccata	tcttgggta	aagattgatg	aagaattttg	taggcgattg	3660
45	aaagaaggaa	ctagaatgag	ggcccctgat	tatactacac	cagaaatgta	ccagaccatg	3720
	ctggactgct	ggcacgggga	gcccagtcag	agaccacgct	tttcagagtt	ggtggaacat	3780
	ttgggaaatc	tcttgcaagc	taatgctcag	caggatggca	aagactacat	tgttcttccg	3840
	atatcagaga	ctttgagcat	ggaagaggat	tctggactct	ctctgcctac	ctcaccctgt	3900
	tcoctgtatg	aggaggagga	agtatgtgac	cccaaattcc	attatgacaa	cacagcagga	3960
	atcagtcagt	atctgcagaa	cagtaagcga	aagagccggc	ctgtgagtgt	aaaaacattt	4020
50	gaagatatcc	cgttagaaga	accagaagta	aaagtaatcc	cagatgacaa	ccagacggac	4080
	agtggtatgg	ttcttgccctc	agaagagctg	aaaactttgg	aagacagaac	caaattatct	4140
	ccatcttttg	gtggaatggg	gcccagcaaa	agcagggagt	ctgtggcatc	tgaaggctca	4200
	aaccagacaa	gcggtacca	gtccggatat	cactccgatg	acacagacac	caccgtgtac	4260
	tccagtgagg	aagcagaact	tttaaagctg	atagagattg	gagtgcaaac	cggtagcaca	4320
	gccagattc	tccagcctga	ctcggggacc	acactgagct	ctcctcctgt	ttaaaaggaa	4380
55	gcatccacac	cccaactccc	ggacatcaca	tgagaggtct	gctcagattt	tgaagtgttg	4440

<210> 11
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <221> misc_RNA
 <222> (1) ... (19)
 <223> ribonucleotide
 10
 <221> misc feature
 <222> (20) ... (21)
 <223> deoxyribonucleotide
 15
 <400> 11
 ucaucacgaa guggugaagt t 21
 20
 <210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> Targeting sequence
 <221> misc_RNA
 <222> (1) ... (19)
 <223> ribonucleotides
 30
 <221> misc feature
 <222> (20) ... (21)
 <223> deoxyribonucleotides
 35
 <400> 12
 cuucaccacu ucgugaugat t 21
 40
 <210> 13
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 45
 <400> 13
 aacgtacttg cagatgtgac a 21
 50
 <210> 14
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence
 <400> 14

EP 1 578 933 B9

gttcatggat gtctatcag 19

<210> 15
<211> 19
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 15
tcgagaccct ggtggacat 19

<210> 16
15 <211> 19
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 16
tgacgagggc ctggagtgt 19

25 <210> 17
<211> 19
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 17
35 tgacgagggc ctggagtgt 19

<210> 18
<211> 19
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 18
45 catcaccatg cagattatg 19

<210> 19
<211> 19
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 19
acctaccaa ggccagcac 19

<210> 20

EP 1 578 933 B9

<211> 19
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Targeting sequence

<400> 20
ggccagcaca taggagaga 19

10 <210> 21
<211> 19
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Targeting sequence

20 <400> 21
caaatgtgaa tgcagacca 19

<210> 22
<211> 19
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Targeting sequence

30 <400> 22
atgtgaatgc agaccaaag 19

<210> 23
<211> 19
35 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

40 <400> 23
tgcagaccaa agaaagata 19

<210> 24
<211> 19
45 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

50 <400> 24
agaaagatag agcaagaca 19

55 <210> 25
<211> 19
<212> DNA
<213> Artificial Sequence

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 25
gaaagataga gcaagacaa 19

<210> 26
<211> 19
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 26
gatagagcaa gacaagaaa 19

<210> 27
<211> 19
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 27
gacaagaaaa tcctgtgg 19

<210> 28
<211> 19
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 28
gaaaatccct gtggcctt 19

40 <210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

<400> 29
50 aatccctgtg gccttgct 19

<210> 30
<211> 19
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

EP 1 578 933 B9

<400> 30
tccctgtggg ccttgctca 19

5
<210> 31
<211> 19
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 31
gcatttggtt gtacaagat 19

15
<210> 32
<211> 19
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 32 19
gatccgcaga cgtgtaaata 19

25
<210> 33
<211> 19
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 33 19
atgttcctgc aaaaacaca 19

35
<210> 34
<211> 19
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

45
<400> 34 19
tgttcctgca aaaacacag 19

<210> 35
<211> 19
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Targeting sequence

55
<400> 35 19
aaacacagac tcgcgttgc 19

<210> 36
<211> 19
<212> DNA
<213> Artificial Sequence
5

<220>
<223> Targeting sequence

<400> 36 19
10 aacacagact cgcgttgca 19

<210> 37
<211> 19
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Targeting sequence

20 <400> 37
acacagactc gcgttgcaa 19

<210> 38
<211> 19
25 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence
30

<400> 38
cacagactcg cggtgcaag 19

<210> 39
<211> 19
35 <212> DNA
<213> Artificial Sequence

<220>
40 <223> Targeting sequence

<400> 39
ggcgaggcag cttgagtta 19

45 <210> 40
<211> 19
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

<400> 40
55 acgaacgtac ttgcagatg 19

<210> 41
<211> 19
<212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 41
cgaacgtact tgcagatgt 19

<210> 42
<211> 19
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 42
cgtacttgca gatgtgaca 19

20

<210> 43
<211> 19
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

30

<400> 43
gtggcccag gctgcaccc 19

35

<210> 44
<211> 19
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Targeting sequence

45

<400> 44
ggaggagggc agaatcatc 19

<210> 45
<211> 19
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Targeting sequence

55

<400> 45
gtgggaagt tcatgatg 19

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Targeting sequence
 <400> 46
 aatcatcacg aagtggtaa g 21
 5
 <210> 47
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 47
 aagttcatgg atgtctatca g 21
 15
 <210> 48
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 48
 aatcgagacc ctggtggaca t 21
 25
 <210> 49
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 49 21
 aatgacgagg gcctggagt g 21
 35
 <210> 50
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 50 21
 aacatcacca tgcagattat g 21
 45
 <210> 51
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 51 21

EP 1 578 933 B9

aaacctcacc aaggccagca c 21

<210> 52
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 52 21
aaggccagca cataggagag a 21

<210> 53
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 53 21
aacaaatgtg aatgcagacc a 21

<210> 54
25 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
30 <223> Targeting sequence

<400> 54
35 aaatgtgaat gcagaccaa g 21

<210> 55
40 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 55
45 aatgcagacc aaagaaagat a 21

<210> 56
50 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 56
55 aaagaaagat agagcaagac a 21

<210> 57

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 57
 aagaaagata gagcaagaca a 21
 10
 <210> 58
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 58
 20 aagatagagc aagacaagaa aat 23
 <210> 59
 <211> 23
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 59
 aagacaagaa aatccctgtg ggc 23
 <210> 60
 <211> 23
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40
 <400> 60
 aagaaaatcc ctgtggcct tgc 23
 <210> 61
 <211> 23
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 61
 aatccctgtg ggccttgctc aga 23
 55
 <210> 62
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 62
 5 aagcatttgt ttgtacaaga tcc 23

 <210> 63
 <211> 23
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 63
 15 aagatccgca gacgtgtaa tgt 23

 <210> 64
 <211> 23
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 64
 aaatgttctt gcaaaaacac aga 23

 <210> 65
 <211> 23
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 65
 aatgttctg caaaaacaca gac 23

 <210> 66
 <211> 23
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 45
 <400> 66
 50 aaaaacacag actcgcttg caa 23

 <210> 67
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 67
aaaacacaga ctgcggtgc aag 23

5 <210> 68
<211> 23
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 68
aaacacagac tcgcggtgca agg 23

15 <210> 69
<211> 23
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 69
aacacagact cgcggtgcaa ggc 23

25 <210> 70
<211> 23
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 70
aaggcgaggc agcttgagtt aaa 23

35 <210> 71
<211> 23
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 71
aacgaacgt actgcagat gtg 23

50 <210> 72
<211> 23
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 72
aacgaacgta cttgcagatg tga 23

<210> 73
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 73
 10 aagtgggcc aggctgcacc cat 23
 <210> 74
 <211> 23
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 74
 aaggaggagg gcagaatcat cac 23
 <210> 75
 <211> 23
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 75
 aagtggtgaa gttcatggat gtc 23
 <210> 76
 <211> 23
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 76
 aaaatccctg tggccttgc tca 23
 <210> 77
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <221> misc_RNA
 <222> (1)...(19)
 55 <223> ribonucleotides
 <221> misc feature
 <222> (20) ... (21)

<223> deoxyribonucleotides
 <400> 77
 5 accucaccaa ggccagcact t 21
 <210> 78
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10 <220>
 <223> Targeting sequence
 <221> misc_RNA
 15 <222> (1)...(19)
 <223> ribonucleotides
 <221> misc_feature
 <222> (20) ... (21)
 20 <223> deoxyribonucleotides
 <400> 78
 gugcuggccu uggugaggut t 21
 25 <210> 79
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Targeting sequence
 <400> 79
 35 ggctacgtcc agcgcacc 18
 <210> 80
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Targeting sequence
 <400> 80
 45 aaaccucacc aaagccagca c 21
 <210> 81
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 55 <400> 81
 ggcagaatca tcacgaagtg g 21
 <210> 82

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 82
 cctggtggac atctccagg a 21
 10
 <210> 83
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 83
 20 gagatcgagt acatctcaa g 21
 <210> 84
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 84
 tggagtgtgt gccactgag g 21
 <210> 85
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 85
 gagctccta cagcacaaca a 21
 <210> 86
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 86
 ttgctcagag cggagaaagc a 21
 55 <210> 87
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 87
 5 cacacactcg cgttgcaagg c 21

 <210> 88
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 88
 15 tcaccatgca gattatgcfg a 21

 <210> 89
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 89
 tagagcaaga caagaaaatc c 21

 <210> 90
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 90
 ccgcagacgt gtaaagtgc c 21

 <210> 91
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 91
 50 aagcaggcca gacctgcat c 21

 <210> 92
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 92
aatgcagggg ggaagcagcc c 21

5 <210> 93
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 93
aagcagccca taaatgtct t 21

15 <210> 94
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 94
aaatgtctt tgcctgaaat g 21

25 <210> 95
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 95
aatgtcttt gcctgaaatg g 21

35 <210> 96
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 96
aaatgtgag taaggaaagc g 21

<210> 97
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

55 <400> 97
aatgtgagt aaggaaagcg a 21

<210> 98
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 98
 10 aaggaaagcg aaaggctgag c 21
 <210> 99
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 99
 aaagcgaaag gctgagcata a 21
 <210> 100
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 100
 aagcgaaagg ctgagcataa c 21
 <210> 101
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 101
 aaaggctgag cataactaaa t 21
 <210> 102
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 102
 aaggctgagc ataactaaat c 21
 55 <210> 103
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 103
aactaatct gcctgtggaa g 21

<210> 104
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 104
aatctgcct gtgaagaaa t 21

20

<210> 105
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

<400> 105
aatctgcctg tggaagaaat g 21

30

<210> 106
<211> 21
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Targeting sequence

<400> 106
aagaaatggc aaacaattct g 21

40

<210> 107
<211> 21
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Targeting sequence

<400> 107
aatggcaaa caattctgca g 21

50

<210> 108
<211> 21
<212> DNA
<213> Artificial Sequence

55

<220>

<223> Targeting sequence
 <400> 108
 aatggcaaac aattctgcag t 21
 5
 <210> 109
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 109
 aaacaattct gcagtactt a 21
 15
 <210> 110
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 110
 aacaattctg cagtactt a 21
 25
 <210> 111
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 111
 aattctgcag tactttaacc t 21
 35
 <210> 112
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 112
 aacctgaac acagctcaag c 21
 45
 <210> 113
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 113

EP 1 578 933 B9

aacacagctc aagcaaacca c 21

5 <210> 114
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 114
aagcaaacca cactggcttc t 21

15 <210> 115
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

25 <400> 115
aaaccacact ggcttctaca g 21

30 <210> 116
<211> 21
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Targeting sequence

<400> 116
aaccacactg gcttctacag c 21

40 <210> 117
<211> 21
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

<400> 117
aaatatctag ctgtacctac t 21

50 <210> 118
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 118
aaatatctagc tgtacctact t 21

<210> 119

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 119
 aaagaagaag gaaacagaat c 21
 10
 <210> 120
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 120
 20 aagaagaagg aaacagaatc t 21
 <210> 121
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 121
 aagaaggaaa cagaatctgc a 21
 <210> 122
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40
 <400> 122
 aaggaaacag aatctgcaat c 21
 <210> 123
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 123
 aaacagaatc tgcaatctat a 21
 55
 <210> 124
 <211> 21
 <212> DNA
 <213> Artificial Sequence

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 124
aacagaatct gcaatctata t 21

<210> 125
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 125
aatctgcaat ctatatatt a 21

<210> 126
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 126
aatctatata ttattagtg a 21

<210> 127
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 127
aaatccccga aattatacac a 21

40 <210> 128
<211> 21
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

<400> 128
50 aatccccgaa attatacaca t 21

<210> 129
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

EP 1 578 933 B9

<400> 129
aaattataca catgactgaa g 21

5 <210> 130
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 130
aattatacac atgactgaag g 21

15 <210> 131
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 131
aaggaagga gctcgtcatt c 21

25 <210> 132
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 132
aaggagctc gtcattccct g 21

35 <210> 133
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 133
aacatcactg ttactttaa a 21

45 <210> 134
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

55 <400> 134
aaaaaagttt ccacttgaca c 21

<210> 135
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 135 21
 10 aaaaagtttc cacttgacac t 21
 <210> 136
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 136
 aaaagttcc acttgacact t 21
 <210> 137
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 137
 aaagttcca cttgacactt t 21
 <210> 138
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 138
 aagttccac ttgacactt g 21
 <210> 139
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 139
 55 aaaacgcata atctgggaca g 21
 <210> 140
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 140
aaacgcataa tctgggacag t 21

<210> 141
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 141
aacgcataat ctgggacagt a 21

20

<210> 142
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

30

<400> 142
aatctgggac agtagaaagg g 21

35

<210> 143
<211> 21
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Targeting sequence

45

<400> 143
aaagggcttc atcatatcaa a 21

<210> 144
<211> 21
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Targeting sequence

55

<400> 144
aagggcttca tcatatcaaa t 21

<210> 145
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

EP 1 578 933 B9

<223> Targeting sequence

<400> 145
5 aaatgcaacg tacaagaaa t 21

<210> 146
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 146
15 aatgcaacgt acaaagaaat a 21

<210> 147
<211> 21
<212> DNA
20 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 147 21
25 aacgtacaaa gaaatagggc t 21

<210> 148
<211> 21
<212> DNA
30 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 148 21
35 aaagaaatag ggctctgac c 21

<210> 149
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 149 21
45 aagaaatagg gctctgacc t 21

<210> 150
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
55 <223> Targeting sequence

<400> 150 21

5 aaatagggct tctgacctgt g 21
 <210> 151
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 10 <223> Targeting sequence
 <400> 151 21
 aaatagggctt ctgacctgtg a 21
 <210> 152
 15 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 20 <223> Targeting sequence
 <400> 152
 aagcaacagt caatgggcat t 21
 25 <210> 153
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Targeting sequence
 <400> 153
 35 aacagtcaat gggcattgt a 21
 <210> 154
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Targeting sequence
 <400> 154
 45 aatgggcatt tgtataagac a 21
 <210> 155
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 55 <400> 155
 aagacaaact atctcacaca t 21
 <210> 156

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 156
 aaactatctc acacatcgac a 21
 10
 <210> 157
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 157
 20 aactatctca cacatcgaca a 21
 <210> 158
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 158
 aaaccaatac aatcatagat g 21
 <210> 159
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40
 <400> 159
 aaccaataca atcatagatg t 21
 <210> 160
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 160
 aatacaatca tagatgtcca a 21
 55
 <210> 161
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 161
 5 aatcatagat gtccaaataa g 21

 <210> 162
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 162
 aaataagcac accacgcccc a 21

 <210> 163
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 163
 aataagcaca ccacgccag t 21

 <210> 164
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 164
 aagcacacca cgcccagtca a 21

 <210> 165
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 165
 aaattactta gaggccatac t 21

 <210> 166
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 55

EP 1 578 933 B9

<400> 166
 aattacttag aggccatact c 21

5
 <210> 167
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Targeting sequence

<400> 167
 aattgtactg ctaccactcc c 21

15
 <210> 168
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20
 <220>
 <223> Targeting sequence

25
 <400> 168
 aacacgagag ttcaaatgac c 21

30
 <210> 169
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

35
 <400> 169
 aatgacctg gagttaccct g 21

40
 <210> 170
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

45
 <400> 170
 aatgacctgg agttaccctg a 21

50
 <210> 171
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

55
 <400> 171
 aaaaaataa gagagcttcc g 21

<210> 172
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 172
 10 aaaaaataag agagcttccg t 21
 <210> 173
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 173
 aaaaataaga gagcttccgt a 21
 <210> 174
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 174
 aaaataagag agcttccgta a 21
 <210> 175
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 175
 aaataagaga gcttccgtaa g 21
 <210> 176
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 176
 aataagagag cttccgtaag g 21
 55 <210> 177
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 177
 aagagagctt ccgtaaggcg a 21
 <210> 178
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 15
 <400> 178
 aaggcgacga atgaccaaa g 21
 <210> 179
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 25
 <400> 179
 aattgaccaa agcaattccc a 21
 <210> 180
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 35
 <400> 180
 aaagcaattc ccatgccaac a 21
 <210> 181
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 45
 <400> 181
 aagcaattcc catgccaaca t 21
 <210> 182
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>

<223> Targeting sequence

 <400> 182
 aattcccatg ccaacatatt c 21
 5

 <210> 183
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 183
 aacatattct acagtgtct t 21
 15

 <210> 184
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 184
 aaaatgcaga acaaagacaa a 21
 25

 <210> 185
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 185
 aatgcagaac aaagacaaag g 21

 <210> 186
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 186
 aacaaagaca aaggactta t 21

 <210> 187
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 187

EP 1 578 933 B9

aaagacaaag gactttatac t 21

<210> 188
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 188
aagacaaagg actttatac t 21

<210> 189
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 189
aaaggacttt atactgtcg t 21

25 <210> 190
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 190
35 aaggacttta tactgtcgt g 21

<210> 191
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 191
45 aaggagtgga ccatcattca a 21

<210> 192
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 192
aaatctgta acacctcagt g 21

<210> 193

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 193
 aatctgtaa cacctcagtg c 21
 10 <210> 194
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 194
 20 aacacctcag tgcatatata t 21
 <210> 195
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 195
 aaagcattca tcaactgtgaa a 21
 <210> 196
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 196
 aagcattcat cactgtgaaa c 21
 <210> 197
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 197
 aaacatcgaa aacagcaggt g 21
 55 <210> 198
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 198
 5 aacatcgaaa acagcaggtg c 21

 <210> 199
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 199
 15 aaaacagcag gtgcttgaaa c 21

 <210> 200
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 200
 25 aaacagcagg tgcttgaaac c 21

 <210> 201
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 201
 35 aacagcaggt gcttgaaacc g 21

 <210> 202
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 202
 45 aaaccgtagc tggcaagcgg t 21

 <210> 203
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 203
 aaccgtagct ggcaagcggc c 21

 5 <210> 204
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 10 <220>
 <223> Targeting sequence

 <400> 204
 aaccgtagct ggcaagcggc c 21

 15 <210> 205
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Targeting sequence

 <400> 205
 aaagtgagg cattccctc g 21
 25
 <210> 206
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence

 <400> 206
 aagtgaggc attccctcg c 21
 35
 <210> 207
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence

 45 <400> 207
 aaggcattc cctgccgga a 21

 <210> 208
 <211> 21
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 55
 <400> 208
 aagttgatg gttaaagat g 21

<210> 209
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 209
 10 aaaagatggg ttacctgcga c 21
 <210> 210
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 210
 aaagatgggt tacctgcgac t 21
 <210> 211
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 211
 aagatgggtt acctgcgact g 21
 <210> 212
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 212
 aaatctgctc gctattgac t 21
 <210> 213
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 213
 55 aatctgctcg ctattgact c 21
 <210> 214
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 214
 aattatcaag gacgtaactg a 21
 <210> 215
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 215
 aaggacgtaa ctgaagagga t 21
 20 <210> 216
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 216
 30 aactgaagag gatgcagggga a 21
 <210> 217
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 217
 40 aagaggatgc aggaattat a 21
 <210> 218
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 218
 aattatacaa tcttgctgag c 21
 <210> 219
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 219
 aatctgtctg agcataaaac a 21
 5

 <210> 220
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 220
 aaaacagtca aatgtgtta a 21
 15

 <210> 221
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 221
 aaacagtcaa atgtgttaa a 21
 25

 <210> 222
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 222
 aacagtcaaa tgtgttaaa a 21

 <210> 223
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 223
 aaatgtgtt aaaaacctca c 21

 <210> 224
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 224

aatgtgttta aaaacctcac t 21

 <210> 225
 <211> 21
 5 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 10

 <400> 225
 aaaaacctca ctgccactct a 21

 <210> 226
 15 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 20 <223> Targeting sequence

 <400> 226
 aaaacctcac tgccactcta a 21
 25
 <210> 227
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence

 <400> 227
 35 aaacctcact gccactctaa t 21

 <210> 228
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence

 <400> 228
 45 aacctcactg ccactcta t 21

 <210> 229
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 55
 <400> 229
 aattgtcaat gtgaaacccc a 21

 <210> 230

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 230
 aatgtgaaac cccagattta c 21
 10
 <210> 231
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 231
 20 aaacccaga ttacgaaaa g 21
 <210> 232
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 232
 aacccagat ttacgaaaag g 21
 <210> 233
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 233
 aaaaggccgt gtcacgttt c 21
 <210> 234
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 234
 aaaggccgtg tcacgtttc c 21
 55 <210> 235
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 235
 5 aaggccgtgt catcgttcc a 21

 <210> 236
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 236
 aaatcctgac ttgtaccgca t 21

 <210> 237
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 237
 aatcctgact tgtaccgcat a 21

 <210> 238
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 238
 aacctacaat caagtggtc t 21

 <210> 239
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 239
 50 aatcaagtgg ttctgcacc c 21

 <210> 240
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 240
aagtggttct ggcaccctg t 21

5 <210> 241
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 241
aaccataatc attccgaagc a 21

15 <210> 242
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 242
aatcattccg aagcaagggtg t 21

25 <210> 243
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 243
aagcaagggtg tgactttgt t 21

35 <210> 244
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 244
aagggtgac tttgtcca a 21

50 <210> 245
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 245
aataatgaag agtccttat c 21

<210> 246
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 246
 10 aatgaagagt cctttatcct g 21
 <210> 247
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 247
 aagagtcctt tatcctggat g 21
 <210> 248
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 248
 aacatgggaa acagaattga g 21
 <210> 249
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 249
 aaacagaatt gagagcatca c 21
 <210> 250
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 250
 55 aacagaattg agagcatcac t 21
 <210> 251
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 251
 aattgagagc atcactcagc g 21
 <210> 252
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 252
 aataatagaa ggaaagaata a 21
 20 <210> 253
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 253
 30 aatagaagga aagaataaga t 21
 <210> 254
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 254
 40 aaggaaagaa taagatggct a 21
 <210> 255
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 255
 aaagaataag atggctagca c 21
 <210> 256
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 256
 aagaataaga tggctagcac c 21
 5

 <210> 257
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 257
 aataagatgg ctgacacctt g 21
 15

 <210> 258
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 258
 aagatggcta gcaccttgg t 21
 25

 <210> 259
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 259
 aatttctgga atctacattt g 21

 <210> 260
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 260
 aatctacatt tgcatagctt c 21

 <210> 261
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 261

EP 1 578 933 B9

aataaagttg ggactgtggg a 21

<210> 262
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 262
aaagttggga ctgtgggaag a 21

<210> 263
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 263
aagttgggac tgtgggaaga a 21

25 <210> 264
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 264
35 aagaaacata agctttata t 21

<210> 265
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 265
45 aaacataagc tttatatca c 21

<210> 266
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 266
aacataagct tttatatcac a 21

<210> 267

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 267
 aagctttat atcacagatg t 21
 10 <210> 268
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 268
 20 aaatggggtt catgtaact t 21
 <210> 269
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 269
 aatgggttc atgtaact g 21
 <210> 270
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 270
 aacttgaaa aaatgccgac g 21
 <210> 271
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 271
 aaaaaatgcc gacggaagga g 21
 55 <210> 272
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 272
 5 aaaaatgccg acggaaggag a 21

 <210> 273
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 273
 aaaatgccga cggaaggaga g 21

 <210> 274
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 274
 aaatgccgac ggaaggagag g 21

 <210> 275
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 275
 aatgccgacg gaaggagagg a 21

 <210> 276
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 276
 aaggagagga cctgaaactg t 21

 50 <210> 277
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 277
 aaactgtctt gcacagtaa c 21

5
 <210> 278
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Targeting sequence

<400> 278
 aactgtcttg cacagttaac a 21

15
 <210> 279
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20
 <220>
 <223> Targeting sequence

<400> 279
 aacaagtctt tatacagaga c 21

25
 <210> 280
 <211> 21
 <212> DNA
 <213> Artificial Sequence

30
 <220>
 <223> Targeting sequence

<400> 280
 aagttcttat acagagacgt t 21

35
 <210> 281
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Targeting sequence

45
 <400> 281
 aataacagaa caatgcacta c 21

50
 <210> 282
 <211> 21
 <212> DNA
 <213> Artificial Sequence

55
 <220>
 <223> Targeting sequence

<400> 282
 aacagaacaa tgactacag t 21

<210> 283
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 283
 10 aacaatgcac tacagtatta g 21
 <210> 284
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 284
 aatgcactac agtattagca a 21
 <210> 285
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 285
 aagcaaaaaa tggccatcac t 21
 <210> 286
 <211> 21
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 286
 aaaaaatggc catcactaag g 21
 <210> 287
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Targeting sequence
 <400> 287
 50 aaaaaatggcc atcactaagg a 21
 <210> 288
 <211> 21
 <212> DNA
 55

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 288
 aaaatggcca tcactaagga g 21
 <210> 289
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 289
 aaatggccat cactaaggag c 21
 20 <210> 290
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 290
 30 aatggccatc actaaggagc a 21
 <210> 291
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 291
 40 aaggagcact ccatcactct t 21
 <210> 292
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 292
 aatctacca tcatgaatgt t 21
 <210> 293
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 293
 aatgtttccc tgcaagattc a 21
 5

 <210> 294
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 294
 aagattcagg cacctatgcc t 21
 15

 <210> 295
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 295
 aatgtataca caggggaaga a 21
 25

 <210> 296
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 296
 aagaaatcct ccagaagaaa g 21

 <210> 297
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 297
 aatctcca gaagaagaa a 21

 <210> 298
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 298

EP 1 578 933 B9

	aatcctccag aagaaagaaa t	21
	<210> 299	
	<211> 21	
5	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Targeting sequence	
10		
	<400> 299	
	aagaaagaaa ttacaatcag a	21
	<210> 300	
15	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
20	<223> Targeting sequence	
	<400> 300	
	aaagaaatta caatcagaga t	21
25	<210> 301	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Targeting sequence	
	<400> 301	
35	aagaaattac aatcagagat c	21
	<210> 302	
	<211> 21	
	<212> DNA	
40	<213> Artificial Sequence	
	<220>	
	<223> Targeting sequence	
	<400> 302	
45	aaattacaat cagagatcag g	21
	<210> 303	
	<211> 21	
	<212> DNA	
50	<213> Artificial Sequence	
	<220>	
	<223> Targeting sequence	
55	<400> 303	
	aattacaatc agagatcagg a	21
	<210> 304	

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 304
 aatcagagat caggaagcac c 21
 10 <210> 305
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 305
 20 aagcaccata cctcctgcga a 21
 <210> 306
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 306
 aaacctcagt gatcacacag t 21
 <210> 307
 <211> 20
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 307
 aacctcagt atcacacagt 20
 <210> 308
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 308
 aatggtgtcc ccgagcctca g 21
 55 <210> 309
 <211> 21
 <212> DNA
 <213> Artificial Sequence

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 309
aaaaacaacc acaaataca a 21

<210> 310
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 310
aaaacaacca caaatacaa c 21

<210> 311
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 311
aaacaaccac aaaatacaac a 21

<210> 312
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 312
aacaaccaca aaatacaaca a 21

40 <210> 313
<211> 21
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

50 <400> 313
aaccacaaaa tacaacaaga g 21

<210> 314
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

EP 1 578 933 B9

<400> 314
aaaatacaac aagagcctgg a 21

5
<210> 315
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 315
aaatacaaca agagcctgga a 21

15
<210> 316
<211> 21
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 316
aatacaaca gagcctggaa t 21

25
<210> 317
<211> 21
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 317
aacaagagcc tggattatt t 21

35
<210> 318
<211> 21
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

45
<400> 318
aagagcctgg aattattta g 21

50
<210> 319
<211> 21
<212> DNA
<213> Artificial Sequence

55
<220>
<223> Targeting sequence

<400> 319
aattattta ggaccaggaa g 21

<210> 320
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 320
 10 aagcagcagc ctgtttattg a 21
 <210> 321
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 321
 aaagagtcac agaagaggat g 21
 <210> 322
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 322
 aagagtcaca gaagaggatg a 21
 <210> 323
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 323
 aagaggatga aggtgtctat c 21
 <210> 324
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 324
 55 aaggtgtcta tcaactgcaaa g 21
 <210> 325
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 325
 aaagccacca accagaaggg c 21
 <210> 326
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 326
 aagccaccaa ccagaagggc t 21
 20 <210> 327
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 327
 30 aaccagaagg gctctgtgga a 21
 <210> 328
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 328
 40 aagggctctg tggaaagttc a 21
 <210> 329
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 329
 aaagttcagc atacctcact g 21
 <210> 330
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 330
 aagttcagca tacctcactg t 21
 5

 <210> 331
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 331
 aaggaacctc ggacaagtct a 21
 15

 <210> 332
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 332
 aacctcggac aagtctaatt t 21
 25

 <210> 333
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 333
 aagtctaatt tggagctgat c 21

 <210> 334
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 334
 aatctggagc tgatcactct a 21

 <210> 335
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 335

EP 1 578 933 B9

aacatgcacc tgtgtggctg c 21

<210> 336
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 336
aacctcttt atccgaaaa t 21

<210> 337
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 337
aaaaatgaaa aggtcttct c 21

25 <210> 338
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 338
35 aaaatgaaaa ggtcttctc t 21

<210> 339
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 339
45 aaatgaaaag gtcttctct g 21

<210> 340
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 340
aatgaaaagg tcttctctg a 21

<210> 341

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 341
 10 aaaaggtctt ctctgaaat a 21
 <210> 342
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 342
 20 aaaggtcttc tctgaaata a 21
 <210> 343
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 343
 aaggtcttct tctgaaataa a 21
 <210> 344
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 344
 aaataagac tgactaccta t 21
 <210> 345
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 345
 aataaagact gactacctat c 21
 55 <210> 346
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 346
 5 aaagactgac tacctatcaa t 21

 <210> 347
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 347
 aagactgact acctatcaat t 21

 <210> 348
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 348
 aattataatg gaccagatg a 21

 <210> 349
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 349
 aatggacca gatgaagttc c 21

 40 <210> 350
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 45 <220>
 <223> Targeting sequence

 <400> 350
 50 aagttcctt ggatgagcag t 21

 <210> 351
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 351
 aagtgggagt ttgcccgga g 21

5 <210> 352
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Targeting sequence

<400> 352
 aaactgggca aatcacttg a 21

15 <210> 353
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Targeting sequence

<400> 353
 aactgggcaa atcacttga a 21

25 <210> 354
 <211> 21
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Targeting sequence

<400> 354
 aatcacttg gaagaggggc t 21

35 <210> 355
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Targeting sequence

<400> 355
 aatcacttg aagagggct t 21

45 <210> 356
 <211> 21
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Targeting sequence

55 <400> 356
 aagagggct tttgaaaag t 21

<210> 357
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 357
 aaaagtggtt caagcatcag c 21
 10
 <210> 358
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 358
 aaagtgggtc aagcatcagc a 21
 20
 <210> 359
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> Targeting sequence
 <400> 359
 aagtgggtca agcatcagca t 21
 30
 <210> 360
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 <223> Targeting sequence
 <400> 360
 aagcatcagc attggcatt a 21
 40
 <210> 361
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45
 <220>
 <223> Targeting sequence
 <400> 361
 aagaaatcac ctacgtgccg g 21
 50
 <210> 362
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 362
aaatcaccta cgtgccggac t 21

<210> 363
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 363
aatcacctac gtgccggact g 21

<210> 364
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 364
aaaatgctga aagagggggc c 21

<210> 365
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 365
aatgctgaa agagggggcc a 21

40 <210> 366
<211> 21
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

50 <400> 366
aatgctgaaa gagggggcca c 21

<210> 367
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

EP 1 578 933 B9

<400> 367
aaagaggggg ccacggccag c 21

5 <210> 368
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 368
aagagggggc cacggccagc g 21

15 <210> 369
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 369
aaagctctga tgactgagct a 21

25 <210> 370
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 370
aagctctgat gactgagcta a 21

35 <210> 371
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 371
aaaaatcttg acccacattg g 21

50 <210> 372
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 372
aaaatcttga cccacattg c 21

<210> 373
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 373
 10 aaatcttgac ccacattggc c 21
 <210> 374
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 374
 aatcttgacc cacattggcc a 21
 <210> 375
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 375
 aacgtggtta acctgctggg a 21
 <210> 376
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 376
 aacctgctgg gagcctgcac c 21
 <210> 377
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 377
 55 aagcaaggag ggcctctgat g 21
 <210> 378
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 378
 aaggagggcc tctgatggtg a 21
 <210> 379
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 15
 <400> 379
 aatactgcaa atatggaat c 21 <210> 380
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 25
 <400> 380
 aaatatggaa atctctcaa c 21
 <210> 381
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 35
 <400> 381
 aatatgaaa tctctcaac t 21
 <210> 382
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 45
 <400> 382
 aatctctcc aactaccta a 21
 <210> 383
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 55

EP 1 578 933 B9

<400> 383
aatctctcca actacctcaa g 21

5
<210> 384
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 384
aactacctca agagcaaacg t 21

15
<210> 385
<211> 21
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 385
aagagcaaac gtgactatt t 21

25
<210> 386
<211> 21
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 386
aaacgtgact tatttttct c 21

35
<210> 387
<211> 21
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

45
<400> 387
aacgtgact atttttctc a 21

<210> 388
<211> 21
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Targeting sequence

55
<400> 388
aacaaggatg cagcactaca c 21

<210> 389
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 389
 10 aaggatgcag cactacacat g 21
 <210> 390
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 390
 aagaaagaaa aaatggagcc a 21
 <210> 391
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 391
 aaagaaaaaa tggagccagg c 21
 <210> 392
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 392
 aagaaaaaat ggagccaggc c 21
 <210> 393
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 393
 55 aaaaaatgga gccaggcctg g 21
 <210> 394
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 394
 aaaaatggag ccaggcctgg a 21
 <210> 395
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 395
 aaaatggagc caggcctgga a 21
 20 <210> 396
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 396
 30 aatggagcc aggcctggaa c 21
 <210> 397
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 397
 40 aatggagcca ggctggaac a 21
 <210> 398
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 398
 aacaaggcaa gaaaccaaga c 21
 <210> 399
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

EP 1 578 933 B9

<223> Targeting sequence
 <400> 399
 aaggcaagaa accaagacta g 21
 5
 <210> 400
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 400
 aagaaaccaa gactagatag c 21
 15
 <210> 401
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 401
 aaaccaagac tagatagcgt c 21
 25
 <210> 402
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 402
 aaccaagact agatagcgtc a 21
 35
 <210> 403
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 403
 aagactagat agcgtcacca g 21
 45
 <210> 404
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 404

EP 1 578 933 B9

aaagctttgc gagctccggc t 21

<210> 405
<211> 20
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 405
aagctttgcg agctccggct 20

<210> 406
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 406
aagataaaag tctgagtgat g 21

25 <210> 407
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 407
35 aaaagtctga gtgatgttga g 21

<210> 408
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 408
45 aaagtctgag tgatgttgag g 21

<210> 409
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 409
aagtctgagt gatgttgagg a 21

<210> 410

<211> 21
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Targeting sequence

<400> 410
aagaggagga ttctgacggt t 21

10 <210> 411
<211> 21
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Targeting sequence

20 <400> 411
aaggagccca tcactatgga a 21

<210> 412
<211> 21
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Targeting sequence

30 <400> 412
aagatctgat ttcttacagt t 21

<210> 413
<211> 21
35 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

40 <400> 413
aagtggccag aggcattgag t 21

<210> 414
<211> 21
45 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

50 <400> 414
aaagtgcatt catcgggacc t 21

55 <210> 415
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 415
 5 aagtcattc atcgggacct g 21

 <210> 416
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 416
 aaacattctt ttatctgaga a 21

 <210> 417
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 417
 aacattcttt tatctgagaa c 21

 <210> 418
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35 <400> 418
 aacaacgtgg tgaagattg t 21

 <210> 419
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 419
 aacgtggtga agattgtga t 21

 <210> 420
 <211> 21
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 55 <400> 420

EP 1 578 933 B9

aagattgtg atttggcct t 21

<210> 421
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 421
aagaaccccg attatgtgag a 21

<210> 422
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 422
aaccccgatt atgtgagaaa a 21

25 <210> 423
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 423
35 aaaaggagat actcgacttc c 21

<210> 424
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 424
45 aaaggagata ctcgacttc t 21

<210> 425
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 425
aaggagatac tcgacttct c 21

<210> 426

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 426
 10 aaatggatgg ctctgaatc t 21
 <210> 427
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 427
 20 aatggatggc tcctgaatct a 21
 <210> 428
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 428
 aatctatctt tgacaaaatc t 21
 <210> 429
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 429
 aaaatctaca gcaccaagag c 21
 <210> 430
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 430
 aatctacag caccaagagc g 21
 55 <210> 431
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 431
 5 aatctacagc accaagagcg a 21

 <210> 432
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 432
 aagagcgacg tgggtctta c 21

 <210> 433
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 433
 aaatctctc cttaggtggg t 21

 <210> 434
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 434
 aatctctcc ttaggtggg c 21

 40 <210> 435
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 45 <220>
 <223> Targeting sequence

 <400> 435
 50 aatgatga ggactttgc a 21

 <210> 436
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 436
aatggatgag gacttttgca g 21

5 <210> 437
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 437
aaggcatgag gatgagagct c 21

15 <210> 438
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 438
aaatctatca gatcatgctg g 21

25 <210> 439
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 439
aatctatcag atcatgctgg a 21

35 <210> 440
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 440
aaaagaaagg ccaagattg c 21

50 <210> 441
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 441
aaagaaaggc caagattgc a 21

<210> 442
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 442
 10 aagaaaggcc aagattgca g 21
 <210> 443
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 443
 aaaggccaag attgcagaa c 21
 <210> 444
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 444
 aaggccaaga ttgcagaac t 21
 <210> 445
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 445
 aagattgca gaactgtgg a 21
 <210> 446
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 446
 55 aactgtgga aaaactaggt g 21
 <210> 447
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 447
aaaaactagg tgattgctt c 21

<210> 448
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 448
aaaactaggt gattgcttc a 21

20

<210> 449
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

30

<400> 449
aaactagtg attgcttca a 21

35

<210> 450
<211> 21
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Targeting sequence

45

<400> 450
aactagtgga ttgcttcaa g 21

<210> 451
<211> 21
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Targeting sequence

55

<400> 451
aagcaaatgt acaacaggat g 21

<210> 452
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Targeting sequence
 <400> 452
 5 aaatgtacaa caggatggta a 21
 <210> 453
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10 <220>
 <223> Targeting sequence
 <400> 453
 15 aatgtacaac aggatggtaa a 21
 <210> 454
 <211> 21
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 25 <400> 454
 aacaggatgg taaagactac a 21
 <210> 455
 <211> 21
 <212> DNA
 30 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 35 <400> 455
 aaagactaca toccaatcaa t 21
 <210> 456
 <211> 21
 <212> DNA
 40 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 45 <400> 456
 aagactacat cccaatcaat g 21
 <210> 457
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 55 <400> 457

EP 1 578 933 B9

aatcaatgcc atactgacag g 21

<210> 458
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 458
 aatgccatac tgacaggaaa t 21

<210> 459
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 459
 aaatagtggg ttacatact c 21

<210> 460
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 460
 aatagtgggt ttacatactc a 21

<210> 461
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 461
 aactctgcc ttcttgagg a 21

<210> 462
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 462
 aaggaaagta ttcagctcc g 21

<210> 463

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 463
 aaagtatttc agctccgaag t 21
 10
 <210> 464
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 464
 20 aagtattca gctccgaagt t 21
 <210> 465
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 465
 aagtttaatt caggaagctc t 21
 <210> 466
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40
 <400> 466
 aattcaggaa gctctgatga t 21
 <210> 467
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 467
 aagctctgat gatgtcagat a 21
 55
 <210> 468
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 468
 5 aaatgcttc aagttcatga g 21

 <210> 469
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 469
 aatgcttca agttcatgag c 21

 <210> 470
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 470
 aagttcatga gcctggaaag a 21

 <210> 471
 30 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 35 <223> Targeting sequence

 <400> 471
 aaagaatcaa aaccttgaa g 21

 40 <210> 472
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 45 <220>
 <223> Targeting sequence

 <400> 472
 50 aagaatcaaa accttgaag a 21

 <210> 473
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 473
 aatcaaaacc ttgaagaac t 21

5
 <210> 474
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Targeting sequence

<400> 474
 aaaaccttg aagaacttt a 21

15
 <210> 475
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20
 <220>
 <223> Targeting sequence

<400> 475
 aaaccttga agaacttta c 21

25
 <210> 476
 <211> 21
 <212> DNA
 <213> Artificial Sequence

30
 <220>
 <223> Targeting sequence

<400> 476
 aaccttgaa gaactttac c 21

35
 <210> 477
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Targeting sequence

<400> 477
 aagaacttt accgaatgcc a 21

45
 <210> 478
 <211> 21
 <212> DNA
 <213> Artificial Sequence

50
 <220>
 <223> Targeting sequence

55
 <400> 478
 aactttacc gaatgccacc t 21

<210> 479
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 479
 aatgccacct ccatgtttga t 21
 10
 <210> 480
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15
 <220>
 <223> Targeting sequence
 <400> 480
 20 aaaccaagg cctcgctcaa g 21
 <210> 481
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 481
 aaaccaagg cctcgctcaa g 21
 <210> 482
 <211> 21
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 482
 aaccaaggc ctcgctcaag a 21
 <210> 483
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45
 <220>
 <223> Targeting sequence
 50 <400> 483
 aaggcctcg ctaagattga c 21
 55 <210> 484
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 484
 5 aagattgact tgagagtaac c 21

 <210> 485
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 485
 aaccagtaaa agtaaggagt c 21

 <210> 486
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 486
 aaaagtaagg agtcggggct g 21

 <210> 487
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 487
 aaagtaagga gtcggggctg t 21

 <210> 488
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 488
 aagtaaggag tcggggctgt c 21

 <210> 489
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 489
aaggagtcgg ggctgtctga t 21

5 <210> 490
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 490
aaggcaagcg caggtcacc t 21

15 <210> 491
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 491
gcaccagca catcatgcaa g 21

25 <210> 492
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 492
ggctgagcat aactaaatct g 21

35 <210> 493
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 493
gcttctacag ctgcaaatat c 21

<210> 494
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

55 <400> 494
gagctcgtca ttccctgccg g 21

<210> 495
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 495
 10 ccaaagcaat tccatgcc a 21
 <210> 496
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 496
 tgctgagcat aaaacagtca a 21
 <210> 497
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 497
 ttgcatagct tccaataaag t 21
 <210> 498
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 498
 agtgcacaca cagtgccat c 21
 <210> 499
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 499
 55 gatgaagttc cttggatga g 21
 <210> 500
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 500
 tacacatgga gcctaagaaa g 21
 <210> 501
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15
 <223> Targeting sequence
 <400> 501
 gagctccggc ttcaggaag a 21
 <210> 502
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 25
 <223> Targeting sequence
 <400> 502
 tctacagcac caagagcgac g 21
 <210> 503
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 35
 <223> Targeting sequence
 <400> 503
 tctgatgatg tcagatatgt a 21
 <210> 504
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 504
 gcctcgctca agattgact g 21
 <210> 505
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45
 <220>

<223> Targeting sequence

 <400> 505
 aaaaagacat actacaatt a 21
 5

 <210> 506
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 506
 aaaagacata ctacaatta a 21
 15

 <210> 507
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 507
 aaagacatac ttacaattaa g 21
 25

 <210> 508
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 508
 aagacatact tacaattaag g 21

 <210> 509
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 509
 aattaaggct aatacaactc t 21

 <210> 510
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 510

EP 1 578 933 B9

aaggctaata caactctca a 21

<210> 511
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 511
aatacaactc ttcaaattac t 21

<210> 512
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 512
aactctcaa attactgca g 21

25 <210> 513
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 513
35 aaattactg caggggacag a 21

<210> 514
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 514
45 aattactgc aggggacaga g 21

<210> 515
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 515
aataatcaga gtggcagtga g 21

<210> 516

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 516
 10 aatcagagtg gcagtgagca a 21
 <210> 517
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 517
 20 aaaggtgga ggtgactgag t 21
 <210> 518
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 518
 aaggtggag gtgactgagt g 21
 <210> 519
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 519
 aagacactca caattcaaa a 21
 <210> 520
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 520
 aattcaaaa gtgatcgaa a 21
 55 <210> 521
 <211> 21
 <212> DNA
 <213> Artificial Sequence

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 521
aaaagtgatc ggaaatgaca c 21

<210> 522
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 522
aaagtgatcg gaaatgacac t 21

<210> 523
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 523
aagtgatcgg aaatgacact g 21

<210> 524
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 524
aaatgacact ggagcctaca a 21

<210> 525
<211> 21
40 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

45 <400> 525
aatgacactg gagcctaca g 21

<210> 526
<211> 21
50 <212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

EP 1 578 933 B9

<400> 526
aagtgtctt accgggaaac t 21

5 <210> 527
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 527
aaactgactt ggcctcgtc a 21

15 <210> 528
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 528
aactgacttg gcctcgtca t 21

25 <210> 529
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 529
aagattacag atctccattt a 21

35 <210> 530
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 530
aacatggagt cgtgtacatt a 21

45 <210> 531
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

<400> 531
aacaaaaaca aaactgtggt g 21

55 <210> 532

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 532
 10 aaaaacaaaa ctgtggtgat t 21
 <210> 533
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 533
 20 aaaacaaaac tgggtgatt c 21
 <210> 534
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 534
 aaacaaaact gttgtgattc c 21
 <210> 535
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 535
 aacaaaactg tgggtattcc a 21
 <210> 536
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Targeting sequence
 50 <400> 536
 aaaactgtgg tgattccatg t 21
 55 <210> 537
 <211> 21
 <212> DNA
 <213> Artificial Sequence

EP 1 578 933 B9

<220>
<223> Targeting sequence

5 <400> 537
aaactgtggt gattccatgt c 21

<210> 538
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 538
aactgtggtg attccatgtc t 21

<210> 539
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 539
aaatctcaac gtgtcacttt g 21

<210> 540
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 540
aatctcaacg tgcactttg t 21

<210> 541
<211> 21
40 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

45 <400> 541
aacgtgtcac tttgcaag a 21

<210> 542
<211> 21
50 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 542

EP 1 578 933 B9

aagataccca gaaaagagat t 21

<210> 543
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 543
aaaagagatt tggcctgat g 21

<210> 544
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 544
aaagagattt gtcctgatg g 21

25 <210> 545
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 545
35 aagagatttg ttcctgatgg t 21

<210> 546
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 546
45 aacagaattt cctgggacag c 21

<210> 547
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 547
aatttctgg gacagcaaga a 21

<210> 548

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 548
 aagaagggt ttactattcc c 21
 10 <210> 549
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 549
 20 aagggttta ctattcccag c 21
 <210> 550
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 550
 aagcaaaaat taatgatgaa a 21
 <210> 551
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 551
 aaaaattaat gatgaaagt a 21
 <210> 552
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 552
 aaaattaatg atgaaagtta c 21
 55 <210> 553
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 553
 5 aaattaatga tgaagttac c 21

 <210> 554
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 554
 aattaatgat gaaagttacc a 21

 <210> 555
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 555
 aatgatgaaa gttaccagtc t 21

 <210> 556
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 556
 aaagttacca gtctattatg t 21

 <210> 557
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 557
 aagttaccag tctattatg a 21

 <210> 558
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 55

EP 1 578 933 B9

<400> 558
aattgaacta tctgtggag a 21

5 <210> 559
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 559
aactatctgt tggagaaaag c 21

15 <210> 560
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 560
aaaagcttgt ctaaattgt a 21

25 <210> 561
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 561
aaagctgtc ttaaattgta c 21

35 <210> 562
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 562
aagctgtct taaattgtac a 21

45 <210> 563
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

55 <400> 563
aaattgtaca gcaagaactg a 21

EP 1 578 933 B9

<210> 564
<211> 21
<212> DNA
<213> Artificial Sequence
5
<220>
<223> Targeting sequence

<400> 564
10 aattgtacag caagaactga a 21

<210> 565
<211> 21
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Targeting sequence
20
<400> 565
aagaactgaa ctaaagtgg g 21

<210> 566
<211> 21
25 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence
30
<400> 566
aactgaacta aatgtgggga t 21

<210> 567
35 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Targeting sequence

<400> 567
aactaaatgt ggggattgac t 21

45 <210> 568
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

<400> 568
55 aaatgtgggg attgactca a 21

<210> 569
<211> 21
<212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 569
 aatgtgggga ttgactcaa c 21
 <210> 570
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 570
 aactgggaat acccttctc g 21
 20 <210> 571
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 571
 30 aatacccttc ttcgaagcat c 21
 <210> 572
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 572
 40 aagcatcagc ataagaaact t 21
 <210> 573
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 573
 aagaaactg taaaccgaga c 21
 <210> 574
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 574
 aaactgtaa accgagacct a 21
 5

 <210> 575
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 575
 aactgtaaa ccgagaccta a 21
 15

 <210> 576
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 576
 aaaccgagac ctaaaaaccc a 21
 25

 <210> 577
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 577
 aaccgagacc taaaaccca g 21

 <210> 578
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 578
 aaaaaccag tctgggagt g 21

 <210> 579
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 579

aaaaccagct ctgggagtga g 21
 <210> 580
 <211> 21
 5 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 10
 <400> 580
 aaaccagtc tgggagtgag a 21
 <210> 581
 15 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 20 <223> Targeting sequence
 <400> 581
 aaccagctct gggagtgaga t 21
 25 <210> 582
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Targeting sequence
 <400> 582
 35 aagaaatttt tgagcacctt a 21
 <210> 583
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Targeting sequence
 <400> 583
 45 aaattttga gcacctaac t 21
 <210> 584
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 55 <400> 584
 aatttttgag caccttaact a 21
 <210> 585

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 585
 aactatagat ggtgaacc g 21
 10 <210> 586
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 586
 20 aaccggagt gaccaaggat t 21
 <210> 587
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 587
 aaggattgta cacctgtgca g 21
 <210> 588
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 588
 aagaagaaca gcacattgt c 21
 <210> 589
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 589
 aagaacagca cattgtcag g 21
 55 <210> 590
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 590
 5 aacagcacat ttgtcagggt c 21

 <210> 591
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 591
 aaaaaccttt tgttgctttt g 21

 <210> 592
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 592
 aaaacctttt gttgctttt g 21

 <210> 593
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 593
 aaaccttttg ttgcttttg a 21

 40 <210> 594
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 45 <220>
 <223> Targeting sequence

 <400> 594
 50 aacctttgt tgcttttga a 21

 <210> 595
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

<400> 595
 aagtgcatg gaatctctgg t 21

5 <210> 596
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Targeting sequence

<400> 596
 aatctctggt ggaagccacg g 21

15 <210> 597
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Targeting sequence

<400> 597
 aagccacggt gggggagcgt g 21

25 <210> 598
 <211> 21
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Targeting sequence

<400> 598
 aatccctgcg aagtacctg g 21

35 <210> 599
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Targeting sequence

<400> 599
 aagtacctg gttaccacc c 21

45 <210> 600
 <211> 21
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Targeting sequence

55 <400> 600
 aaataaatg gtataaaat g 21

<210> 601
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 601
 10 aataaaatgg tataaaaatg g 21
 <210> 602
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 602
 aaaatggtat aaaaatggaa t 21
 <210> 603
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 603
 aaatggtata aaaatggaat a 21
 <210> 604
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 604
 aatggtataa aatggaata c 21
 <210> 605
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 605
 55 aaaaatggaa tacccttga g 21
 <210> 606
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 606
aaaatggaat accccttgag t 21

<210> 607
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 607
aaatggaata ccccttgagt c 21

20

<210> 608
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

<400> 608
aatggaatac cccttgagtc c 21

30

<210> 609
<211> 21
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Targeting sequence

<400> 609
aatacccctt gagtccaatc a 21

40

<210> 610
<211> 21
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Targeting sequence

<400> 610
aatcacacaa ttaaagcggg g 21

50

<210> 611
<211> 21
<212> DNA
<213> Artificial Sequence

55

<220>

<223> Targeting sequence
 <400> 611
 aattaaagcg gggcatgtac t 21
 5
 <210> 612
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 612
 aaagcggggc atgtactgac g 21
 15
 <210> 613
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 613
 aagcggggca tgtactgacg a 21
 25
 <210> 614
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 614
 aagtgagtga aagagacaca g 21
 35
 <210> 615
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 615
 aaagagacac aggaaattac a 21
 45
 <210> 616
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 616

EP 1 578 933 B9

aagagacaca ggaaattaca c 21

<210> 617
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 617
aaattacact gtcacacctta c 21

<210> 618
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 618
aattacactg tcacacctta c 21

25 <210> 619
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 619
35 aatcccattt caaaggagaa g 21

<210> 620
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 620
45 aaaggagaag cagagccatg t 21

<210> 621
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 621
aaggagaagc agagccatgt g 21

<210> 622

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 622
 aagcagagcc atgtgtctc t 21
 10 <210> 623
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 623
 20 aatctctaa tctcctctg g 21
 <210> 624
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 624
 aatctcta atctcctgtg g 21
 <210> 625
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 625
 aatctctct gtggattcct a 21
 <210> 626
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 626
 aaacgctgac atgtacggtc t 21
 55 <210> 627
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 627
 5 aacgctgaca tgtacggtct a 21

 <210> 628
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 628
 aagagtgcgc caacgagccc a 21

 <210> 629
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 629
 aacgagccca gccaaagtgt c 21

 <210> 630
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 630
 aagctgtctc agtgacaaac c 21

 <210> 631
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 45 <400> 631
 aaaccatac cctgtgaag a 21

 <210> 632
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 55

EP 1 578 933 B9

	<400> 632	
	aaccataacc cttgtgaaga a	21
5	<210> 633	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Targeting sequence	
	<400> 633	
	aagaatggag aagtgtggag g	21
15	<210> 634	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Targeting sequence	
	<400> 634	
25	aatggagaag tgtggaggac t	21
	<210> 635	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Targeting sequence	
	<400> 635	
35	aagtgtggag gactccagg g	21
	<210> 636	
	<211> 21	
	<212> DNA	
40	<213> Artificial Sequence	
	<220>	
	<223> Targeting sequence	
45	<400> 636	
	aaataaaatt gaagtaata a	21
	<210> 637	
	<211> 21	
50	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Targeting sequence	
55	<400> 637	
	aataaaattg aagtaataa a	21

<210> 638
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 638
 10 aaaattgaag ttaataaaaa t 21
 <210> 639
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 639
 aaattgaagt taataaaaat c 21
 <210> 640
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 640
 aattgaagtt aataaaaatc a 21
 <210> 641
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 641
 aagttaataa aaatcaattt g 21
 <210> 642
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 642
 55 aataaaaatc aattgctct a 21
 <210> 643
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 643
 aaaaatcaat ttgctctaat t 21
 <210> 644
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 644
 aaaatcaatt tgctctaatt g 21
 20 <210> 645
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 645
 30 aaatcaattt gctctaattg a 21
 <210> 646
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 646
 40 aatcaattg ctctaattga a 21
 <210> 647
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 647
 aattgctct aattgaagga a 21
 <210> 648
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence
 <400> 648
 aattgaagga aaaaacaaaa c 21
 5
 <210> 649
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 649
 aaggaaaaa caaaactgta a 21
 15
 <210> 650
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 650
 aaaaaacaaa actgtaagta c 21
 25
 <210> 651
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 651
 aaaaacaaaa ctgtaagtac c 21
 35
 <210> 652
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 652
 aaaacaaaac tgtaagtacc c 21
 45
 <210> 653
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 653

EP 1 578 933 B9

aaacaaaact gtaagtaccc t 21

<210> 654
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 654
aacaaaactg taagtaccct t 21

<210> 655
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 655
aaaactgtaa gtaccctgt t 21

25 <210> 656
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 656
35 aaactgtaag taccctgtt a 21

<210> 657
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 657
45 aactgtaagt acccttgta t 21

<210> 658
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 658
aagtaccctt gttatccaag c 21

<210> 659

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 659
 aagcggcaaa tgtgtcagct t 21
 10
 <210> 660
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 660
 20 aaatgtgtca gctttgtaca a 21
 <210> 661
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 661
 aatgtgtcag cttgtacaa a 21
 <210> 662
 <211> 21
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 662
 aaatgtgaag cgtcaacaa a 21
 <210> 663
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Targeting sequence
 50 <400> 663
 aatgtgaagc ggtcaacaaa g 21
 55 <210> 664
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 664
 5 aagcggcaaa caaagtcggg a 21

 <210> 665
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 665
 15 aacaaagtcg ggagaggaga g 21

 <210> 666
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 666
 aaagtcggga gaggagagag g 21

 <210> 667
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 667
 aagtcgggag aggagagagg g 21

 <210> 668
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 45
 <400> 668
 50 aaattacttt gcaacctgac a 21

 <210> 669
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 669
aattactttg caacctgaca t 21

5
<210> 670
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 670
aacctgacat gcagcccact g 21

15
<210> 671
<211> 21
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 671
aacctcacat ggtacaagct t 21

25
<210> 672
<211> 21
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 672
aagcttgcc cacagcctct g 21

35
<210> 673
<211> 21
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

<400> 673
aatccatgtg ggagagttgc c 21

45
<210> 674
<211> 21
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Targeting sequence

55
<400> 674
aagaacttg atactcttg g 21

<210> 675
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 675
 10 aacttgata ctcttgaa a 21
 <210> 676
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 676
 aaattgaatg ccacatggt c 21
 <210> 677
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 677
 aattgaatgc caccatgttc t 21
 <210> 678
 <211> 21
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 678
 aatgccacca tgttctctaa t 21
 <210> 679
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 679
 55 aatagcacia atgacatttt g 21
 <210> 680
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 680
aaatgacatt ttgatcatgg a 21

<210> 681
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 681
aatgacattt tgatcatgga g 21

20

<210> 682
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

<400> 682
aagaatgcat cctgcagga c 21

30

<210> 683
<211> 21
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Targeting sequence

<400> 683
aatgcatcct tgcaggacca a 21

40

<210> 684
<211> 21
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Targeting sequence

<400> 684
aaggagacta tgtctgcctt g 21

50

<210> 685
<211> 21
<212> DNA
<213> Artificial Sequence

55

<220>

<223> Targeting sequence
 <400> 685
 aagacaggaa gaccaagaaa a 21
 5
 <210> 686
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 686
 aagaccaaga aaagacattg c 21
 15
 <210> 687
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 687
 aagaaaagac attgcgtggt c 21
 25
 <210> 688
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 688
 aaaagacatt gcgtggtcag g 21
 35
 <210> 689
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 689
 aaagacattg cgtggtcagg c 21
 45
 <210> 690
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 690

EP 1 578 933 B9

aagacattgc gtggtcaggc a 21

<210> 691
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 691 21
 aaacctggag aatcagacga c 21

<210> 692
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 692
 aacctggaga atcagacgac a 21

<210> 693
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 693
 aatcagacga caagtattgg g 21

<210> 694
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 694
 aagtattggg gaaagcatcg a 21

<210> 695
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 695
 aaagcatcga agtctcatgc a 21

<210> 696

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 696
 aagcatcgaa gtctcatgca c 21
 10 <210> 697
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 697
 20 aatccccctc cacagatcat g 21
 <210> 698
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 698
 aaagataatg agaccctgt a 21
 <210> 699
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 699
 aagataatga gaccctgta g 21
 <210> 700
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 700
 aatgagacc ttgtagaaga c 21
 55 <210> 701
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 701
 5 aagactcagg cattgtattg a 21

 <210> 702
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 702
 15 aaggatggga accggaacct c 21

 <210> 703
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 25
 <400> 703
 aaccggaacc tcactatccg c 21

 <210> 704
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 35
 <400> 704
 aacctcacta tccgcagagt g 21

 <210> 705
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence
 45
 <400> 705
 50 aaggaggacg aaggcctcta c 21

 <210> 706
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 55
 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 706
aaggcctcta cacctgccag g 21

5 <210> 707
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 707
aaaagtgag gcattttca t 21

15 <210> 708
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 708
aaagtgagg cattttcat a 21

25 <210> 709
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 709
aagtgaggc attttcata a 21

35 <210> 710
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 710
aatagaaggt gccaggaaa a 21

50 <210> 711
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 711
aaggtgccca ggaaaagacg a 21

<210> 712
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 712
 10 aaaagacgaa cttggaatc a 21
 <210> 713
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 713
 aaagacgaac ttggaatca t 21
 <210> 714
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 714
 aagacgaact tggaatcat t 21
 <210> 715
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 715
 aacttgaaa tcattattct a 21
 <210> 716
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 716
 55 aatcattat tctagtagc a 21
 <210> 717
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 717
 aatcattatt ctagtaggca c 21
 <210> 718
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 718
 aagcgggcca atggaggga a 21
 20 <210> 719
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 719
 30 aatggagggg aactgaagac a 21
 <210> 720
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 720
 40 aactgaagac aggctactg t 21
 <210> 721
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 721
 aagacaggct actgtccat c 21
 <210> 722
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence

 <400> 722
 aactccatt ggatgaacat t 21
 5

 <210> 723
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 723
 aacattgga acgactgcct t 21
 15

 <210> 724
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 724
 aacgactgcc ttatgatgcc a 21
 25

 <210> 725
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 725
 aaatggaat tccccagaga c 21

 <210> 726
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 726
 aatggaatt cccagagac c 21

 <210> 727
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 727

EP 1 578 933 B9

aattcccag agaccggctg a 21

<210> 728
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 728
aagctaggta agcctcttg c 21

<210> 729
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 729
aagcctcttg gccgtggtc c 21

25 <210> 730
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 730
35 aagtgattga agcagatgcc t 21

<210> 731
<211> 21
<212> DNA
40 <213> Artificial Sequence

<220>
<223> Targeting sequence

<400> 731
45 aagcagatgc ctttgaatt g 21

<210> 732
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 732
aattgacaag acagcaactt g 21

<210> 733

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 733
 aagacagcaa cttgcaggac a 21
 10 <210> 734
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 734
 20 aactgcagg acagtagcag t 21
 <210> 735
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 735
 aaaatgttga aagaaggagc a 21
 <210> 736
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 736
 aaatgtgaa agaaggagca a 21
 <210> 737
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 737
 aatgtgaaa gaaggagca c 21
 55 <210> 738
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 738
 5 aaagaaggag caacacacag t 21

 <210> 739
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 739
 15 aagaaggagc aacacacagt g 21

 <210> 740
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 740
 25 aaggagcaac acacagtgag c 21

 <210> 741
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 741
 35 aacacacagt gagcatcgag c 21

 <210> 742
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 742
 45 aactcaagat cctcattcat a 21

 <210> 743
 <211> 21
 <212> DNA
 55 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 743
aagatcctca ttcatttgg t 21

5
<210> 744
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 744
aatgtgtca accttctagg t 21

15
<210> 745
<211> 21
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 745
aaccttctag gtcctgtac c 21

25
<210> 746
<211> 21
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 746
aagccaggag ggccactcat g 21

35
<210> 747
<211> 21
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

<400> 747
aattctgcaa atttgaaac c 21

45
<210> 748
<211> 21
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Targeting sequence

55
<400> 748
aaattggaa acctgtccac t 21

<210> 749
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 749
 10 aattggaaa cctgtccact t 21
 <210> 750
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 750
 aaacctgtcc acttacctga g 21
 <210> 751
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 751
 aacctgtcca cttacctgag g 21
 <210> 752
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 752
 aagagaaatg aattgtccc c 21
 <210> 753
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 753
 55 aaatgaatt gtcccctaca a 21
 <210> 754
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 754
aatgaattg tccctacaa g 21

<210> 755
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 755
aattgtccc ctacaagacc a 21

20

<210> 756
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

30

<400> 756
aagaccaaag gggcacgatt c 21

35

<210> 757
<211> 21
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Targeting sequence

45

<400> 757
aaaggggcac gattccgtca a 21

<210> 758
<211> 21
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Targeting sequence

55

<400> 758
aaggggcacg attccgtcaa g 21

<210> 759
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Targeting sequence
 <400> 759
 aagggaaaga ctacgttga g 21
 5
 <210> 760
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 760
 aaagactacg ttgagcaat c 21
 15
 <210> 761
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 761
 aagactacgt tggagcaatc c 21
 25
 <210> 762
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 762
 aatccctgtg gatctgaaac g 21
 35
 <210> 763
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 763
 aaacggcgt tggacagcat c 21
 45
 <210> 764
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 764

EP 1 578 933 B9

aacggcgctt ggacagcatc a 21

<210> 765
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 765
 aagtcctca gtgatgtaga a 21

<210> 766
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 766
 aagaagagga agctcctgaa g 21

<210> 767
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 767
 aagaggaagc tcctgaagat c 21

<210> 768
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 768
 aagctcctga agatctgtat a 21

<210> 769
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

<400> 769
 aagatctgta taaggactc c 21

<210> 770

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 770
 aaggactcc tgacctgga g 21
 10 <210> 771
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 771
 20 aagtgctaa gggcatggag t 21
 <210> 772
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 772
 aagggcatgg agttcttggc a 21
 <210> 773
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 773
 aaagtgtatc cacagggacc t 21
 <210> 774
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 774
 aagtgtatcc acagggacct g 21
 55 <210> 775
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 775
 5 aaatcctc ttatcgaga a 21

 <210> 776
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 15 <400> 776
 aaatcctct tatcgagaa g 21

 <210> 777
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 25 <400> 777
 aaatcctct tatcgagaa g 21

 <210> 778
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 35 <400> 778
 aagaacgtgg taaatctg t 21

 <210> 779
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 45 <220>
 <223> Targeting sequence

 <400> 779
 50 aacgtggtta aaatctgtga c 21

 <210> 780
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 780
aaaatctgtg actttggctt g 21

5 <210> 781
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 781
aaatctgtga ctttgcttg g 21

15 <210> 782
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 782
aatctgtgac ttggcttg c 21

25 <210> 783
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 783
aaagatccag attatgtcag a 21

35 <210> 784
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 784
aagatccaga ttatgcaga a 21

45 <210> 785
<211> 21
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Targeting sequence

55 <400> 785
aaaaggagat gctcgctcc c 21

<210> 786
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 786
 10 aaaggagatg ctcgcctccc t 21
 <210> 787
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 787
 aaggagatgc tcgcctccct t 21
 <210> 788
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 788
 aatggatgg cccagaaac a 21
 <210> 789
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 789
 aatggatggc cccagaaaca a 21
 <210> 790
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 790
 55 aaacaatttt tgacagagtg t 21
 <210> 791
 <211> 21
 <212> DNA

EP 1 578 933 B9

<213> Artificial Sequence

<220>
<223> Targeting sequence

5

<400> 791
aacaatttt gacagagtgt a 21

<210> 792
<211> 21
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Targeting sequence

15

<400> 792
aatTTTgac agagTgTaca c 21

20

<210> 793
<211> 21
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Targeting sequence

30

<400> 793
aatccagagt gacgtctggt c 21

35

<210> 794
<211> 21
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Targeting sequence

45

<400> 794
aaatattttc cttaggtgct t 21

<210> 795
<211> 21
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Targeting sequence

55

<400> 795
aatatttcc ttagtgctt c 21

<210> 796
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Targeting sequence

 <400> 796
 aaagattgat gaagaatttt g 21
 5

 <210> 797
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10

 <220>
 <223> Targeting sequence

 <400> 797
 aagattgatg aagaatttg t 21
 15

 <210> 798
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20

 <220>
 <223> Targeting sequence

 <400> 798
 aagaatttg taggcgattg a 21
 25

 <210> 799
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30

 <220>
 <223> Targeting sequence
 35

 <400> 799
 aattttgtag gcgattgaaa g 21

 <210> 800
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40

 <220>
 <223> Targeting sequence
 45

 <400> 800
 aaagaaggaa ctagaatgag g 21

 <210> 801
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50

 <220>
 <223> Targeting sequence
 55

 <400> 801

EP 1 578 933 B9

aagaaggaac tagaatgagg g 21

5 <210> 802
<211> 21
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Targeting sequence

<400> 802
aaggaactag aatgagggcc c 21

15 <210> 803
<211> 21
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Targeting sequence

<400> 803
aactagaatg agggcccctg a 21

25 <210> 804
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 804
aatgagggcc cctgattata c 21

35 <210> 805
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

45 <400> 805
aatgtacca gaccatgctg g 21

50 <210> 806
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 806
aatgtaccag accatgctgg a 21

<210> 807

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 807
 aacatttggg aaatctcttg c 21
 10
 <210> 808
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 808
 20 aaatctcttg caagctaatg c 21
 <210> 809
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 809
 aatctcttgc aagctaatgc t 21
 <210> 810
 <211> 21
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 810
 aagctaatgc tcagcaggat g 21
 <210> 811
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Targeting sequence
 50 <400> 811
 aatgctcagc aggatggcaa a 21
 55 <210> 812
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Targeting sequence

5 <400> 812
aaagactaca ttgtcttc g 21

<210> 813
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Targeting sequence

15 <400> 813
aagactacat tgtcttcg a 21

<210> 814
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

25 <400> 814
aagaggattc tggactctc c 21

<210> 815
<211> 21
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Targeting sequence

35 <400> 815
aagtatgtga ccccaaattc c 21

40 <210> 816
<211> 21
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Targeting sequence

<400> 816
50 aaattccatt atgacaacac a 21

<210> 817
<211> 21
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Targeting sequence

<400> 817
 aattccatta tgacaacaca g 21

5 <210> 818
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Targeting sequence

<400> 818
 aacacagcag gaatcagta g 21

15 <210> 819
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Targeting sequence

<400> 819
 aatcagtcag tatctgcaga a 21

25 <210> 820
 <211> 21
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Targeting sequence

<400> 820
 aacagtaagc gaaagagccg g 21

35 <210> 821
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Targeting sequence

<400> 821
 aagcgaaaga gccggcctgt g 21

45 <210> 822
 <211> 21
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Targeting sequence

55 <400> 822
 aaagagccgg cctgtgagtg t 21

<210> 823
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 823
 10 aagagccggc ctgtgagtgt a 21
 <210> 824
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 824
 aaaaacattt gaagatatcc c 21
 <210> 825
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 825
 aaaacatttg aagatatccc g 21
 <210> 826
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 826
 aaacatttga agatatccc t 21
 <210> 827
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 827
 55 aacatttgaa gatatcccgt t 21
 <210> 828
 <211> 21
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> Targeting sequence
 5
 <400> 828
 aagatatccc gttagaagaa c 21
 <210> 829
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Targeting sequence
 <400> 829
 aagaaccaga agtaaaagta a 21
 20 <210> 830
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Targeting sequence
 <400> 830
 30 aaccagaagt aaaagtaatc c 21
 <210> 831
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Targeting sequence
 <400> 831
 40 aagtaaaagt aatcccagat g 21
 <210> 832
 <211> 21
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 50 <400> 832
 aaaagtaatc ccagatgaca a 21
 <210> 833
 <211> 21
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Targeting sequence
 <400> 833
 aaagtaatcc cagatgacaa c 21
 5
 <210> 834
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Targeting sequence
 <400> 834
 aagtaatccc agatgacaac c 21
 15
 <210> 835
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Targeting sequence
 <400> 835
 aatcccagat gacaaccaga c 21
 25
 <210> 836
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Targeting sequence
 <400> 836
 aaccagacgg acagtggat g 21
 35
 <210> 837
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Targeting sequence
 <400> 837
 aagagctgaa aacttgaa g 21
 45
 <210> 838
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Targeting sequence
 <400> 838

EP 1 578 933 B9

aaaactttgg aagacagaac c 21

<210> 839
<211> 21
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Targeting sequence

<400> 839
aaactttgga agacagaacc a 21

<210> 840
15 <211> 21
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Targeting sequence

<400> 840
aactttggaa gacagaacca a 21

25 <210> 841
<211> 21
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Targeting sequence

<400> 841
35 aagacagaac caaattatct c 21

<210> 842
<211> 21
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Targeting sequence

<400> 842
45 aaccaaatta tctccatct t 21

<210> 843
<211> 21
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Targeting sequence

55 <400> 843
aaattatctc catctttgg t 21

<210> 844

<211> 21
 <212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Targeting sequence
 <400> 844
 aattatctcc atcttttggg g 21
 10
 <210> 845
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Targeting sequence
 <400> 845
 20 aatggtgccc agcaaaagca g 21
 <210> 846
 <211> 21
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 846
 aaaagcaggg agtctgtggc a 21
 <210> 847
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 40 <400> 847
 aaagcagggg gtctgtggca t 21
 <210> 848
 <211> 21
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Targeting sequence
 <400> 848
 aagcaggag tctgtggcat c 21
 55 <210> 849
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Targeting sequence

 <400> 849
 5 aaggctcaaa ccagacaagc g 21

 <210> 850
 <211> 21
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 850
 15 aaaccagaca agcggctacc a 21

 <210> 851
 <211> 21
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 851
 25 aaccagacaa gcggctacca g 21

 <210> 852
 <211> 21
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 852
 35 aagcggctac cagtccggat a 21

 <210> 853
 <211> 21
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

 <400> 853
 45 aagcagaact ttaaagctg a 21

 <210> 854
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Targeting sequence

EP 1 578 933 B9

<400> 854
gacatactta caattaaggc t 21

5
<210> 855
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Targeting sequence

<400> 855
gatttggtcc tgatggtaac a 21

15
<210> 856
<211> 21
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Targeting sequence

<400> 856
tttgagcac ctaactata g 21

25
<210> 857
<211> 21
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Targeting sequence

<400> 857
gagccatgtg gtctctctgg t 21

35
<210> 858
<211> 21
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Targeting sequence

<400> 858
ggtgatctcc tccacgtga c 21

45
<210> 859
<211> 21
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Targeting sequence

55
<400> 859
gtggtcaggc agctcacagt c 21

<210> 860
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Targeting sequence
 <400> 860
 10 cggtgattgc catgttcttc t 21
 <210> 861
 <211> 21
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 20 <400> 861
 ttctagtgctc ctgtaccaag c 21
 <210> 862
 <211> 21
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Targeting sequence
 30 <400> 862
 tgtatccaca gggacctggc g 21
 <210> 863
 <211> 21
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Targeting sequence
 <400> 863
 taccagacca tgctggactg c 21
 <210> 864
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Targeting sequence
 <400> 864
 55 ttatctccat cttttggtgg a 21

Claims

- 5 1. An isolated short interfering ribonucleic acid (siRNA) comprising a sense RNA strand from about 19 to about 25 nucleotides in length and an antisense RNA strand from about 19 to about 25 nucleotides in length, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56.
- 10 2. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the human VEGF mRNA is selected from the group consisting of VEGF₁₂₁ mRNA (SEQ ID NO: 2); VEGF₁₆₅ mRNA (SEQ ID NO: 3); VEGF₁₈₉ mRNA (SEQ ID NO: 4) and VEGF₂₀₆ mRNA (SEQ ID NO: 5).
- 15 3. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense strand comprises SEQ ID NO: 78.
4. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the sense RNA strand comprises one RNA molecule, and the antisense RNA strand comprises one RNA molecule.
- 20 5. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the sense and antisense RNA strands forming the RNA duplex are covalently linked by a single-stranded hairpin.
6. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the siRNA further comprises non-nucleotide material.
- 25 7. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the sense and antisense RNA strands are stabilized against nuclease degradation.
8. The short interfering ribonucleic acid (siRNA) of claim 1, further comprising a 3' overhang.
- 30 9. The short interfering ribonucleic acid (siRNA) of claim 8, wherein the 3' overhang comprises from 1 to about 6 nucleotides.
10. The short interfering ribonucleic acid (siRNA) of claim 8, wherein the 3' overhang comprises about 2 nucleotides.
- 35 11. The short interfering ribonucleic acid (siRNA) of claim 4, wherein the sense RNA strand comprises a first 3' overhang, and the antisense RNA strand comprises a second 3' overhang.
12. The short interfering ribonucleic acid (siRNA) of claim 11, wherein the first and second 3' overhangs separately comprise from 1 to about 6 nucleotides.
- 40 13. The short interfering ribonucleic acid (siRNA) of claim 12, wherein the first 3' overhang comprises a dinucleotide and the second 3' overhang comprises a dinucleotide.
- 45 14. The short interfering ribonucleic acid (siRNA) of claim 13, where the dinucleotide comprising the first and second 3' overhang is dithymidylic acid (TT) or diuridylic acid (uu).
15. The short interfering ribonucleic acid (siRNA) of claim 8, wherein the 3' overhang is stabilized against nuclease degradation.
- 50 16. A retinal pigment epithelial cell comprising the short interfering ribonucleic acid (siRNA) of claim 1.
17. A recombinant plasmid comprising nucleic acid sequences for expressing a short interfering ribonucleic acid (siRNA) comprising a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56.
- 55

18. The recombinant plasmid of claim 17 wherein the nucleic acid sequences express a short interfering ribonucleic acid (siRNA) wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
- 5 19. The recombinant plasmid of claim 17, wherein the nucleic acid sequences for expressing the short interfering ribonucleic acid (siRNA) comprise an inducible or regulatable promoter.
- 10 20. The recombinant plasmid of claim 17, wherein the nucleic acid sequences for expressing the short interfering ribonucleic acid (siRNA) comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
21. The recombinant plasmid of claim 18, wherein the plasmid is pAAV short interfering ribonucleic acid (siRNA).
- 15 22. A recombinant viral vector comprising nucleic acid sequences for expressing a short interfering ribonucleic acid (siRNA) comprising a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56.
- 20 23. The recombinant viral vector of claim 22 wherein the nucleic acid sequences express a short interfering ribonucleic acid (siRNA) wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
- 25 24. The recombinant viral vector of claim 22, wherein the nucleic acid sequences for expressing the short interfering ribonucleic acid (siRNA) comprise an inducible or regulatable promoter.
- 30 25. The recombinant viral vector of claim 22, wherein the nucleic acid sequences for expressing the short interfering ribonucleic acid (siRNA) comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA stand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
- 35 26. The recombinant viral vector of claim 22, wherein the recombinant viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a lentiviral vector, a retroviral vector, and a herpes virus vector.
27. The recombinant viral vector of claim 22, wherein the recombinant viral vector is pseudotyped with surface proteins from vesicular stomatitis virus, rabies virus, Ebola virus, or Mokola virus.
- 40 28. The recombinant viral vector of claim 27, wherein the recombinant viral vector comprises an adeno-associated viral vector.
- 45 29. A pharmaceutical composition comprising an effective amount of a short interfering ribonucleic acid (siRNA) and a pharmaceutically acceptable carrier, wherein the siRNA comprises a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56.
- 50 30. The pharmaceutical composition as claimed in claim 29 wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
- 55 31. The pharmaceutical composition of claim 29, further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes.
32. A pharmaceutical composition comprising the plasmid of claim 17, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32, further comprising lipofectin, lipofectamine, cellfectin, polycations, or liposomes.
- 5 34. A pharmaceutical composition comprising the viral vector of claim 22 and a pharmaceutically acceptable carrier.
35. An effective amount of short interfering ribonucleic acid (siRNA) comprising a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA for use in inhibiting expression of human vascular endothelial growth factor (VEGF) mRNA in a subject wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56.
- 10 36. The short interfering ribonucleic acid (siRNA) of claim 35 wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
- 15 37. The short interfering ribonucleic acid (siRNA) of claim 35, wherein the subject is a human being.
38. The short interfering ribonucleic acid (siRNA) of claim 35, wherein expression of human vascular endothelial growth factor (VEGF) mRNA is inhibited in one or both eyes of the subject.
- 20 39. The short interfering ribonucleic acid (siRNA) of claim 35, wherein expression of human vascular endothelial growth factor (VEGF) mRNA is inhibited in retinal pigment epithelial cells of the subject.
40. The short interfering ribonucleic acid (siRNA) of claim 35, wherein the effective amount of the short interfering ribonucleic acid (siRNA) is from about 1 nM to about 100nM.
- 25 41. The short interfering ribonucleic acid (siRNA) of claim 35, wherein the short interfering ribonucleic acid (siRNA) is administered in conjunction with a delivery agent.
- 30 42. The short interfering ribonucleic acid (siRNA) of claim 41, wherein the delivery agent is selected from the group consisting of lipofectin, lipofectamine, cellfectin, polycations, and liposomes.
43. The short interfering ribonucleic acid (siRNA) of claim 42, wherein the delivery agent is a liposome.
- 35 44. The short interfering ribonucleic acid (siRNA) of claim 43, wherein the liposome comprises a ligand which targets the liposome to cells at or near the site of angiogenesis.
45. The short interfering ribonucleic acid (siRNA) of claim 44, wherein the ligand binds to receptors on tumor cells or vascular endothelial cells.
- 40 46. The short interfering ribonucleic acid (siRNA) of claim 45, wherein the ligand comprises a monoclonal antibody.
47. The short interfering ribonucleic acid (siRNA) of claim 44, wherein the liposome is modified with an opsonization-inhibition moiety.
- 45 48. The short interfering ribonucleic acid (siRNA) of claim 47, wherein the opsonization-inhibiting moiety comprises a PEG, PPG, or derivatives thereof.
- 50 49. The short interfering ribonucleic acid (siRNA) of claim 36, wherein the short interfering ribonucleic acid (siRNA) is expressed from a recombinant plasmid.
- 50 50. The short interfering ribonucleic acid (siRNA) of claim 36, wherein the short interfering ribonucleic acid (siRNA) is expressed from a recombinant viral vector.
- 55 51. The short interfering ribonucleic acid (siRNA) of claim 50, wherein the recombinant viral vector comprises an adenoviral vector, an adeno-associated viral vector, a lentiviral vector, a retroviral vector, or a herpes virus vector.
52. The short interfering ribonucleic acid (siRNA) of claim 51, wherein the recombinant viral vector is pseudotyped with

surface proteins from vesicular stomatitis virus, rabies virus, Ebola virus, or Mokola virus.

- 5
53. The short interfering ribonucleic acid (siRNA) of claim 36, wherein the siRNA is administered by an enteral administration route.
- 10
54. The short interfering ribonucleic acid (siRNA) of claim 53, wherein the enteral administration route is selected from the group consisting of oral, rectal, and intranasal.
- 15
55. The short interfering ribonucleic acid (siRNA) of claim 36, wherein the short interfering ribonucleic acid (siRNA) is administered by a parenteral administration route.
- 20
56. The short interfering ribonucleic acid (siRNA) of claim 55, wherein the parenteral administration route is selected from the group consisting of intraocular administration, intravascular administration, peri- and intra-tissue injection, subcutaneous injection or deposition, subcutaneous infusion, and direct application at or near the site of neovascularization.
- 25
57. The short interfering ribonucleic acid (siRNA) of claim 56, wherein the intravascular administration is selected from the group consisting of intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature.
- 30
58. The short interfering ribonucleic acid (siRNA) of claim 56, wherein the peri- and intra-tissue injection is comprises peri-tumoral injection or intra-tumoral injection.
- 35
59. The short interfering ribonucleic acid (siRNA) of claim 56, wherein the intraocular administration comprises intravitreal, intraretinal, subretinal, subtenon, peri- and retro-orbital, trans-corneal or trans-scleral administration.
- 40
60. The short interfering ribonucleic acid (siRNA) of claim 56, wherein the direct application at or near the site of neovascularization comprises application by catheter, corneal pellet, eye dropper, suppository, an implant comprising a porous material, an implant comprising a non-porous material, or an implant comprising a gelatinous material.
- 45
61. The short interfering ribonucleic acid (siRNA) of claim 56, wherein the site of neovascularization is in the eye, and the direct application at or near the site of neovascularization comprises application by an ocular implant.
- 50
62. The short interfering ribonucleic acid (siRNA) of claim 61, wherein the ocular implant is biodegradable.
- 55
63. An effective amount of short interfering ribonucleic acid (siRNA) comprising a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56 for use in preventing angiogenesis.
64. The short interfering ribonucleic acid (siRNA) of claim 63 wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
65. The short interfering ribonucleic acid (siRNA) of claim 63, wherein the angiogenesis is pathogenic.
66. The short interfering ribonucleic acid (siRNA) of claim 63, wherein the angiogenesis is non-pathogenic.
67. The short interfering ribonucleic acid (siRNA) of claim 66, wherein the non-pathogenic angiogenesis is associated with production of fatty tissues or cholesterol production.
68. The short interfering ribonucleic acid (siRNA) of claim 66, wherein the non-pathogenic angiogenesis comprises endometrial neovascularization.
69. The short interfering ribonucleic acid (siRNA) of claim 63, wherein the angiogenesis is inhibited in one or both eyes of the subject.
70. The short interfering ribonucleic acid (siRNA) of claim 63, wherein the angiogenesis is inhibited in retinal pigment

epithelial cells of the subject.

- 5
71. An effective amount of short interfering ribonucleic acid (siRNA) comprising a sense RNA strand and an antisense RNA strand, wherein the sense and antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in human vascular endothelial growth factor (VEGF) mRNA wherein said target sequence is selected from SEQ ID No. 47, SEQ ID No. 48, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52 and SEQ ID No. 56 for use in treating angiogenic disease such that angiogenesis associated with angiogenic disease is inhibited.
- 10
72. The short interfering ribonucleic acid (siRNA) of claim 71 wherein the sense RNA strand comprises SEQ ID NO: 77, and the antisense RNA strand comprises SEQ ID NO: 78.
- 15
73. The short interfering ribonucleic acid (siRNA) of claim 71, wherein the angiogenic disease comprises a tumor associated with a cancer.
- 20
74. The short interfering ribonucleic acid (siRNA) of claim 73, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, head and neck cancer, brain cancer, abdominal cancer, colon cancer, colorectal cancer, esophagus cancer, gastrointestinal cancer, glioma, liver cancer, tongue cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, Wilm's tumor, multiple myeloma, skin cancer, lymphoma, and blood cancer.
- 25
75. The short interfering ribonucleic acid (siRNA) of claim 71, wherein the angiogenic disease is selected from the group consisting of diabetic retinopathy, age-related macular degeneration, and inflammatory diseases.
- 30
76. The short interfering ribonucleic acid (siRNA) of claim 75, wherein the inflammatory disease is psoriasis or rheumatoid arthritis.
- 35
77. The short interfering ribonucleic acid (siRNA) of claim 71, wherein the short interfering ribonucleic acid (siRNA) is administered in combination with a pharmaceutical agent for treating the angiogenic disease, which pharmaceutical agent is different from the short interfering ribonucleic acid (siRNA).
- 40
78. The short interfering ribonucleic acid (siRNA) of claim 77 wherein the angiogenic disease is cancer, and the pharmaceutical agent comprises a chemotherapeutic agent.
- 45
79. The short interfering ribonucleic acid (siRNA) of claim 78, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, cyclophosphamide, 5-fluorouracil, adriamycin, daunorubicin, and tamoxifen.
80. The short interfering ribonucleic acid (siRNA) of claim 71, wherein the short interfering ribonucleic acid (siRNA) is administered to a subject in combination with another therapeutic method designed to treat the angiogenic disease.
81. The short interfering ribonucleic acid (siRNA) of claim 80, wherein the angiogenic disease is cancer, and the short interfering ribonucleic acid (siRNA) is administered in combination with radiation therapy, chemotherapy or surgery.
82. The short interfering ribonucleic acid (siRNA) of claim 1, wherein the short interfering ribonucleic acid (siRNA) further comprises altered RNA.

Patentansprüche

- 50
1. Eine isolierte kurze interferierende Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang von etwa 19 bis zu etwa 25 Nukleotiden Länge und einen RNA-Gegensinnstrang von etwa 19 bis zu etwa 25 Nukleotiden Länge beinhaltet, wobei der RNA-Sinnstrang und der RNA -Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist.
- 55
2. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei die menschliche VEGF-mRNA aus der

EP 1 578 933 B9

Gruppe, die aus VEGF₁₂₁-mRNA (SEQ ID NO: 2); VEGF₁₆₅-mRNA (SEQ ID NO: 3); VEGF₁₈₉-mRNA (SEQ ID NO: 4) und VEGF₂₀₆-mRNA (SEQ ID NO: 5) besteht, ausgewählt ist.

- 5 3. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der Gegensinnstrang SEQ ID NO: 78 beinhaltet.
4. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei der RNA-Sinnstrang ein RNA-Molekül beinhaltet und der RNA-Gegensinnstrang ein RNA-Molekül beinhaltet.
- 10 5. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang, die den RNA-Doppelstrang bilden, durch eine Einzelstrang-Haarnadelstruktur kovalent verbunden sind.
- 15 6. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei die siRNA ferner Nicht-Nukleotid-Material beinhaltet.
7. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang gegenüber Nukleaseabbau stabilisiert sind.
- 20 8. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, die ferner einen 3'-Überhang beinhaltet.
9. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 8, wobei der 3'-Überhang etwa 1 bis 6 Nucleotide beinhaltet.
- 25 10. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 8, wobei der 3'-Überhang etwa 2 Nucleotide beinhaltet.
- 30 11. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 4, wobei der RNA-Sinnstrang einen ersten 3'-Überhang beinhaltet und der RNA-Gegensinnstrang einen zweiten 3'-Überhang beinhaltet.
- 35 12. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 11, wobei der erste und der zweite 3'-Überhang getrennt etwa 1 bis 6 Nucleotide beinhalten.
13. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 12, wobei der erste 3'-Überhang ein Dinucleotid beinhaltet und der zweite 3'-Überhang ein Dinucleotid beinhaltet.
- 40 14. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 13, wobei das Dinucleotid, das den ersten und den zweiten 3'-Überhang beinhaltet, Dithymidylsäure (TT) oder Diuridylsäure (uu) ist.
- 45 15. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 8, wobei der 3'-Überhang gegenüber Nukleaseabbau stabilisiert ist.
16. Eine Zelle eines retinalen Pigmentepithels, die die kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1 beinhaltet.
- 50 17. Ein rekombinantes Plasmid, das Nucleinsäuresequenzen zum Expressieren einer kurzen interferierenden Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nucleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist.
- 55 18. Rekombinantes Plasmid gemäß Anspruch 17, wobei die Nucleinsäuresequenzen eine kurze interferierende Ribonukleinsäure (siRNA) exprimieren, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der RNA-Gegensinnstrang SEQ ID NO: 78 beinhaltet.
19. Rekombinantes Plasmid gemäß Anspruch 17, wobei die Nucleinsäuresequenzen zum Expressieren der kurzen interferierenden Ribonukleinsäure (siRNA) einen induzierbaren oder regulierbaren Promotor beinhalten.

EP 1 578 933 B9

- 5
20. Rekombinantes Plasmid gemäß Anspruch 17, wobei die Nukleinsäuresequenzen zum Expressieren der kurzen interferierenden Ribonukleinsäure (siRNA) eine RNA-Sinnstrangkodierungssequenz in funktionsbereiter Verbindung mit einer poly-T-Terminationssequenz unter Kontrolle eines menschlichen U6-RNA-Promotors und eine RNA-Gegensinnstrangkodierungssequenz in funktionsbereiter Verbindung mit einer poly-T-Terminationssequenz unter Kontrolle eines menschlichen U6-RNA-Promotors beinhalten.
- 10
21. Rekombinantes Plasmid gemäß Anspruch 18, wobei das Plasmid pAAV-kurze-interferierende-Ribonukleinsäure (pAAVsiRNA) ist.
- 15
22. Ein rekombinanter viraler Vektor, der Nukleinsäuresequenzen zum Expressieren einer kurzen interferierenden Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist.
- 20
23. Rekombinanter viraler Vektor gemäß Anspruch 22, wobei die Nukleinsäuresequenzen eine kurze interferierende Ribonukleinsäure (siRNA) exprimieren, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der RNA-Gegensinnstrang SEQ ID NO: 78 beinhaltet.
- 25
24. Rekombinanter viraler Vektor gemäß Anspruch 22, wobei die Nukleinsäuresequenzen zum Expressieren der kurzen interferierenden Ribonukleinsäure (siRNA) einen induzierbaren oder regulierbaren Promotor beinhalten.
- 30
25. Rekombinanter viraler Vektor gemäß Anspruch 22, wobei die Nukleinsäuresequenzen zum Expressieren der kurzen interferierenden Ribonukleinsäure (siRNA) eine RNA-Sinnstrangkodierungssequenz in funktionsbereiter Verbindung mit einer poly-T-Terminationssequenz unter Kontrolle eines menschlichen U6-RNA-Promotors und eine RNA-Gegensinnstrangkodierungssequenz in funktionsbereiter Verbindung mit einer poly-T-Terminationssequenz unter Kontrolle eines menschlichen U6-RNA-Promotors beinhalten.
- 35
26. Rekombinanter viraler Vektor gemäß Anspruch 22, wobei der rekombinante virale Vektor aus der Gruppe, die aus einem adenoviralen Vektor, einem adeno-assoziierten viralen Vektor, einem lentiviralen Vektor und einem Herpesvirusvektor besteht, ausgewählt ist.
- 40
27. Rekombinanter viraler Vektor gemäß Anspruch 22, wobei der rekombinante virale Vektor mit Oberflächenproteinen von dem Vesicular-Stomatitis-Virus, Tollwutvirus, Ebolavirus oder Mokolavirus pseudotypisiert ist.
- 45
28. Rekombinanter viraler Vektor gemäß Anspruch 27, wobei der rekombinante virale Vektor einen adeno-assoziierten viralen Vektor beinhaltet.
- 50
29. Eine pharmazeutische Zusammensetzung, die eine wirksame Menge einer kurzen interferierenden Ribonukleinsäure (siRNA) und einen pharmazeutisch zulässigen Träger beinhaltet, wobei die siRNA einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist.
- 55
30. Pharmazeutische Zusammensetzung gemäß Anspruch 29, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der Gegensinnstrang SEQ ID NO: 78 beinhaltet.
31. Pharmazeutische Zusammensetzung gemäß Anspruch 29, die ferner Lipofectin, Lipofectamin, Cellfectin, Polykationen oder Liposomen beinhaltet.
32. Eine pharmazeutische Zusammensetzung, die das Plasmid gemäß Anspruch 17 oder ein physiologisch zulässiges Salz davon und einen pharmazeutisch zulässigen Träger beinhaltet.
33. Pharmazeutische Zusammensetzung gemäß Anspruch 32, die ferner Lipofectin, Lipofectamin, Cellfectin, Polykationen oder Liposomen beinhaltet.

EP 1 578 933 B9

34. Eine pharmazeutische Zusammensetzung, die den viralen Vektor gemäß Anspruch 22 und einen pharmazeutisch zulässigen Träger beinhaltet.
- 5 35. Eine wirksame Menge kurzer interferierender Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, zur Verwendung beim Inhibieren der Expression von mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) bei einem Patienten, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist.
- 10 36. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der RNA-Gegensinnstrang SEQ ID NO: 78 beinhaltet.
- 15 37. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei der Patient ein Mensch ist.
38. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei die Expression von mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) in einem Auge oder in beiden Augen des Patienten inhibiert wird.
- 20 39. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei die Expression von mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors in Zellen des retinalen Pigmentepithels des Patienten inhibiert wird.
- 25 40. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei die wirksame Menge der kurzen interferierenden Ribonukleinsäure (siRNA) von etwa 1 nM bis zu etwa 100 nM beträgt.
- 30 41. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 35, wobei die kurze interferierende Ribonukleinsäure (siRNA) zusammen mit einem Übergabemittel verabreicht wird.
- 35 42. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 41, wobei das Übergabemittel aus der Gruppe, die aus Lipofectin, Lipofectamin, Cellfectin, Polykationen und Liposomen besteht, ausgewählt ist.
43. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 42, wobei das Übergabemittel ein Liposom ist.
- 40 44. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 43, wobei das Liposom einen Liganden, der das Liposom auf Zellen an oder nahe der Stelle der Angiogenese als Ziele festlegt, beinhaltet.
- 45 45. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 44, wobei sich der Ligand an Rezeptoren auf Tumorzellen oder Zellen des vaskulären Endothels bindet.
46. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 45, wobei der Ligand einen monoklonalen Antikörper beinhaltet.
- 50 47. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 44, wobei das Liposom mit einem Oponisierungs-Inhibitionsteil modifiziert wird.
48. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 47, wobei der Oponisierungs-Inhibitionsrest ein PEG, PPG oder Derivate davon beinhaltet.
- 55 49. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 36, wobei die kurze interferierende Ribonukleinsäure (siRNA) von einem rekombinanten Plasmid exprimiert wird.
50. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 36, wobei die kurze interferierende Ribonukleinsäure (siRNA) von einem rekombinanten viralen Vektor exprimiert wird.
51. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 50, wobei der rekombinante virale Vektor einen adenoviralen Vektor, einen adeno-assoziierten viralen Vektor, einen lentiviralen Vektor, einen retroviralen Vektor

oder einen Herpesvirusvektor beinhaltet.

- 5
- 52.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 51, wobei der rekombinante virale Vektor mit Oberflächenproteinen von dem Vesicular-Stomatitis-Virus, Tollwutvirus, Ebolavirus oder Mokolavirus pseudotypisiert ist.
- 53.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 36, wobei die siRNA auf einem enteralen Verabreichungsweg verabreicht wird.
- 10 **54.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 53, wobei der enterale Verabreichungsweg aus der Gruppe, die aus oral, rektal und intranasal besteht, ausgewählt ist.
- 55.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 36, wobei die kurze interferierende Ribonukleinsäure (siRNA) auf einem parenteralen Verabreichungsweg verabreicht wird.
- 15 **56.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 55, wobei die parenterale Verabreichungsform aus der Gruppe, die aus intraokulärer Verabreichung, intravaskulärer Verabreichung, Injektion in und um Gewebe, subkutaner Injektion oder Ablagerung, subkutaner Infusion und Direktapplikation an oder nahe der Stelle einer Neovaskularisation besteht, ausgewählt ist.
- 20 **57.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 56, wobei die intravaskuläre Verabreichung aus der Gruppe, die aus intravenöser Bolusinjektion, intravenöser Infusion, intraarterieller Bolusinjektion, intraarterieller Infusion und Einträufelung in die Blutgefäße durch Katheter besteht, ausgewählt ist.
- 25 **58.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 56, wobei die Injektion in und um Gewebe peritumorale Injektion oder intratumorale Injektion beinhaltet.
- 59.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 56, wobei die intraokuläre Verabreichung intravitreale, intraretinale, subretinale Verabreichung, Subtenon-Verabreichung, peri- und retroorbitale, transkorneale oder transsklerale Verabreichung beinhaltet.
- 30 **60.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 56, wobei die Direktapplikation an oder nahe der Stelle einer Neovaskularisation Applikation durch Katheter, korneale Pellets, Pipette, Zäpfchen, ein Implantat, das ein poröses Material beinhaltet, ein Implantat, das ein nicht poröses Material beinhaltet, oder ein Implantat, das ein gallertartiges Material beinhaltet, beinhaltet.
- 35 **61.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 56, wobei sich die Stelle einer Neovaskularisation im Auge befindet und die Direktapplikation an oder nahe der Stelle einer Neovaskularisation Applikation durch ein Okularimplantat beinhaltet.
- 40 **62.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 61, wobei das Okularimplantat biologisch abbaubar ist.
- 63.** Eine wirksame Menge kurzer interferierender Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist, zur Verwendung bei der Prävention von Angiogenese.
- 45 **64.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 63, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der RNA-Gegensinnstrang SEQ ID NO: 78 beinhaltet.
- 65.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 63, wobei die Angiogenese pathogen ist.
- 50 **66.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 63, wobei die Angiogenese nicht pathogen ist.
- 55 **67.** Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 66, wobei die nicht pathogene Angiogenese mit

der Erzeugung von Fettgeweben oder der Erzeugung von Cholesterin assoziiert wird.

- 5
68. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 66, wobei die nicht pathogene Angiogenese endometriale Neovaskularisation beinhaltet.
- 10
69. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 63, wobei die Angiogenese in einem Auge oder in beiden Augen des Patienten inhibiert wird.
- 15
70. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 63, wobei die Angiogenese in Zellen des retinalen Pigmentepithels des Patienten inhibiert wird.
- 20
71. Eine wirksame Menge kurzer interferierender Ribonukleinsäure (siRNA), die einen RNA-Sinnstrang und einen RNA-Gegensinnstrang beinhaltet, wobei der RNA-Sinnstrang und der RNA-Gegensinnstrang einen RNA-Doppelstrang bilden und wobei der RNA-Sinnstrang eine Nukleotidsequenz beinhaltet, die mit einer Zielsequenz in mRNA eines menschlichen vaskulären endothelialen Wachstumsfaktors (VEGF) identisch ist, wobei die Zielsequenz aus SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52 und SEQ ID NO. 56 ausgewählt ist, zur Verwendung bei der Behandlung angiogener Erkrankung, so dass die mit der angiogenen Erkrankung assoziierte Angiogenese inhibiert wird.
- 25
72. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 71, wobei der RNA-Sinnstrang SEQ ID NO: 77 beinhaltet und der RNA-Gegensinnstrang SEQ ID NO: 78 beinhaltet.
- 30
73. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 71, wobei die angiogene Erkrankung einen mit einem Krebs assoziierten Tumor beinhaltet.
- 35
74. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 73, wobei der Krebs aus der Gruppe, die aus Brustkrebs, Lungenkrebs, Kopf- und Halskrebs, Gehirnkrebs, Unterleibskrebs, Darmkrebs, kolorektalem Karzinom, Speiseröhrenkrebs, Magen-Darm-Krebs, Gliom, Leberkrebs, Zungenkrebs, Neuroblastom, Osteosarkom, Eierstockkrebs, Bauchspeicheldrüsenkrebs, Prostatakrebs, Retinoblastom, Wilms-Tumor, multiplem Myelom, Hautkrebs, Lymphom, und Blutkrebs besteht, ausgewählt ist.
- 40
75. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 71, wobei die angiogene Erkrankung aus der Gruppe, die aus diabetischer Retinopathie, altersbedingter Makuladegeneration und entzündlichen Erkrankungen besteht, ausgewählt ist.
- 45
76. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 75, wobei die entzündliche Erkrankung Psoriasis oder rheumatoide Arthritis ist.
- 50
77. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 71, wobei die kurze interferierende Ribonukleinsäure (siRNA) in Kombination mit einem pharmazeutischen Wirkstoff zur Behandlung der angiogenen Erkrankung verabreicht wird, wobei sich der pharmazeutische Wirkstoff von der kurzen interferierenden Ribonukleinsäure (siRNA) unterscheidet.
- 55
78. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 77, wobei die angiogene Erkrankung Krebs ist und der pharmazeutische Wirkstoff einen chemotherapeutischen Wirkstoff beinhaltet.
79. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 78, wobei der chemotherapeutische Wirkstoff aus der Gruppe, die aus Cisplatin, Carboplatin, Cyclophosphamid, 5-Fluorouracil, Adriamycin, Daunorubicin und Tamoxifen besteht, ausgewählt ist.
80. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 71, wobei einem Patienten die kurze interferierende Ribonukleinsäure (siRNA) in Kombination mit einem anderen therapeutischen Verfahren, das zur Behandlung der angiogenen Erkrankung ausgerichtet ist, verabreicht wird.
81. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 80, wobei die angiogene Erkrankung Krebs ist und die kurze interferierende Ribonukleinsäure (siRNA) in Kombination mit Strahlungstherapie, Chemotherapie oder chirurgischem Eingriff verabreicht wird.

82. Kurze interferierende Ribonukleinsäure (siRNA) gemäß Anspruch 1, wobei die kurze interferierende Ribonukleinsäure (siRNA) ferner modifizierte RNA beinhaltet.

5 **Revendications**

1. Un acide ribonucléique interférant court (ARNic) isolé comprenant un brin ARN sens d'environ 19 à environ 25 nucléotides de long et un brin ARN antisens d'environ 19 à environ 25 nucléotides de long, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence de nucléotides identique à une séquence cible de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56.
- 10
2. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où l'ARNm de VEGF humain est sélectionné dans le groupe consistant en ARNm de VEGF₁₂₁ (SEQ ID N° : 2) ; ARNm de VEGF₁₆₅ (SEQ ID N° : 3) ; ARNm de VEGF₁₈₉ (SEQ ID N° : 4) et ARNm de VEGF₂₀₆ (SEQ ID N°: 5).
- 15
3. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où le brin ARN sens comprend SEQ ID N°: 77, et le brin antisens comprend SEQ ID N°: 78.
- 20
4. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où le brin ARN sens comprend une molécule ARN, et le brin ARN antisens comprend une molécule ARN.
5. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où les brins ARN sens et antisens formant le duplex ARN sont liés de façon covalente par une épingle à cheveux à brin unique.
- 25
6. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où l'ARNic comprend en outre du matériau non nucléotidique.
7. L'acide ribonucléique interférant court (ARNic) de la revendication 1, où les brins ARN sens et antisens sont stabilisés contre une dégradation par nucléase.
- 30
8. L'acide ribonucléique interférant court (ARNic) de la revendication 1, comprenant en outre un débordement en 3'.
9. L'acide ribonucléique interférant court (ARNic) de la revendication 8, où le débordement en 3' comprend de 1 à environ 6 nucléotides.
- 35
10. L'acide ribonucléique interférant court (ARNic) de la revendication 8, où le débordement en 3' comprend environ 2 nucléotides.
- 40
11. L'acide ribonucléique interférant court (ARNic) de la revendication 4, où le brin ARN sens comprend un premier débordement en 3', et le brin ARN antisens comprend un deuxième débordement en 3'.
12. L'acide ribonucléique interférant court (ARNic) de la revendication 11, où les premier et deuxième débordements en 3' comprennent séparément de 1 à environ 6 nucléotides.
- 45
13. L'acide ribonucléique interférant court (ARNic) de la revendication 12, où le premier débordement en 3' comprend un dinucléotide et le deuxième débordement en 3' comprend un dinucléotide.
14. L'acide ribonucléique interférant court (ARNic) de la revendication 13, où le dinucléotide comprenant le premier et le deuxième débordement en 3' est un acide dithymidylique (TT) ou un acide diuridylique (uu).
- 50
15. L'acide ribonucléique interférant court (ARNic) de la revendication 8, où le débordement en 3' est stabilisé contre une dégradation par nucléase.
- 55
16. Une cellule épithéliale pigmentaire rétinienne comprenant l'acide ribonucléique interférant court (ARNic) de la revendication 1.
17. Un plasmide recombiné comprenant des séquences d'acide nucléique pour exprimer un acide ribonucléique inter-

férant court (ARNic) comprenant un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans un ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56.

- 5
18. Le plasmide recombiné de la revendication 17 où les séquences d'acide nucléique expriment un acide ribonucléique interférant court (ARNic) où le brin ARN sens comprend SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N°: 78.
- 10
19. Le plasmide recombiné de la revendication 17, où les séquences d'acide nucléique pour exprimer l'acide ribonucléique interférant court (ARNic) comprennent un promoteur inductible ou régulable.
- 15
20. Le plasmide recombiné de la revendication 17, où les séquences d'acide nucléique pour exprimer l'acide ribonucléique interférant court (ARNic) comprennent une séquence codante de brin ARN sens en connexion exploitable avec une séquence de terminaison polyT sous le contrôle d'un promoteur ARN U6 humain, et une séquence codante de brin ARN antisens en connexion exploitable avec une séquence de terminaison polyT sous le contrôle d'un promoteur ARN U6 humain.
- 20
21. Le plasmide recombiné de la revendication 18, où le plasmide est l'acide ribonucléique interférant court pAAV (ARNic).
- 25
22. Un vecteur viral recombiné comprenant des séquences d'acide nucléique pour exprimer un acide ribonucléique interférant court (ARNic) comprenant un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56.
- 30
23. Le vecteur viral recombiné de la revendication 22 où les séquences d'acide nucléique expriment un acide ribonucléique interférant court (ARNic) où le brin ARN sens comprend SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N° : 78.
- 35
24. Le vecteur viral recombiné de la revendication 22, où les séquences d'acide nucléique pour exprimer l'acide ribonucléique interférant court (ARNic) comprennent un promoteur inductible ou régulable.
- 40
25. Le vecteur viral recombiné de la revendication 22, où les séquences d'acide nucléique pour exprimer l'acide ribonucléique interférant court (ARNic) comprennent une séquence codante de brin ARN sens en connexion exploitable avec une séquence de terminaison polyT sous le contrôle d'un promoteur ARN U6 humain, et une séquence codante de brin ARN antisens en connexion exploitable avec une séquence de terminaison polyT sous le contrôle d'un promoteur ARN U6 humain.
- 45
26. Le vecteur viral recombiné de la revendication 22, où le vecteur viral recombiné est sélectionné dans le groupe consistant en un vecteur adénoviral, un vecteur viral adéno-associé, un vecteur lentiviral, un vecteur rétroviral, et un vecteur du virus de l'herpès.
- 50
27. Le vecteur viral recombiné de la revendication 22, où le vecteur viral recombiné est pseudotypé avec des protéines de surface provenant de virus de stomatite vésiculaire, virus rabique, virus d'Ebola, ou virus Mokola.
- 55
28. Le vecteur viral recombiné de la revendication 27, où le vecteur viral recombiné comprend un vecteur viral adéno-associé.
29. Une composition pharmaceutique comprenant une quantité efficace d'un acide ribonucléique interférant court (ARNic) et un support acceptable d'un point de vue pharmaceutique, où l'ARNic comprend un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56.
30. La composition pharmaceutique telle que revendiquée dans la revendication 29 où le brin ARN sens comprend

EP 1 578 933 B9

SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N° : 78.

- 5
31. La composition pharmaceutique de la revendication 29, comprenant en outre de la lipofectine, de la lipofectamine, de la cellfectine, des polycations, ou des liposomes.
- 10
32. Une composition pharmaceutique comprenant le plasmide de la revendication 17, ou un sel acceptable d'un point de vue physiologique de celui-ci, et un support acceptable d'un point de vue pharmaceutique.
- 15
33. La composition pharmaceutique de la revendication 32, comprenant en outre de la lipofectine, de la lipofectamine, de la cellfectine, des polycations, ou des liposomes.
- 20
34. Une composition pharmaceutique comprenant le vecteur viral de la revendication 22 et un support acceptable d'un point de vue pharmaceutique.
- 25
35. Une quantité efficace d'acide ribonucléique interférant court (ARNic) comprenant un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) destiné à être utilisé pour inhiber l'expression du ARNm de facteur de croissance endothélial vasculaire humain (VEGF) chez un sujet où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56.
- 30
36. L'acide ribonucléique interférant court (ARNic) de la revendication 35 où le brin ARN sens comprend SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N° : 78.
- 35
37. L'acide ribonucléique interférant court (ARNic) de la revendication 35, où le sujet est un être humain.
- 40
38. L'acide ribonucléique interférant court (ARNic) de la revendication 35, où l'expression d'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) est inhibée dans un oeil ou dans les deux yeux du sujet.
- 45
39. L'acide ribonucléique interférant court (ARNic) de la revendication 35, où l'expression d'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) est inhibée dans des cellules épithéliales pigmentaires rétinienne du sujet.
- 50
40. L'acide ribonucléique interférant court (ARNic) de la revendication 35, où la quantité efficace de l'acide ribonucléique interférant court (ARNic) est d'environ 1 nM à environ 100 nM.
- 55
41. L'acide ribonucléique interférant court (ARNic) de la revendication 35, où l'acide ribonucléique interférant court (ARNic) est administré en conjonction avec un agent de délivrance.
42. L'acide ribonucléique interférant court (ARNic) de la revendication 41, où l'agent de délivrance est sélectionné dans le groupe consistant en lipofectine, lipofectamine, cellfectine, polycations, et liposomes.
43. L'acide ribonucléique interférant court (ARNic) de la revendication 42, où l'agent de délivrance est un liposome.
44. L'acide ribonucléique interférant court (ARNic) de la revendication 43, où le liposome comprend un ligand qui dirige le liposome vers des cellules au niveau ou à proximité du site d'angiogenèse.
45. L'acide ribonucléique interférant court (ARNic) de la revendication 44, où le ligand se lie à des récepteurs sur des cellules tumorales ou des cellules endothéliales vasculaires.
- 50
46. L'acide ribonucléique interférant court (ARNic) de la revendication 45, où le ligand comprend un anticorps monoclonal.
- 55
47. L'acide ribonucléique interférant court (ARNic) de la revendication 44, où le liposome est modifié avec une fraction opsonisation-inhibition.
48. L'acide ribonucléique interférant court (ARNic) de la revendication 47, où la fraction opsonisation-inhibition comprend un PEG, un PPG, ou des dérivés de ceux-ci.

EP 1 578 933 B9

49. L'acide ribonucléique interférant court (ARNic) de la revendication 36, où l'acide ribonucléique interférant court (ARNic) est exprimé à partir d'un plasmide recombiné.
- 5 50. L'acide ribonucléique interférant court (ARNic) de la revendication 36, où l'acide ribonucléique interférant court (ARNic) est exprimé à partir d'un vecteur viral recombiné.
- 10 51. L'acide ribonucléique interférant court (ARNic) de la revendication 50, où le vecteur viral recombiné comprend un vecteur adénoviral, un vecteur viral adéno-associé, un vecteur lentiviral, un vecteur rétroviral, ou un vecteur du virus de l'herpès.
- 15 52. L'acide ribonucléique interférant court (ARNic) de la revendication 51, où le vecteur viral recombiné est pseudotypé avec des protéines de surface provenant de virus stomatite vésiculaire, virus rabique, virus d'Ebola, ou virus Mokola.
- 20 53. L'acide ribonucléique interférant court (ARNic) de la revendication 36, où l'ARNic est administré par une voie d'administration entérale.
- 25 54. L'acide ribonucléique interférant court (ARNic) de la revendication 53, où la voie d'administration entérale est sélectionnée dans le groupe consistant en voie orale, rectale, et intranasale.
- 30 55. L'acide ribonucléique interférant court (ARNic) de la revendication 36, où l'acide ribonucléique interférant court (ARNic) est administré par une voie d'administration parentérale.
- 35 56. L'acide ribonucléique interférant court (ARNic) de la revendication 55, où la voie d'administration parentérale est sélectionnée dans le groupe consistant en administration intraoculaire, administration intravasculaire, injection péri- et intra-tissulaire, injection ou dépôt sous-cutanées, perfusion sous-cutanée, et application directe au niveau ou à proximité du site de néovascularisation.
- 40 57. L'acide ribonucléique interférant court (ARNic) de la revendication 56, où l'administration intravasculaire est sélectionnée dans le groupe consistant en injection bolus intraveineuse, perfusion intraveineuse, injection bolus intra-artérielle, perfusion intra-artérielle et instillation par sonde dans la vasculature.
- 45 58. L'acide ribonucléique interférant court (ARNic) de la revendication 56, où l'injection péri- et intra-tissulaire se compose d'injection péri-tumorale ou d'injection intratumorale.
- 50 59. L'acide ribonucléique interférant court (ARNic) de la revendication 56, où l'administration intraoculaire comprend une administration intravitréenne, intrarétiniennne, sous-rétiniennne, sous-Tenon, péri- et rétro-orbitaire, trans-cornéenne ou trans-sclérale.
- 55 60. L'acide ribonucléique interférant court (ARNic) de la revendication 56, où l'application directe au niveau ou à proximité du site de néovascularisation comprend une application par sonde, pastille cornéenne, compte-gouttes oculaire, suppositoire, un implant comprenant un matériau poreux, un implant comprenant un matériau non poreux, ou un implant comprenant un matériau gélatineux.
61. L'acide ribonucléique interférant court (ARNic) de la revendication 56, où le site de néovascularisation se trouve dans l'oeil, et l'application directe au niveau ou à proximité du site de néovascularisation comprend une application par un implant oculaire.
62. L'acide ribonucléique interférant court (ARNic) de la revendication 61, où l'implant oculaire est biodégradable.
63. Une quantité efficace d'acide ribonucléique interférant court (ARNic) comprenant un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56 afin d'être utilisée pour empêcher une angiogenèse.
64. L'acide ribonucléique interférant court (ARNic) de la revendication 63 où le brin ARN sens comprend SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N° : 78.

EP 1 578 933 B9

65. L'acide ribonucléique interférant court (ARNic) de la revendication 63, où l'angiogenèse est pathogène.
66. L'acide ribonucléique interférant court (ARNic) de la revendication 63, où l'angiogenèse est non pathogène.
- 5 67. L'acide ribonucléique interférant court (ARNic) de la revendication 66, où l'angiogenèse non pathogène est associée à la production de tissus adipeux ou la production de cholestérol.
68. L'acide ribonucléique interférant court (ARNic) de la revendication 66, où l'angiogenèse non pathogène comprend une néovascularisation endométriale.
- 10 69. L'acide ribonucléique interférant court (ARNic) de la revendication 63, où l'angiogenèse est inhibée dans un oeil ou dans les deux yeux du sujet.
70. L'acide ribonucléique interférant court (ARNic) de la revendication 63, où l'angiogenèse est inhibée dans des cellules épithéliales pigmentaires rétinienne du sujet.
- 15 71. Une quantité efficace d'acide ribonucléique interférant court (ARNic) comprenant un brin ARN sens et un brin ARN antisens, où les brins ARN sens et antisens forment un duplex ARN, et où le brin ARN sens comprend une séquence nucléotidique identique à une séquence cible dans de l'ARNm de facteur de croissance endothélial vasculaire humain (VEGF) où ladite séquence cible est sélectionnée parmi SEQ ID N° 47, SEQ ID N° 48, SEQ ID N° 50, SEQ ID N° 51, SEQ ID N° 52 et SEQ ID N° 56 afin d'être utilisée pour traiter une maladie angiogénique de telle sorte qu'une angiogenèse associée à une maladie angiogénique soit inhibée.
- 20 72. L'acide ribonucléique interférant court (ARNic) de la revendication 71 où le brin ARN sens comprend SEQ ID N° : 77, et le brin ARN antisens comprend SEQ ID N° : 78.
- 25 73. L'acide ribonucléique interférant court (ARNic) de la revendication 71, où la maladie angiogénique comprend une tumeur associée à un cancer.
- 30 74. L'acide ribonucléique interférant court (ARNic) de la revendication 73, où le cancer est sélectionné dans le groupe consistant en cancer du sein, cancer du poumon, cancer de la tête et du cou, cancer du cerveau, cancer abdominal, cancer du côlon, cancer colorectal, cancer de l'oesophage, cancer gastrointestinal, gliome, cancer du foie, cancer de la langue, neuroblastome, ostéosarcome, cancer ovarien, cancer du pancréas, cancer de la prostate, rétinoblastome, tumeur de Wilm, myélome multiple, cancer de la peau, lymphome, et cancer du sang.
- 35 75. L'acide ribonucléique interférant court (ARNic) de la revendication 71, où la maladie angiogénique est sélectionnée dans le groupe consistant en rétinopathie diabétique, dégénérescence maculaire liée à l'âge, et maladies inflammatoires.
- 40 76. L'acide ribonucléique interférant court (ARNic) de la revendication 75, où la maladie inflammatoire est du psoriasis ou de l'arthrite rhumatoïde.
77. L'acide ribonucléique interférant court (ARNic) de la revendication 71, où l'acide ribonucléique interférant court (ARNic) est administré en combinaison avec un agent pharmaceutique pour traiter la maladie angiogénique, lequel agent pharmaceutique est différent de l'acide ribonucléique interférant court (ARNic).
- 45 78. L'acide ribonucléique interférant court (ARNic) de la revendication 77 où la maladie angiogénique est un cancer, et l'agent pharmaceutique comprend un agent chimiothérapeutique.
- 50 79. L'acide ribonucléique interférant court (ARNic) de la revendication 78, où l'agent chimiothérapeutique est sélectionné dans le groupe consistant en cisplatine, carboplatine, cyclophosphamide, 5-fluorouracile, adriamycine, daunorubicine, et tamoxifène.
80. L'acide ribonucléique interférant court (ARNic) de la revendication 71, où l'acide ribonucléique interférant court (ARNic) est administré à un sujet en combinaison avec une autre méthode thérapeutique conçue pour traiter la maladie angiogénique.
- 55 81. L'acide ribonucléique interférant court (ARNic) de la revendication 80, où la maladie angiogénique est un cancer,

EP 1 578 933 B9

et l'acide ribonucléique interférant court (ARNic) est administré en combinaison avec une radiothérapie, une chimiothérapie ou une intervention chirurgicale.

- 5 **82.** L'acide ribonucléique interférant court (ARNic) de la revendication 1, où l'acide ribonucléique interférant court (ARNic) comprend en outre un ARN modifié.

10

15

20

25

30

35

40

45

50

55




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 39841702 P [0001]
- US 29422802 A [0001]
- US 20010021772 A, Uhlmann [0008]
- US 20020086356 A, Tuschl [0046]
- US 5252479 A [0061]
- US 5139941 A [0061]
- WO 9413788 A [0061]
- WO 9324641 A [0061]
- US 4235871 A [0080]
- US 4501728 A [0080]
- US 4837028 A [0080]
- US 5019369 A [0080]
- US 4920016 A [0083]
- US 5902598 A [0091]
- US 6375972 A [0091]
- US 6331313 B [0091]
- US 6355271 B, Bell [0102]
- US 60398417 B [0148]
- US 10294228 B [0148]

Non-patent literature cited in the description

- Kim ES et al. *PNAS USA*, 2002, vol. 99, 11399-11404 [0008]
- Holash J et al. *PNAS USA*, 2002, vol. 99, 11393-11398 [0008]
- Fire A et al. *Nature*, 1998, vol. 391, 806-811 [0009]
- Elbashir SM et al. *Genes Dev*, 2001, vol. 15, 188-200 [0009]
- Elbashir SM et al. *Nature*, 2001, vol. 411, 494-498 [0010]
- McCaffrey AP et al. *Nature*, 2002, vol. 418, 38-39 [0010]
- Xia H et al. *Nat. Biotech.*, 2002, vol. 20, 1006-1010 [0010] [0060]
- Novina CD et al. *Nat. Med.*, 2002, vol. 8, 681-686 [0010]
- Busting SA. *J. Mol. Endocrinol.*, 2000, vol. 25, 169-193 [0026]
- Tuschl T et al. *The siRNA User Guide*, 11 October 2002 [0040]
- Tuschl, T. *Nat. Biotechnol.*, 2002, vol. 20, 446-448 [0051]
- Brummelkamp TR et al. *Science*, 2002, vol. 296, 550-553 [0051]
- Miyagishi M et al. *Nat. Biotechnol.*, 2002, vol. 20, 497-500 [0051]
- Paddison PJ et al. *Genes Dev.*, 2002, vol. 16, 948-958 [0051]
- Lee NS et al. *Nat. Biotechnol.*, 2002, vol. 20, 500-505 [0051]
- Paul CP et al. *Nat. Biotechnol.*, 2002, vol. 20, 505-508 [0051]
- Dornburg R. *Gene Therap.*, 1995, vol. 2, 301-310 [0058]
- Eglitis MA. *Biotechniques*, 1988, vol. 6, 608-614 [0058]
- Miller AD. *Hum Gene Therap.*, 1990, vol. 1, 5-14 [0058]
- Anderson WF. *Nature*, 1998, vol. 392, 25-30 [0058]
- Samulski R et al. *J. Virol.*, 1987, vol. 61, 3096-3101 [0061]
- Fisher KJ et al. *J. Virol.*, 1996, vol. 70, 520-532 [0061]
- Samulski R et al. *J. Virol.*, 1989, vol. 63, 3822-3826 [0061]
- Szoka et al. *Ann. Rev. Biophys. Bioeng.*, 1980, vol. 9, 467 [0080]
- Gabizon et al. *P.N.A.S, USA*, 1988, vol. 18, 6949-53 [0084]
- Acheampong AA et al. *Drug Metabol. and Disposition*, 2002, vol. 30, 421-429 [0092]
- Bennett et al. *Hum. Gene Ther.*, 1996, vol. 7, 1763-1769 [0094]
- Ambati J et al. *Progress in Retinal and Eye Res.*, 2002, vol. 21, 145-151 [0094]
- Remington's Pharmaceutical Science. Mack Publishing Company, 1985 [0098]
- Altschul et al. *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0106]
- Altschul et al. *Nucleic Acids Res.*, 1997, vol. 25, 3389-3402 [0106]